BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for the Study of the Liver (EASL);  European Association for the Study of Diabetes (EASD);  European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388-1402. [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004] [Cited by in Crossref: 1478] [Cited by in F6Publishing: 1253] [Article Influence: 295.6] [Reference Citation Analysis]
Number Citing Articles
1 Marziou A, Aubert B, Couturier C, Astier J, Philouze C, Obert P, Landrier JF, Riva C. Combined Beneficial Effect of Voluntary Physical Exercise and Vitamin D Supplementation in Diet-induced Obese C57BL/6J Mice. Med Sci Sports Exerc 2021;53:1883-94. [PMID: 33787528 DOI: 10.1249/MSS.0000000000002664] [Reference Citation Analysis]
2 Ponti F, De Cinque A, Fazio N, Napoli A, Guglielmi G, Bazzocchi A. Ultrasound imaging, a stethoscope for body composition assessment. Quant Imaging Med Surg 2020;10:1699-722. [PMID: 32742962 DOI: 10.21037/qims-19-1048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
3 Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology. 2019;70:1119-1133. [PMID: 31070259 DOI: 10.1002/hep.30702] [Cited by in Crossref: 88] [Cited by in F6Publishing: 83] [Article Influence: 88.0] [Reference Citation Analysis]
4 Pisetta C, Chillè C, Pelizzari G, Pigozzi MG, Salvetti M, Paini A, Muiesan ML, De Ciuceis C, Ricci C, Rizzoni D. Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease. High Blood Press Cardiovasc Prev 2020;27:321-30. [DOI: 10.1007/s40292-020-00389-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Adams LC, Lübbe F, Bressem K, Wagner M, Hamm B, Makowski MR. Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study. PLoS One 2018;13:e0206450. [PMID: 30427909 DOI: 10.1371/journal.pone.0206450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
6 Koot BGP, Nobili V. Screening for non-alcoholic fatty liver disease in children: do guidelines provide enough guidance? Obes Rev 2017;18:1050-60. [PMID: 28544608 DOI: 10.1111/obr.12556] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
7 Pappachan JM, Babu S, Krishnan B, Ravindran NC. Non-alcoholic Fatty Liver Disease: A Clinical Update. J Clin Transl Hepatol. 2017;5:384-393. [PMID: 29226105 DOI: 10.14218/jcth.2017.00013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
8 Becares N, Gage MC, Voisin M, Shrestha E, Martin-Gutierrez L, Liang N, Louie R, Pourcet B, Pello OM, Luong TV, Goñi S, Pichardo-Almarza C, Røberg-Larsen H, Diaz-Zuccarini V, Steffensen KR, O'Brien A, Garabedian MJ, Rombouts K, Treuter E, Pineda-Torra I. Impaired LXRα Phosphorylation Attenuates Progression of Fatty Liver Disease. Cell Rep 2019;26:984-995.e6. [PMID: 30673619 DOI: 10.1016/j.celrep.2018.12.094] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 25.0] [Reference Citation Analysis]
9 Pembroke T, Deschenes M, Lebouché B, Benmassaoud A, Sewitch M, Ghali P, Wong P, Halme A, Vuille-Lessard E, Pexos C, Klein MB, Sebastiani G. Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis. J Hepatol 2017;67:801-8. [PMID: 28527666 DOI: 10.1016/j.jhep.2017.05.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
10 Buchard B, Teilhet C, Abeywickrama Samarakoon N, Massoulier S, Joubert-Zakeyh J, Blouin C, Reynes C, Sabatier R, Biesse-Martin AS, Vasson MP, Abergel A, Demidem A. Two Metabolomics Phenotypes of Human Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease According to Fibrosis Severity. Metabolites 2021;11:54. [PMID: 33466889 DOI: 10.3390/metabo11010054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Buzás GM. Helicobacter pylori and non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2020;66:267-79. [PMID: 32724031 DOI: 10.23736/S1121-421X.20.02671-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Grzych G, Vonghia L, Bout MA, Weyler J, Verrijken A, Dirinck E, Chevalier Curt MJ, Van Gaal L, Paumelle R, Francque S, Tailleux A, Haas JT, Staels B. Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. J Clin Endocrinol Metab 2020;105:dgaa175. [PMID: 32271385 DOI: 10.1210/clinem/dgaa175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
13 Zhou W, Wang Y, Wu Y, Yang J, Xu L, Yang Y. Serum CTRP3 level is inversely associated with nonalcoholic fatty liver disease: A 3-y longitudinal study. Clin Chim Acta 2018;479:79-83. [PMID: 29305845 DOI: 10.1016/j.cca.2018.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Goossens N, Jornayvaz FR. Translational Aspects of Diet and Non-Alcoholic Fatty Liver Disease. Nutrients 2017;9:E1077. [PMID: 28956824 DOI: 10.3390/nu9101077] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
15 Fiorentino TV, Succurro E, Sciacqua A, Andreozzi F, Perticone F, Sesti G. Non‐alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance. Diabetes Metab Res Rev 2020;36. [DOI: 10.1002/dmrr.3333] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
16 Di Costanzo A, Belardinilli F, Bailetti D, Sponziello M, D'Erasmo L, Polimeni L, Baratta F, Pastori D, Ceci F, Montali A, Girelli G, De Masi B, Angeloni A, Giannini G, Del Ben M, Angelico F, Arca M. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Sci Rep 2018;8:3702. [PMID: 29487372 DOI: 10.1038/s41598-018-21939-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 11.7] [Reference Citation Analysis]
17 Piguet AC, Guarino M, Potaczek DP, Garn H, Dufour JF. Hepatic gene expression in mouse models of non-alcoholic fatty liver disease after acute exercise. Hepatol Res 2019;49:637-52. [PMID: 30811073 DOI: 10.1111/hepr.13323] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
18 Kim HY, Nam JY, Lee J, Lee HA, Chang Y, Lee HY, Cho H, Lee DH, Cho YY, Cho EJ, Yu SJ, Lee JM, Kim YJ, Yoon J. Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area. Aliment Pharmacol Ther 2018;47:1490-501. [DOI: 10.1111/apt.14623] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
19 Teixeira J, Marroni CA, Zubiaurre PR, Henz A, Faina L, Pinheiro LK, Mottin CC, Fernandes SA. Phase angle and non-alcoholic fatty liver disease before and after bariatric surgery. World J Hepatol 2020;12:1004-19. [PMID: 33312425 DOI: 10.4254/wjh.v12.i11.1004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71. [PMID: 33577920 DOI: 10.1016/j.jhep.2021.01.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Funuyet-Salas J, Martín-Rodríguez A, Pérez-San-Gregorio MÁ, Romero-Gómez M. Influence of Psychological Biomarkers on Therapeutic Adherence by Patients with Non-Alcoholic Fatty Liver Disease: A Moderated Mediation Model. J Clin Med 2021;10:2208. [PMID: 34065216 DOI: 10.3390/jcm10102208] [Reference Citation Analysis]
22 Fitriakusumah Y, Lesmana CRA, Bastian WP, Jasirwan COM, Hasan I, Simadibrata M, Kurniawan J, Sulaiman AS, Gani RA. The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience. BMC Gastroenterol 2019;19:43. [PMID: 30894137 DOI: 10.1186/s12876-019-0960-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
23 Pembroke T, Sebastiani G. Hepatic steatosis, hepatitis C, and human immunodeficiency viruses: A complex interplay: Correspondence. Hepatology 2017;66:673-4. [DOI: 10.1002/hep.29218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Huang J, Xue W, Wang M, Wu Y, Singh M, Zhu Y, Kumar R, Lin S. MAFLD Criteria May Overlook a Subtype of Patient with Steatohepatitis and Significant Fibrosis. Diabetes Metab Syndr Obes 2021;14:3417-25. [PMID: 34349535 DOI: 10.2147/DMSO.S316096] [Reference Citation Analysis]
25 Huber Y, Pfirrmann D, Gebhardt I, Labenz C, Gehrke N, Straub BK, Ruckes C, Bantel H, Belda E, Clément K, Leeming DJ, Karsdal MA, Galle PR, Simon P, Schattenberg JM. Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. Aliment Pharmacol Ther 2019;50:930-9. [PMID: 31342533 DOI: 10.1111/apt.15427] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 14.0] [Reference Citation Analysis]
26 El Hadi H, Vettor R, Rossato M. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth? Antioxidants (Basel) 2018;7:E12. [PMID: 29337849 DOI: 10.3390/antiox7010012] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 14.0] [Reference Citation Analysis]
27 Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, Gosmann C, Simmons A, Leitzinger C, Eberhagen C, Borchard S, Schmitt S, Hauck SM, von Toerne C, Jastroch M, Walheim E, Rust C, Gerbes AL, Popper B, Mayr D, Schnurr M, Vollmar AM, Denk G, Zischka H. Mitochondrial adaptation in steatotic mice. Mitochondrion 2018;40:1-12. [PMID: 28935446 DOI: 10.1016/j.mito.2017.08.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
28 Karlas T, Weiße T, Petroff D, Beer S, Döhring C, Gnatzy F, Niederwieser D, Behre G, Mössner J, Fischer J, Tröltzsch M, Wiegand J, Keim V, Franke G. Predicting hepatic complications of allogeneic hematopoietic stem cell transplantation using liver stiffness measurement. Bone Marrow Transplant 2019;54:1738-46. [DOI: 10.1038/s41409-019-0464-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Milaciu MV, Ciumărnean L, Matei DM, Vesa ȘC, Sabin O, Bocșan IC, Pop RM, Negrean V, Buzoianu AD, Acalovschi M. Cytokines, paraoxonase-1, periostin and non-invasive liver fibrosis scores in patients with non-alcoholic fatty liver disease and persistently elevated aminotransferases: A pilot study. Exp Ther Med 2021;21:533. [PMID: 33815606 DOI: 10.3892/etm.2021.9965] [Reference Citation Analysis]
30 Arrese M, Barrera F, Triantafilo N, Arab JP. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations. Expert Review of Gastroenterology & Hepatology 2019;13:849-66. [DOI: 10.1080/17474124.2019.1649981] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
31 Labenz C, Huber Y, Michel M, Nagel M, Galle PR, Kostev K, Schattenberg JM. Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. Hepatol Commun 2020;4:1293-301. [PMID: 32923833 DOI: 10.1002/hep4.1541] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 11.0] [Reference Citation Analysis]
32 Tada T, Iijima H, Kobayashi N, Yoshida M, Nishimura T, Kumada T, Kondo R, Yano H, Kage M, Nakano C, Aoki T, Aizawa N, Ikeda N, Takashima T, Yuri Y, Ishii N, Hasegawa K, Takata R, Yoh K, Sakai Y, Nishikawa H, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S. Usefulness of Attenuation Imaging with an Ultrasound Scanner for the Evaluation of Hepatic Steatosis. Ultrasound in Medicine & Biology 2019;45:2679-87. [DOI: 10.1016/j.ultrasmedbio.2019.05.033] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 16.0] [Reference Citation Analysis]
33 Amor AJ, Pinyol M, Solà E, Catalan M, Cofán M, Herreras Z, Amigó N, Gilabert R, Sala-vila A, Ros E, Ortega E. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia. Journal of Clinical Lipidology 2017;11:551-561.e7. [DOI: 10.1016/j.jacl.2017.02.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
34 Sridharan K, Sivaramakrishnan G, Sequeira RP, Elamin A. Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Postgrad Med J 2018;94:556-65. [PMID: 30341231 DOI: 10.1136/postgradmedj-2018-135967] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
35 Forlano R, Harlow C, Mullish BH, Thursz MR, Manousou P, Yee M. Binge-eating disorder is associated with an unfavorable body mass composition in patients with non-alcoholic fatty liver disease. Int J Eat Disord 2021. [PMID: 34272900 DOI: 10.1002/eat.23584] [Reference Citation Analysis]
36 Lyu J, Imachi H, Fukunaga K, Sato S, Kobayashi T, Dong T, Saheki T, Matsumoto M, Iwama H, Zhang H, Murao K. Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. Mol Metab 2020;34:16-26. [PMID: 32180556 DOI: 10.1016/j.molmet.2019.12.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 Sheridan DA, Aithal G, Alazawi W, Allison M, Anstee Q, Cobbold J, Khan S, Fowell A, McPherson S, Newsome PN, Oben J, Tomlinson J, Tsochatzis E. Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey. Frontline Gastroenterol 2017;8:252-9. [PMID: 29067150 DOI: 10.1136/flgastro-2017-100806] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
38 Guillaume M, Moal V, Delabaudiere C, Zuberbuhler F, Robic MA, Lannes A, Metivier S, Oberti F, Gourdy P, Fouchard-Hubert I, Selves J, Michalak S, Peron JM, Cales P, Bureau C, Boursier J. Direct comparison of the specialised blood fibrosis tests FibroMeterV2G and Enhanced Liver Fibrosis score in patients with non-alcoholic fatty liver disease from tertiary care centres. Aliment Pharmacol Ther 2019;50:1214-22. [PMID: 31617224 DOI: 10.1111/apt.15529] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
39 Han JM, Kim HI, Lee YJ, Lee JW, Kim KM, Bae JC. Differing Associations between Fatty Liver and Dyslipidemia According to the Degree of Hepatic Steatosis in Korea. J Lipid Atheroscler 2019;8:258-66. [PMID: 32821716 DOI: 10.12997/jla.2019.8.2.258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
40 Ratziu V, Marchesini G. When the journey from obesity to cirrhosis takes an early start. Journal of Hepatology 2016;65:249-51. [DOI: 10.1016/j.jhep.2016.05.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
41 Kwak JH, Jun DW, Lee SM, Cho YK, Lee KN, Lee HL, Lee OY, Choi HS, Yoon BC. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: A cross-sectional study. Clin Nutr. 2018;37:1550-1557. [PMID: 28918170 DOI: 10.1016/j.clnu.2017.08.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
42 Bekkelund SI, Jorde R. Alanine Aminotransferase and Body Composition in Obese Men and Women. Dis Markers 2019;2019:1695874. [PMID: 31534560 DOI: 10.1155/2019/1695874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
43 Stols-gonçalves D, Hovingh GK, Nieuwdorp M, Holleboom AG. NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin? Trends in Endocrinology & Metabolism 2019;30:891-902. [DOI: 10.1016/j.tem.2019.08.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 15.5] [Reference Citation Analysis]
44 Troelstra MA, Witjes JJ, van Dijk AM, Mak AL, Gurney-Champion O, Runge JH, Zwirs D, Stols-Gonçalves D, Zwinderman AH, Ten Wolde M, Monajemi H, Ramsoekh S, Sinkus R, van Delden OM, Beuers UH, Verheij J, Nieuwdorp M, Nederveen AJ, Holleboom AG. Assessment of Imaging Modalities Against Liver Biopsy in Nonalcoholic Fatty Liver Disease: The Amsterdam NAFLD-NASH Cohort. J Magn Reson Imaging 2021. [PMID: 33991378 DOI: 10.1002/jmri.27703] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Mansour D, Grapes A, Herscovitz M, Cassidy P, Vernazza J, Broad A, Anstee QM, McPherson S. Embedding assessment of liver fibrosis into routine diabetic review in primary care. JHEP Rep 2021;3:100293. [PMID: 34179738 DOI: 10.1016/j.jhepr.2021.100293] [Reference Citation Analysis]
46 Méndez-Giménez L, Becerril S, Moncada R, Valentí V, Fernández S, Ramírez B, Catalán V, Gómez-Ambrosi J, Soveral G, Malagón MM, Diéguez C, Rodríguez A, Frühbeck G. Gastric Plication Improves Glycemia Partly by Restoring the Altered Expression of Aquaglyceroporins in Adipose Tissue and the Liver in Obese Rats. Obes Surg 2017;27:1763-74. [PMID: 28054299 DOI: 10.1007/s11695-016-2532-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
47 Athithan L, Gulsin GS, House MJ, Pang W, Brady EM, Wormleighton J, Parke KS, Graham-Brown M, St Pierre TG, Levelt E, McCann GP. A comparison of liver fat fraction measurement on MRI at 3T and 1.5T. PLoS One 2021;16:e0252928. [PMID: 34255778 DOI: 10.1371/journal.pone.0252928] [Reference Citation Analysis]
48 Cardoso AC, A Villela-Nogueira C, de Figueiredo-Mendes C, Leão Filho H, Pinto Silva RA, Valle Tovo C, Perazzo H, Matteoni AC, de Carvalho-Filho RJ, Lisboa Bittencourt P. Brazilian Society of Hepatology and Brazilian College of Radiology practice guidance for the use of elastography in liver diseases. Ann Hepatol 2021;22:100341. [PMID: 33737252 DOI: 10.1016/j.aohep.2021.100341] [Reference Citation Analysis]
49 Maciejewska D, Drozd A, Skonieczna-Żydecka K, Skórka-Majewicz M, Dec K, Jakubczyk K, Pilutin A, Stachowska E. Eicosanoids in Nonalcoholic Fatty Liver Disease (NAFLD) Progression. Do Serum Eicosanoids Profile Correspond with Liver Eicosanoids Content during NAFLD Development and Progression? Molecules 2020;25:E2026. [PMID: 32349225 DOI: 10.3390/molecules25092026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
50 Senoner T, Schindler S, Stättner S, Öfner D, Troppmair J, Primavesi F. Associations of Oxidative Stress and Postoperative Outcome in Liver Surgery with an Outlook to Future Potential Therapeutic Options. Oxid Med Cell Longev 2019;2019:3950818. [PMID: 30906502 DOI: 10.1155/2019/3950818] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
51 O'Gorman P, Naimimohasses S, Monaghan A, Kennedy M, Melo AM, Ní Fhloinn D, Doherty DG, Beddy P, Finn SP, Moore JB, Gormley J, Norris S. Improvement in histological endpoints of MAFLD following a 12-week aerobic exercise intervention. Aliment Pharmacol Ther 2020;52:1387-98. [PMID: 32717123 DOI: 10.1111/apt.15989] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
52 Arai T, Atsukawa M, Tsubota A, Kawano T, Koeda M, Yoshida Y, Tanabe T, Okubo T, Hayama K, Iwashita A, Itokawa N, Kondo C, Kaneko K, Kawamoto C, Hatori T, Emoto N, Iio E, Tanaka Y, Iwakiri K. Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease. PLoS One 2019;14:e0224184. [PMID: 31721770 DOI: 10.1371/journal.pone.0224184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
53 Alberti G, Gana JC, Santos JL. Fructose, Omega 3 Fatty Acids, and Vitamin E: Involvement in Pediatric Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E3531. [PMID: 33212947 DOI: 10.3390/nu12113531] [Reference Citation Analysis]
54 Klaebel JH, Rakipovski G, Andersen B, Lykkesfeldt J, Tveden-Nyborg P. Dietary Intervention Accelerates NASH Resolution Depending on Inflammatory Status with Minor Additive Effects on Hepatic Injury by Vitamin E Supplementation. Antioxidants (Basel) 2020;9:E808. [PMID: 32882802 DOI: 10.3390/antiox9090808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
55 Shengir M, Krishnamurthy S, Ghali P, Deschenes M, Wong P, Chen T, Sebastiani G. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome. World J Gastroenterol 2020;26:7046-60. [PMID: 33311949 DOI: 10.3748/wjg.v26.i44.7046] [Reference Citation Analysis]
56 Karlas T, Weise L, Kuhn S, Krenzien F, Mehdorn M, Petroff D, Linder N, Schaudinn A, Busse H, Keim V, Pratschke J, Wiegand J, Splith K, Schmelzle M. Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease. J Transl Med 2017;15:106. [PMID: 28521774 DOI: 10.1186/s12967-017-1208-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
57 Tobari M, Hashimoto E. Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. Gut Liver 2020;14:537-45. [PMID: 31887811 DOI: 10.5009/gnl19236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
58 Thorp A, Stine JG. Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep 2020;19:402-11. [PMID: 33767944 DOI: 10.1007/s11901-020-00543-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
59 Xavier SA, Monteiro SO, Arieira CM, Castro FD, Magalhães JT, Leite SM, Marinho CM, Cotter JB. US-FLI score - Is it possible to predict the steatosis grade with an ultrasonographic score? Mol Genet Metab 2021;132:204-9. [PMID: 33558081 DOI: 10.1016/j.ymgme.2021.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Katsagoni CN, Papatheodoridis GV, Papageorgiou MV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, Fragopoulou E, Kontogianni MD. A "healthy diet-optimal sleep" lifestyle pattern is inversely associated with liver stiffness and insulin resistance in patients with nonalcoholic fatty liver disease. Appl Physiol Nutr Metab 2017;42:250-6. [PMID: 28133993 DOI: 10.1139/apnm-2016-0492] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
61 Lesmana CRA, Pakasi LS, Sudoyo AW, Krisnuhoni E, Lesmana LA. The Clinical Significance of Colon Polyp Pathology in Nonalcoholic Fatty Liver Disease (NAFLD) and Its Impact on Screening Colonoscopy in Daily Practice. Can J Gastroenterol Hepatol 2020;2020:6676294. [PMID: 33376713 DOI: 10.1155/2020/6676294] [Reference Citation Analysis]
62 Piñero F, Pages J, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Ameigeiras B, D'Amico C, Gaite L, Bermúdez C, Cobos M, Rosales C, Romero G, McCormack L, Reggiardo V, Colombato L, Gadano A, Silva M. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. World J Hepatol 2018;10:41-50. [PMID: 29399277 DOI: 10.4254/wjh.v10.i1.41] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
63 Gummesson A, Strömberg U, Schmidt C, Kullberg J, Angerås O, Lindgren S, Hjelmgren O, Torén K, Rosengren A, Fagerberg B, Brandberg J, Bergström G. Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: A cross-sectional, population-based study in middle-aged subjects. PLoS One 2018;13:e0202666. [PMID: 30133541 DOI: 10.1371/journal.pone.0202666] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
64 Ke MY, Xu T, Fang Y, Ye YP, Li ZJ, Ren FG, Lu SY, Zhang XF, Wu RQ, Lv Y, Dong J. Liver fibrosis promotes immune escape in hepatocellular carcinoma via GOLM1-mediated PD-L1 upregulation. Cancer Lett 2021;513:14-25. [PMID: 33992711 DOI: 10.1016/j.canlet.2021.05.007] [Reference Citation Analysis]
65 Ismaiel A, Dumitraşcu DL. Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review. Front Med (Lausanne) 2019;6:202. [PMID: 31616668 DOI: 10.3389/fmed.2019.00202] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 18.5] [Reference Citation Analysis]
66 Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, Asaad I, Lawitz E, Poordad F, Kowdley KV, Alkhouri N. Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. World J Hepatol 2019;11:710-8. [PMID: 31749901 DOI: 10.4254/wjh.v11.i10.710] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
67 Zelber-Sagi S, Bord S, Dror-Lavi G, Smith ML, Towne SD, Buch A, Webb M, Yeshua H, Nimer A, Shibolet O. Role of illness perception and self-efficacy in lifestyle modification among non-alcoholic fatty liver disease patients. World J Gastroenterol. 2017;23:1881-1890. [PMID: 28348495 DOI: 10.3748/wjg.v23.i10.1881] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 22] [Article Influence: 7.5] [Reference Citation Analysis]
68 Jarvis H, Craig D, Barker R, Spiers G, Stow D, Anstee QM, Hanratty B. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. PLoS Med. 2020;17:e1003100. [PMID: 32353039 DOI: 10.1371/journal.pmed.1003100] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 26.0] [Reference Citation Analysis]
69 Caballeria L, Augustin S, Broquetas T, Morillas RM, Vergara M, Virolés S, Hernández MR, Serra I, Goday A, Vila L, Siso-Almirall A, Solans R, Fernández-Real JM, Carrión JA, Graupera I, Ginès P. Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. Med Clin (Barc) 2019;153:169-77. [PMID: 31178295 DOI: 10.1016/j.medcli.2019.01.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
70 Koyama N, Yamazaki T, Kanetsuki Y, Hirota J, Asai T, Mitsumoto Y, Mizuno M, Shima T, Kanbara Y, Arai S. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma. J Gastroenterol. 2018;53:770-779. [PMID: 29086016 DOI: 10.1007/s00535-017-1398-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
71 Radun R, Trauner M. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. Semin Liver Dis 2021. [PMID: 34289507 DOI: 10.1055/s-0041-1731707] [Reference Citation Analysis]
72 Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018;68:335-352. [PMID: 29122390 DOI: 10.1016/j.jhep.2017.09.021] [Cited by in Crossref: 224] [Cited by in F6Publishing: 197] [Article Influence: 56.0] [Reference Citation Analysis]
73 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Reference Citation Analysis]
74 Sargeant JA, Gray LJ, Bodicoat DH, Willis SA, Stensel DJ, Nimmo MA, Aithal GP, King JA. The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis: Exercise, intrahepatic triglyceride and hepatic insulin sensitivity. Obesity Reviews 2018;19:1446-59. [DOI: 10.1111/obr.12719] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
75 Qiu T, Ling W, Li J, Lu Q, Lu C, Li X, Zhu C, Luo Y. Can ultrasound elastography identify mass-like focal fatty change (FFC) from liver mass? Medicine (Baltimore). 2017;96:e8088. [PMID: 28953628 DOI: 10.1097/md.0000000000008088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
76 Fujii H, Fukumoto S, Enomoto M, Uchida-Kobayashi S, Kimura T, Tamori A, Nadatani Y, Takashima S, Nishimoto N, Kawada N. The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. Sci Rep 2021;11:13844. [PMID: 34226630 DOI: 10.1038/s41598-021-93435-x] [Reference Citation Analysis]
77 Ciećko-Michalska I, Szczepanek M, Tobiasz-Adamczyk B, Mach T. Non-alcoholic fatty liver disease in Poland: how and at what stage is diagnosed, and how is treated. A survey study. Prz Gastroenterol 2019;14:173-7. [PMID: 31649787 DOI: 10.5114/pg.2019.88165] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Ilan Y. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment. Ann Gastroenterol 2018;31:296-304. [PMID: 29720855 DOI: 10.20524/aog.2018.0248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
79 Lee CH, Fu Y, Yang SJ, Chi CC. Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis. Nutrients 2020;12:E2769. [PMID: 32932796 DOI: 10.3390/nu12092769] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
80 Chun HS, Kim MN, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Kim SU. Risk stratification using sarcopenia status among subjects with metabolic dysfunction-associated fatty liver disease. J Cachexia Sarcopenia Muscle 2021. [PMID: 34337887 DOI: 10.1002/jcsm.12754] [Reference Citation Analysis]
81 Ruiz de Morales JMG, Puig L, Daudén E, Cañete JD, Pablos JL, Martín AO, Juanatey CG, Adán A, Montalbán X, Borruel N, Ortí G, Holgado-martín E, García-vidal C, Vizcaya-morales C, Martín-vázquez V, González-gay MÁ. Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews 2020;19:102429. [DOI: 10.1016/j.autrev.2019.102429] [Cited by in Crossref: 57] [Cited by in F6Publishing: 42] [Article Influence: 57.0] [Reference Citation Analysis]
82 Nascimbeni F, Pellegrini E, Lugari S, Mondelli A, Bursi S, Onfiani G, Carubbi F, Lonardo A. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. Atherosclerosis 2019;284:66-74. [DOI: 10.1016/j.atherosclerosis.2019.02.028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 15.0] [Reference Citation Analysis]
83 Mori S, Arima N, Ito M, Fujiyama S, Kamo Y, Ueki Y. Non-alcoholic steatohepatitis-like pattern in liver biopsy of rheumatoid arthritis patients with persistent transaminitis during low-dose methotrexate treatment. PLoS One 2018;13:e0203084. [PMID: 30142184 DOI: 10.1371/journal.pone.0203084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
84 Mantovani A, Dalbeni A. Treatments for NAFLD: State of Art. Int J Mol Sci 2021;22:2350. [PMID: 33652942 DOI: 10.3390/ijms22052350] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
85 Altamirano J, Qi Q, Choudhry S, Abdallah M, Singal AK, Humar A, Bataller R, Borhani AA, Duarte-Rojo A. Non-invasive diagnosis: non-alcoholic fatty liver disease and alcoholic liver disease. Transl Gastroenterol Hepatol. 2020;5:31. [PMID: 32258535 DOI: 10.21037/tgh.2019.11.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
86 Chen L, Du S, Lu L, Lin Z, Jin W, Hu D, Jiang X, Xin Y, Xuan S. The additive effects of the TM6SF2 E167K and PNPLA3 I148M polymorphisms on lipid metabolism. Oncotarget 2017;8:74209-16. [PMID: 29088779 DOI: 10.18632/oncotarget.18474] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
87 Beckmann S, Drent G, Ruppar T, Nikolić N, De Geest S. Body Weight Parameters are Related to Morbidity and Mortality After Liver Transplantation: A Systematic Review and Meta-analysis. Transplantation 2019;103:2287-303. [PMID: 31283679 DOI: 10.1097/TP.0000000000002811] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
88 Milaciu MV, Vesa ȘC, Bocșan IC, Ciumărnean L, Sâmpelean D, Negrean V, Pop RM, Matei DM, Pașca S, Răchișan AL, Buzoianu AD, Acalovschi M. Paraoxonase-1 Serum Concentration and PON1 Gene Polymorphisms: Relationship with Non-Alcoholic Fatty Liver Disease. J Clin Med 2019;8:E2200. [PMID: 31847187 DOI: 10.3390/jcm8122200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
89 Mazzotti A, Caletti MT, Marchignoli F, Forlani G, Marchesini G. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? Dig Liver Dis 2017;49:235-40. [PMID: 28089623 DOI: 10.1016/j.dld.2016.12.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
90 Saitta C, Pollicino T, Raimondo G. Obesity and liver cancer. Ann Hepatol 2019;18:810-5. [PMID: 31543467 DOI: 10.1016/j.aohep.2019.07.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
91 Lee HH, Cho Y, Choi YJ, Huh BW, Lee BW, Kang ES, Park SW, Cha BS, Lee EJ, Lee YH, Huh KB. Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study. Cardiovasc Diabetol 2020;19:81. [PMID: 32534588 DOI: 10.1186/s12933-020-01064-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
92 Galaski J, Weiler-Normann C, Schakat M, Zachou K, Muratori P, Lampalzer S, Haag F, Schramm C, Lenzi M, Dalekos GN, Lohse AW. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. J Hepatol 2021;74:312-20. [PMID: 32730794 DOI: 10.1016/j.jhep.2020.07.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
93 Foschi FG, Domenicali M, Giacomoni P, Dall'Aglio AC, Conti F, Borghi A, Bevilacqua V, Napoli L, Mirici F, Cucchetti A, Ercolani G, Gardini AC, Bellentani S, Gastaldelli A, Giuffrè M, Tiribelli C, Bedogni G; Bagnacavallo Study Group. Is there an association between commonly employed biomarkers of liver fibrosis and liver stiffness in the general population? Ann Hepatol 2020;19:380-7. [PMID: 32451205 DOI: 10.1016/j.aohep.2020.04.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
94 Luukkonen PK, Qadri S, Lehtimäki TE, Juuti A, Sammalkorpi H, Penttilä AK, Hakkarainen A, Orho-Melander M, Arola J, Yki-Järvinen H. The PNPLA3-I148M Variant Confers an Antiatherogenic Lipid Profile in Insulin-resistant Patients. J Clin Endocrinol Metab 2021;106:e300-15. [PMID: 33064150 DOI: 10.1210/clinem/dgaa729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
95 Klisić A, Kavarić N, Abenavoli L, Stanišić V, Spasojević-Kalimanovska V, Kotur-Stevuljević J, Ninić A. Is endocan a novel potential biomarker of liver steatosis and fibrosis? J Med Biochem 2020;39:363-71. [PMID: 33269025 DOI: 10.2478/jomb-2019-0042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
96 Noureddin M, Wong MM, Todo T, Lu SC, Sanyal AJ, Mena EA. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World J Gastroenterol. 2018;24:1269-1277. [PMID: 29568207 DOI: 10.3748/wjg.v24.i11.1269] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
97 Colombo M. EASL clinical practice guidelines for the management of occupational liver diseases. Liver Int 2020;40 Suppl 1:136-41. [PMID: 32077606 DOI: 10.1111/liv.14349] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Moore MP, Cunningham RP, Dashek RJ, Mucinski JM, Rector RS. A Fad too Far? Dietary Strategies for the Prevention and Treatment of NAFLD. Obesity (Silver Spring) 2020;28:1843-52. [PMID: 32893456 DOI: 10.1002/oby.22964] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
99 Lee SJ, Kim SU. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2019;13:523-30. [PMID: 31018719 DOI: 10.1080/17474124.2019.1608820] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
100 Ratziu V. Non-pharmacological interventions in non-alcoholic fatty liver disease patients. Liver Int 2017;37 Suppl 1:90-6. [PMID: 28052636 DOI: 10.1111/liv.13311] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
101 Li H, Gu Y, Wu X, Rayamajhi S, Bian S, Zhang Q, Meng G, Liu L, Wu H, Zhang S, Wang Y, Zhang T, Wang X, Thapa A, Sun S, Wang X, Jia Q, Song K, Niu K. Association between consumption of edible seaweeds and newly diagnosed non-alcohol fatty liver disease: The TCLSIH Cohort Study. Liver Int 2021;41:311-20. [PMID: 32885579 DOI: 10.1111/liv.14655] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
102 Trivedi HD, Suri J, Oh D, Schwartz J, Goyes D, Idriss R, Curry MP, Lai M. The presence of diabetes impacts liver fibrosis and steatosis by transient elastography in a primary care population. Ann Hepatol 2021;24:100336. [PMID: 33647502 DOI: 10.1016/j.aohep.2021.100336] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Wu J, Zhang R, Shen F, Yang R, Zhou D, Cao H, Chen G, Pan Q, Fan J. Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH). Med Sci Monit 2018;24:6946-67. [PMID: 30270343 DOI: 10.12659/MSM.909747] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
104 Doulberis M, Polyzos SA, Papaefthymiou A, Katsinelos P, Kiosses C, Kountouras J. Treatment of nonalcoholic fatty liver disease: from adult trials to perspectives in the management of children and adolescents. Expert Opin Pharmacother 2020;21:247-51. [PMID: 31893958 DOI: 10.1080/14656566.2019.1702967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
105 Sandra S, Lesmana CRA, Purnamasari D, Kurniawan J, Gani RA. Hyperuricemia as an independent risk factor for non-alcoholic fatty liver disease (NAFLD) progression evaluated using controlled attenuation parameter-transient elastography: Lesson learnt from tertiary referral center. Diabetes Metab Syndr 2019;13:424-8. [PMID: 30641737 DOI: 10.1016/j.dsx.2018.10.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
106 Singh A, Le P, Lopez R, Alkhouri N. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients. Hepatol Int 2018;12:37-43. [PMID: 29318450 DOI: 10.1007/s12072-017-9840-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
107 Ivancovsky-Wajcman D, Fliss-Isakov N, Salomone F, Webb M, Shibolet O, Kariv R, Zelber-Sagi S. Dietary vitamin E and C intake is inversely associated with the severity of nonalcoholic fatty liver disease. Dig Liver Dis 2019;51:1698-705. [PMID: 31281067 DOI: 10.1016/j.dld.2019.06.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
108 Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis. Diabetes Metab J. 2019;43:31-45. [PMID: 30793550 DOI: 10.4093/dmj.2019.0011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 40.0] [Reference Citation Analysis]
109 Crossan C, Majumdar A, Srivastava A, Thorburn D, Rosenberg W, Pinzani M, Longworth L, Tsochatzis EA. Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. Liver Int. 2019;39:2052-2060. [PMID: 31332938 DOI: 10.1111/liv.14198] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
110 Baratta F, Pastori D, Bartimoccia S, Cammisotto V, Cocomello N, Colantoni A, Nocella C, Carnevale R, Ferro D, Angelico F, Violi F, Del Ben M. Poor Adherence to Mediterranean Diet and Serum Lipopolysaccharide are Associated with Oxidative Stress in Patients with Non-Alcoholic Fatty Liver Disease. Nutrients 2020;12:E1732. [PMID: 32531941 DOI: 10.3390/nu12061732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
111 Alswat KA, Fallatah HI, Al-Judaibi B, Elsiesy HA, Al-Hamoudi WK, Qutub AN, Alturaify N, Al-Osaimi A. Position statement on the diagnosis and management of non-alcoholic fatty liver disease. Saudi Med J 2019;40:531-40. [PMID: 31219486 DOI: 10.15537/smj.2019.6.23980] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
112 Kang SH, Lee HW, Yoo JJ, Cho Y, Kim SU, Lee TH, Jang BK, Kim SG, Ahn SB, Kim H, Jun DW, Choi JI, Song DS, Kim W, Jeong SW, Kim MY, Koh H, Jeong S, Lee JW, Cho YK; Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:363-401. [PMID: 34154309 DOI: 10.3350/cmh.2021.0178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Mitrovic M, Sistilli G, Horakova O, Rossmeisl M. Omega-3 phospholipids and obesity-associated NAFLD: Potential mechanisms and therapeutic perspectives. Eur J Clin Invest 2021;:e13650. [PMID: 34291454 DOI: 10.1111/eci.13650] [Reference Citation Analysis]
114 Kasper P, Martin A, Lang S, Demir M, Steffen HM. Hypertension in NAFLD: An uncontrolled burden. J Hepatol 2021;74:1258-60. [PMID: 33485968 DOI: 10.1016/j.jhep.2021.01.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
115 Sarabhai T, Kahl S, Szendroedi J, Markgraf DF, Zaharia OP, Barosa C, Herder C, Wickrath F, Bobrov P, Hwang JH, Jones JG, Roden M. Monounsaturated fat rapidly induces hepatic gluconeogenesis and whole-body insulin resistance. JCI Insight 2020;5:134520. [PMID: 32434996 DOI: 10.1172/jci.insight.134520] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
116 Yen YH, Lin MT, Kuo FY, Chang KC, Tsai MC, Tseng PL, Wu CK, Lin JT, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients. Liver Int 2018;38:1064-73. [PMID: 29164767 DOI: 10.1111/liv.13633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
117 Principi M, Iannone A, Losurdo G, Mangia M, Shahini E, Albano F, Rizzi SF, La Fortezza RF, Lovero R, Contaldo A, Barone M, Leandro G, Ierardi E, Di Leo A. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors. Inflamm Bowel Dis. 2018;24:1589-1596. [PMID: 29688336 DOI: 10.1093/ibd/izy051] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
118 Kazankov K, Alisi A, Møller HJ, De Vito R, Rittig S, Mahler B, Nobili V, Grønbæk H. Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 2018;67:635-42. [PMID: 30074574 DOI: 10.1097/MPG.0000000000002111] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
119 Ratziu V. Back to Byzance: Querelles byzantines over NASH and fibrosis. Journal of Hepatology 2017;67:1134-6. [DOI: 10.1016/j.jhep.2017.09.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
120 Hagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Grønbaek H, Ismail M, Jepsen P, Kanwal F, Kramer J, Lazarus JV, Long MT, Loomba R, Newsome PN, Rowe IA, Ryu S, Schattenberg JM, Serper M, Sheron N, Simon TG, Tapper EB, Wild S, Wong VW, Yilmaz Y, Zelber-Sagi S, Åberg F. Administrative Coding in Electronic Health Care Record-Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology 2021;74:474-82. [PMID: 33486773 DOI: 10.1002/hep.31726] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
121 Fuse K, Kadota A, Kondo K, Morino K, Fujiyoshi A, Hisamatsu T, Kadowaki S, Miyazawa I, Ugi S, Maegawa H, Miura K, Ueshima H. Liver fat accumulation assessed by computed tomography is an independent risk factor for diabetes mellitus in a population-based study: SESSA (Shiga Epidemiological Study of Subclinical Atherosclerosis). Diabetes Research and Clinical Practice 2020;160:108002. [DOI: 10.1016/j.diabres.2020.108002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Carter A, Brackley SM, Gao J, Mann JP. The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: A rare condition that mimics NAFLD. J Hepatol. 2019;70:142-150. [PMID: 30315827 DOI: 10.1016/j.jhep.2018.09.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
123 Munteanu M, Pais R, Peta V, Deckmyn O, Moussalli J, Ngo Y, Rudler M, Lebray P, Charlotte F, Thibault V, Lucidarme O, Ngo A, Imbert-Bismut F, Housset C, Thabut D, Ratziu V, Poynard T; FibroFrance Group. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Aliment Pharmacol Ther 2018;48:1117-27. [PMID: 30334263 DOI: 10.1111/apt.14990] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
124 Chen X, Li K, Yip R, Perumalswami P, Branch AD, Lewis S, Del Bello D, Becker BJ, Yankelevitz DF, Henschke CI. Hepatic steatosis in participants in a program of low-dose CT screening for lung cancer. Eur J Radiol 2017;94:174-9. [PMID: 28712697 DOI: 10.1016/j.ejrad.2017.06.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
125 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
126 Khoo J, Hsiang JC, Taneja R, Koo SH, Soon GH, Kam CJ, Law NM, Ang TL. Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int. 2019;39:941-949. [PMID: 30721572 DOI: 10.1111/liv.14065] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
127 Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol 2021;36:1497-507. [PMID: 33217052 DOI: 10.1111/jgh.15353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
128 Zusi C, Mantovani A, Olivieri F, Morandi A, Corradi M, Miraglia Del Giudice E, Dauriz M, Valenti L, Byrne CD, Targher G, Maffeis C. Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. Digestive and Liver Disease 2019;51:1586-92. [DOI: 10.1016/j.dld.2019.05.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
129 Lu H, Yuan X, Zhang Y, Han M, Liu S, Han K, Liang P, Cheng J. HCBP6 deficiency exacerbates glucose and lipid metabolism disorders in non-alcoholic fatty liver mice. Biomed Pharmacother 2020;129:110347. [PMID: 32535386 DOI: 10.1016/j.biopha.2020.110347] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
130 van Dalem J, Driessen JHM, Burden AM, Stehouwer CDA, Klungel OH, de Vries F, Brouwers MCGJ. Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. Hepatology 2021. [PMID: 34129693 DOI: 10.1002/hep.32012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Samji NS, Snell PD, Singal AK, Satapathy SK. Racial Disparities in Diagnosis and Prognosis of Nonalcoholic Fatty Liver Disease. Clin Liver Dis (Hoboken) 2020;16:66-72. [PMID: 32922753 DOI: 10.1002/cld.948] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
132 Enomoto H, Aizawa N, Hasegawa K, Ikeda N, Sakai Y, Yoh K, Takata R, Yuri Y, Kishino K, Shimono Y, Ishii N, Takashima T, Nishimura T, Nishikawa H, Iwata Y, Iijima H, Nishiguchi S. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients. Int J Mol Sci 2020;21:E3089. [PMID: 32349377 DOI: 10.3390/ijms21093089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
133 Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol 2018;14:99-114. [DOI: 10.1038/nrendo.2017.173] [Cited by in Crossref: 142] [Cited by in F6Publishing: 109] [Article Influence: 35.5] [Reference Citation Analysis]
134 Liu SY, Wong VW, Wong SK, Wong GL, Lai CM, Lam CC, Shu SS, Chan HL, Ng EK. A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. Sci Rep 2021;11:5416. [PMID: 33686111 DOI: 10.1038/s41598-021-83782-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Lonardo A, Leoni S, Alswat KA, Fouad Y. History of Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E5888. [PMID: 32824337 DOI: 10.3390/ijms21165888] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
136 Akahane T, Akahane M, Namisaki T, Kaji K, Moriya K, Kawaratani H, Takaya H, Sawada Y, Shimozato N, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mitoro A, Yoshiji H. Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. J Clin Med 2020;9:E1635. [PMID: 32481684 DOI: 10.3390/jcm9061635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
137 Bellentani S, Tiribelli C. Is it time to change NAFLD and NASH nomenclature? The Lancet Gastroenterology & Hepatology 2017;2:547-8. [DOI: 10.1016/s2468-1253(17)30146-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
138 Moon S, Chung GE, Joo SK, Park JH, Chang MS, Yoon JW, Koo BK, Kim W. A PNPLA3 Polymorphism Confers Lower Susceptibility to Incident Diabetes Mellitus in Subjects With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00472-9. [PMID: 33905771 DOI: 10.1016/j.cgh.2021.04.038] [Reference Citation Analysis]
139 Cariou B, Byrne CD, Loomba R, Sanyal AJ. Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. Diabetes Obes Metab 2021;23:1069-83. [PMID: 33464677 DOI: 10.1111/dom.14322] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
140 Wehmeyer MH, Zyriax BC, Jagemann B, Roth E, Windler E, Schulze Zur Wiesch J, Lohse AW, Kluwe J. Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. Medicine (Baltimore) 2016;95:e3887. [PMID: 27281105 DOI: 10.1097/MD.0000000000003887] [Cited by in Crossref: 41] [Cited by in F6Publishing: 22] [Article Influence: 10.3] [Reference Citation Analysis]
141 Malnick S, Maor Y. The Interplay between Alcoholic Liver Disease, Obesity, and the Metabolic Syndrome. Visc Med 2020;36:198-205. [PMID: 32775350 DOI: 10.1159/000507233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
142 Guber RD, Takyar V, Kokkinis A, Fox DA, Alao H, Kats I, Bakar D, Remaley AT, Hewitt SM, Kleiner DE, Liu CY, Hadigan C, Fischbeck KH, Rotman Y, Grunseich C. Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy. Neurology 2017;89:2481-90. [PMID: 29142082 DOI: 10.1212/WNL.0000000000004748] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
143 Wang B, Zhao Z, Liu S, Wang S, Chen Y, Xu Y, Xu M, Wang W, Ning G, Li M, Wang T, Bi Y. Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease. Diabetes Res Clin Pract 2021;177:108873. [PMID: 34051282 DOI: 10.1016/j.diabres.2021.108873] [Reference Citation Analysis]
144 Shepherd EL, Karim S, Newsome PN, Lalor PF. Inhibition of vascular adhesion protein-1 modifies hepatic steatosis in vitro and in vivo. World J Hepatol 2020;12:931-48. [PMID: 33312420 DOI: 10.4254/wjh.v12.i11.931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
145 Mantovani A, Dalbeni A. NAFLD, MAFLD and DAFLD. Dig Liver Dis 2020;52:1519-20. [PMID: 33012657 DOI: 10.1016/j.dld.2020.09.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
146 Lv S, Jiang S, Liu S, Dong Q, Xin Y, Xuan S. Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol 2018;6:217-21. [PMID: 29951367 DOI: 10.14218/JCTH.2018.00021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
147 Deng Y, Zhao Q, Gong R. Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017-2018. Diabetes Metab Syndr Obes 2021;14:1751-61. [PMID: 33911888 DOI: 10.2147/DMSO.S292926] [Reference Citation Analysis]
148 Tada T, Kumada T, Toyoda H, Kobayashi N, Sone Y, Oguri T, Kamiyama N. Utility of Attenuation Coefficient Measurement Using an Ultrasound-Guided Attenuation Parameter for Evaluation of Hepatic Steatosis: Comparison With MRI-Determined Proton Density Fat Fraction. AJR Am J Roentgenol. 2019;212:332-341. [PMID: 30476453 DOI: 10.2214/ajr.18.20123] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
149 Wang Y, Zhou W, Wu C, Zhang Y, Lin T, Sun Y, Liu W, Tao T. Circulating osteopontin and its association with liver fat content in non-obese women with polycystic ovary syndrome: a case control study. Reprod Biol Endocrinol 2018;16:31. [PMID: 29587769 DOI: 10.1186/s12958-018-0331-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
150 Bugianesi E, Rosso C, Cortez-Pinto H. How to diagnose NAFLD in 2016. J Hepatol. 2016;65:643-644. [PMID: 27401791 DOI: 10.1016/j.jhep.2016.05.038] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
151 Petta S, Wong VW, Cammà C, Hiriart J, Wong GL, Marra F, Vergniol J, Chan AW, Di Marco V, Merrouche W, Chan HL, Barbara M, Le-bail B, Arena U, Craxì A, de Ledinghen V. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values: STEATOHEPATITIS/METABOLIC LIVER DISEASE. Hepatology 2017;65:1145-55. [DOI: 10.1002/hep.28843] [Cited by in Crossref: 126] [Cited by in F6Publishing: 101] [Article Influence: 25.2] [Reference Citation Analysis]
152 Pu K, Wang Y, Bai S, Wei H, Zhou Y, Fan J, Qiao L. Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis. BMC Gastroenterol 2019;19:51. [PMID: 30961539 DOI: 10.1186/s12876-019-0961-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 24.0] [Reference Citation Analysis]
153 Geh D, Anstee QM, Reeves HL. NAFLD-Associated HCC: Progress and Opportunities. J Hepatocell Carcinoma 2021;8:223-39. [PMID: 33854987 DOI: 10.2147/JHC.S272213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
154 Marjot T, Sbardella E, Moolla A, Hazlehurst JM, Tan GD, Ainsworth M, Cobbold JFL, Tomlinson JW. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital. Diabet Med 2018;35:89-98. [DOI: 10.1111/dme.13540] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
155 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol. 2016;22:9674-9693. [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 57] [Article Influence: 16.3] [Reference Citation Analysis]
156 D'Errico A, Riefolo M, Serenari M, De Pace V, Santandrea G, Monica M, de Cillia C, Ravaioli M, Cescon M, Vasuri F; Pathology Unit for organ safety of the S. Orsola-Malpighi Hospital Bologna: Alberto Bagni Giacomo Caprara Benedetta Fabbrizio Deborah Malvi Maria Giulia Pirini Maria Lucia Tardio. The histological assessment of liver fibrosis in grafts from extended criteria donors predicts the outcome after liver transplantation: A retrospective study. Dig Liver Dis 2020;52:185-9. [PMID: 31155489 DOI: 10.1016/j.dld.2019.05.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Honda Y, Ozaki A, Iwaki M, Kobayashi T, Nogami A, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Yoneda M, Saito S, Nagashima Y, Nakajima A. Protective effect of SGL5213, a potent intestinal sodium-glucose cotransporter 1 inhibitor, in nonalcoholic fatty liver disease in mice. J Pharmacol Sci 2021;147:176-83. [PMID: 34384565 DOI: 10.1016/j.jphs.2021.07.002] [Reference Citation Analysis]
158 He K, Li Y, Guo X, Zhong L, Tang S. Food groups and the likelihood of non-alcoholic fatty liver disease: a systematic review and meta-analysis. Br J Nutr 2020;:1-13. [PMID: 32138796 DOI: 10.1017/S0007114520000914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 12.0] [Reference Citation Analysis]
159 Nass KJ, van den Berg EH, Faber KN, Schreuder TC, Blokzijl H, Dullaart RP. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study. Metabolism 2017;72:37-46. [DOI: 10.1016/j.metabol.2017.04.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
160 Chang PE, Goh GBB, Leow WQ, Shen L, Lim KH, Tan CK. Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease. PLoS One 2018;13:e0199166. [PMID: 29924825 DOI: 10.1371/journal.pone.0199166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
161 Ratziu V. The painful reality of end-stage liver disease in NASH. Lancet Gastroenterol Hepatol 2018;3:8-10. [PMID: 29254618 DOI: 10.1016/S2468-1253(17)30365-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
162 Damiani G, Leone S, Fajgenbaum K, Bragazzi NL, Pacifico A, Conic RR, Pigatto PD, Maiorana C, Poli P, Berti E, Pace MC, Malagoli P, Bettoli V, Fiore M. Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: A multi-center retrospective analysis. World J Hepatol 2019;11:391-401. [PMID: 31114643 DOI: 10.4254/wjh.v11.i4.391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
163 Wong VW, Wong GL, Woo J, Abrigo JM, Chan CK, Shu SS, Leung JK, Chim AM, Kong AP, Lui GC, Chan HL, Chu WC. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. Clin Gastroenterol Hepatol 2021;19:2161-2171.e5. [PMID: 33137486 DOI: 10.1016/j.cgh.2020.10.046] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
164 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
165 Jang EH, Chang Y, Ryu S, Kim S, Kim YH, Sung KC, Cho YK, Lee SJ, Shin H, Wild SH, Byrne CD. Cardiovascular Health Metrics in the Development and Regression of Nonalcoholic Fatty Liver Disease: A Cohort Study. J Clin Med 2019;8:E610. [PMID: 31064105 DOI: 10.3390/jcm8050610] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
166 Jonas W, Schürmann A. Genetic and epigenetic factors determining NAFLD risk. Mol Metab 2021;50:101111. [PMID: 33160101 DOI: 10.1016/j.molmet.2020.101111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
167 Feksa DL, Coelho RP, Aparecida da Costa Güllich A, Dal Ponte ES, da Costa Escobar Piccoli J, Manfredini V. Extract of Citrus maxima (pummelo) leaves improve hepatoprotective activity in Wistar rats submitted to the induction of non-alcoholic hepatic steatosis. Biomedicine & Pharmacotherapy 2018;98:338-46. [DOI: 10.1016/j.biopha.2017.12.070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
168 Suárez M, Boqué N, Del Bas JM, Mayneris-Perxachs J, Arola L, Caimari A. Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease. Nutrients 2017;9:E1052. [PMID: 28937599 DOI: 10.3390/nu9101052] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
169 Ducancelle A, Leroy V, Vergniol J, Sturm N, Le Bail B, Zarski JP, Nguyen Khac E, Salmon D, de Ledinghen V, Calès P. A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases. Journal of Clinical Gastroenterology 2017;51:639-49. [DOI: 10.1097/mcg.0000000000000788] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
170 Abenavoli L, Milic N, Di Renzo L, Preveden T, Medić-Stojanoska M, De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J Gastroenterol 2016;22:7006-16. [PMID: 27610012 DOI: 10.3748/wjg.v22.i31.7006] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 86] [Article Influence: 23.8] [Reference Citation Analysis]
171 Lian J, Fu J. Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes: A Network Meta-Analysis. Front Endocrinol (Lausanne) 2021;12:649018. [PMID: 33841337 DOI: 10.3389/fendo.2021.649018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Palmer M, Jennings L, Silberg DG, Bliss C, Martin P. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis. BMC Pharmacol Toxicol 2018;19:10. [PMID: 29548345 DOI: 10.1186/s40360-018-0200-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
173 Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab 2021. [PMID: 34324263 DOI: 10.1111/dom.14484] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Rey E, Meléndez-Rodríguez F, Marañón P, Gil-Valle M, Carrasco AG, Torres-Capelli M, Chávez S, Del Pozo-Maroto E, Rodríguez de Cía J, Aragonés J, García-Monzón C, González-Rodríguez Á. Hypoxia-inducible factor 2α drives hepatosteatosis through the fatty acid translocase CD36. Liver Int 2020;40:2553-67. [PMID: 32432822 DOI: 10.1111/liv.14519] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
175 Nirengi S, Fujibayashi M, Furuno S, Uchibe A, Kawase Y, Sukino S, Kawaguchi Y, Minato S, Kotani K, Sakane N. Nonalcoholic Fatty Liver Disease in University Rugby Football Players. Front Endocrinol (Lausanne) 2018;9:341. [PMID: 29973915 DOI: 10.3389/fendo.2018.00341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
176 Albracht-Schulte K, Gonzalez S, Jackson A, Wilson S, Ramalingam L, Kalupahana NS, Moustaid-Moussa N. Eicosapentaenoic Acid Improves Hepatic Metabolism and Reduces Inflammation Independent of Obesity in High-Fat-Fed Mice and in HepG2 Cells. Nutrients 2019;11:E599. [PMID: 30871035 DOI: 10.3390/nu11030599] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
177 Leow WQ, Bedossa P, Liu F, Wei L, Lim KH, Wan WK, Ren Y, Chang JP, Tan CK, Wee A, Goh GB. An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. Diagnostics (Basel) 2020;10:E643. [PMID: 32872090 DOI: 10.3390/diagnostics10090643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
178 Weiskirchen R, Tacke F. The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis. Curr Hepatology Rep 2018;17:324-35. [DOI: 10.1007/s11901-018-0421-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
179 Ando Y, Jou JH. Nonalcoholic Fatty Liver Disease and Recent Guideline Updates.Clin Liver Dis (Hoboken). 2021;17:23-28. [PMID: 33552482 DOI: 10.1002/cld.1045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
180 Janac J, Zeljkovic A, Jelic-Ivanovic Z, Dimitrijevic-Sreckovic V, Miljkovic M, Stefanovic A, Munjas J, Vekic J, Kotur-Stevuljevic J, Spasojević-Kalimanovska V. The association between lecithin-cholesterol acyltransferase activity and fatty liver index. Ann Clin Biochem 2019;56:583-92. [PMID: 31084205 DOI: 10.1177/0004563219853596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
181 Netanel C, Goitein D, Rubin M, Kleinbaum Y, Katsherginsky S, Hermon H, Tsaraf K, Tachlytski I, Herman A, Safran M, Ben-Ari Z. The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests. Am J Surg 2021;222:214-9. [PMID: 33309037 DOI: 10.1016/j.amjsurg.2020.11.045] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
182 Lang S, Martin A, Zhang X, Farowski F, Wisplinghoff H, J G T Vehreschild M, Krawczyk M, Nowag A, Kretzschmar A, Scholz C, Kasper P, Roderburg C, Mohr R, Lammert F, Tacke F, Schnabl B, Goeser T, Steffen HM, Demir M. Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. Liver Int 2021;41:1576-91. [PMID: 33896117 DOI: 10.1111/liv.14899] [Reference Citation Analysis]
183 Proietti M, Marzona I, Vannini T, Colacioppo P, Tettamanti M, Foresta A, Fortino I, Merlino L, Lip GYH, Roncaglioni MC. Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study. Eur Heart J Cardiovasc Pharmacother 2021;7:f84-92. [PMID: 32129845 DOI: 10.1093/ehjcvp/pvaa015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Luo Z, Hu H, Liu S, Zhang Z, Li Y, Zhou L. Comprehensive analysis of the translatome reveals the relationship between the translational and transcriptional control in high fat diet-induced liver steatosis. RNA Biol 2021;18:863-74. [PMID: 32967529 DOI: 10.1080/15476286.2020.1827193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Tiao MM, Lin YJ, Yu HR, Sheen JM, Lin IC, Lai YJ, Tain YL, Huang LT, Tsai CC. Resveratrol ameliorates maternal and post-weaning high-fat diet-induced nonalcoholic fatty liver disease via renin-angiotensin system. Lipids Health Dis 2018;17:178. [PMID: 30055626 DOI: 10.1186/s12944-018-0824-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
186 Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver disease. Expert Review of Gastroenterology & Hepatology 2018;12:331-9. [DOI: 10.1080/17474124.2018.1439379] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
187 Verhelst X, Dias AM, Colombel JF, Vermeire S, Van Vlierberghe H, Callewaert N, Pinho SS. Protein Glycosylation as a Diagnostic and Prognostic Marker of Chronic Inflammatory Gastrointestinal and Liver Diseases. Gastroenterology 2020;158:95-110. [PMID: 31626754 DOI: 10.1053/j.gastro.2019.08.060] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
188 Strebinger G, Müller E, Feldman A, Aigner E. Lysosomal acid lipase deficiency - early diagnosis is the key. Hepat Med 2019;11:79-88. [PMID: 31213932 DOI: 10.2147/HMER.S201630] [Cited by in Crossref: 12] [Article Influence: 6.0] [Reference Citation Analysis]
189 Zuo G, Xuan L, Xin Z, Xu Y, Lu J, Chen Y, Dai M, Zhang D, Wang W, Li M, Bi Y, Ning G, Xu M. New Nonalcoholic Fatty Liver Disease and Fibrosis Progression Associate With the Risk of Incident Chronic Kidney Disease. J Clin Endocrinol Metab 2021:dgab425. [PMID: 34125886 DOI: 10.1210/clinem/dgab425] [Reference Citation Analysis]
190 Al-Qarni R, Iqbal M, Al-Otaibi M, Al-Saif F, Alfadda AA, Alkhalidi H, Bamehriz F, Hassanain M. Validating candidate biomarkers for different stages of non-alcoholic fatty liver disease. Medicine (Baltimore) 2020;99:e21463. [PMID: 32898995 DOI: 10.1097/MD.0000000000021463] [Reference Citation Analysis]
191 Wijarnpreecha K, Kim D, Raymond P, Scribani M, Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. Eur J Gastroenterol Hepatol 2019;31:1121-8. [PMID: 30888971 DOI: 10.1097/MEG.0000000000001397] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
192 Sohn W, Kwon HJ, Chang Y, Ryu S, Cho YK. Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00706-0. [PMID: 34224877 DOI: 10.1016/j.cgh.2021.06.042] [Reference Citation Analysis]
193 Önnerhag K, Hartman H, Nilsson PM, Lindgren S. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scandinavian Journal of Gastroenterology 2019;54:328-34. [DOI: 10.1080/00365521.2019.1583366] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
194 Saokaew S, Kanchanasurakit S, Thawichai K, Duangprom P, Wannasri M, Khankham S, Kositamongkol C, Chaiyakunapruk N, Phisalprapa P. Association of non-alcoholic fatty liver disease and all-cause mortality in hospitalized cardiovascular disease patients: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24557. [PMID: 33592910 DOI: 10.1097/MD.0000000000024557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
195 Khoo S, Wong VW, Goh GB, Fan J, Chan WK, Seto WK, Chow WC. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2020;35:320-5. [PMID: 31336392 DOI: 10.1111/jgh.14794] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
196 Luo J, Sun P, Wang Y, Chen Y, Niu Y, Ding Y, Xu N, Zhang Y, Xie W. Dapagliflozin attenuates steatosis in livers of high-fat diet-induced mice and oleic acid-treated L02 cells via regulating AMPK/mTOR pathway. Eur J Pharmacol 2021;907:174304. [PMID: 34224699 DOI: 10.1016/j.ejphar.2021.174304] [Reference Citation Analysis]
197 Miller EF. Nutrition Management Strategies for Nonalcoholic Fatty Liver Disease: Treatment and Prevention. Clin Liver Dis (Hoboken) 2020;15:144-8. [PMID: 32395240 DOI: 10.1002/cld.918] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
198 Shouhed D, Steggerda J, Burch M, Noureddin M. The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2017;11:797-811. [PMID: 28712339 DOI: 10.1080/17474124.2017.1355731] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
199 Ganguli S, DeLeeuw P, Satapathy SK. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis. Hepat Med 2019;11:159-78. [PMID: 31814783 DOI: 10.2147/HMER.S188991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
200 Staufer K, Dengler M, Huber H, Marculescu R, Stauber R, Lackner C, Dienes HP, Kivaranovic D, Schachner C, Zeitlinger M, Wulkersdorfer B, Rauch P, Prager G, Trauner M, Mikulits W. The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death Dis. 2017;8:e3135. [PMID: 29072690 DOI: 10.1038/cddis.2017.554] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
201 Grefhorst A, van de Peppel IP, Larsen LE, Jonker JW, Holleboom AG. The Role of Lipophagy in the Development and Treatment of Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2020;11:601627. [PMID: 33597924 DOI: 10.3389/fendo.2020.601627] [Reference Citation Analysis]
202 Ayonrinde OT, Oddy WH, Adams LA, Mori TA, Beilin LJ, de Klerk N, Olynyk JK. Infant nutrition and maternal obesity influence the risk of non-alcoholic fatty liver disease in adolescents. Journal of Hepatology 2017;67:568-76. [DOI: 10.1016/j.jhep.2017.03.029] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
203 Pei K, Gui T, Kan D, Feng H, Jin Y, Yang Y, Zhang Q, Du Z, Gai Z, Wu J, Li Y. An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2020;2020:4020249. [PMID: 32733940 DOI: 10.1155/2020/4020249] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
204 Váncsa S, Németh D, Hegyi P, Szakács Z, Hegyi PJ, Pécsi D, Mikó A, Erőss B, Erős A, Pár G. Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease Worsen the Outcome in Acute Pancreatitis: A Systematic Review and Meta-Analysis. J Clin Med 2020;9:E2698. [PMID: 32825458 DOI: 10.3390/jcm9092698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
205 Tenen DG, Chai L, Tan JL. Metabolic alterations and vulnerabilities in hepatocellular carcinoma. Gastroenterol Rep (Oxf) 2021;9:1-13. [PMID: 33747521 DOI: 10.1093/gastro/goaa066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
206 Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver fibrosis assessed by transient elastography is independently associated with albuminuria in the general United States population. Dig Liver Dis 2021;53:866-72. [PMID: 33685807 DOI: 10.1016/j.dld.2021.02.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
207 Charatcharoenwitthaya P, Kuljiratitikal K, Aksornchanya O, Chaiyasoot K, Bandidniyamanon W, Charatcharoenwitthaya N. Moderate-Intensity Aerobic vs Resistance Exercise and Dietary Modification in Patients With Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial. Clin Transl Gastroenterol 2021;12:e00316. [PMID: 33939383 DOI: 10.14309/ctg.0000000000000316] [Reference Citation Analysis]
208 Soto-Angona Ó, Anmella G, Valdés-Florido MJ, De Uribe-Viloria N, Carvalho AF, Penninx BWJH, Berk M. Non-alcoholic fatty liver disease (NAFLD) as a neglected metabolic companion of psychiatric disorders: common pathways and future approaches. BMC Med 2020;18:261. [PMID: 32998725 DOI: 10.1186/s12916-020-01713-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 17.0] [Reference Citation Analysis]
209 Chen LZ, Ding HY, Liu SS, Liu Q, Jiang XJ, Xin YN, Xuan SY. Combining I148M and E167K variants to improve risk prediction for nonalcoholic fatty liver disease in Qingdao Han population, China. Lipids Health Dis 2019;18:45. [PMID: 30738435 DOI: 10.1186/s12944-019-0992-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
210 Cerrito L, Ponziani FR, Garcovich M, Tortora A, Annicchiarico BE, Pompili M, Siciliano M, Gasbarrini A. Regorafenib: a promising treatment for hepatocellular carcinoma. Expert Opin Pharmacother. 2018;19:1941-1948. [PMID: 30345837 DOI: 10.1080/14656566.2018.1534956] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
211 Shiha G, Alswat K, Al Khatry M, Sharara AI, Örmeci N, Waked I, Benazzouz M, Al-Ali F, Hamed AE, Hamoudi W, Attia D, Derbala M, Sharaf-Eldin M, Al-Busafi SA, Zaky S, Bamakhrama K, Ibrahim N, Ajlouni Y, Sabbah M, Salama M, Anushiravani A, Afredj N, Barakat S, Hashim A, Fouad Y, Soliman R. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol 2021;6:57-64. [PMID: 33181119 DOI: 10.1016/S2468-1253(20)30213-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 28.0] [Reference Citation Analysis]
212 Han J, Zhang X, Lau JK, Fu K, Lau HC, Xu W, Chu ES, Lan H, Yu J. Bone marrow-derived macrophage contributes to fibrosing steatohepatitis through activating hepatic stellate cells. J Pathol 2019;248:488-500. [PMID: 30945293 DOI: 10.1002/path.5275] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
213 Gerhardt F, Petroff D, Blank V, Böhlig A, van Bömmel F, Wittekind C, Berg T, Karlas T, Wiegand J. Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). Scand J Gastroenterol 2020;55:706-11. [PMID: 32476514 DOI: 10.1080/00365521.2020.1766554] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 de Gregorio E, Colell A, Morales A, Marí M. Relevance of SIRT1-NF-κB Axis as Therapeutic Target to Ameliorate Inflammation in Liver Disease. Int J Mol Sci 2020;21:E3858. [PMID: 32485811 DOI: 10.3390/ijms21113858] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
215 Hohenester S, Kanitz V, Schiergens T, Einer C, Nagel J, Wimmer R, Reiter FP, Gerbes AL, De Toni EN, Bauer C, Holdt L, Mayr D, Rust C, Schnurr M, Zischka H, Geier A, Denk G. IL-18 but Not IL-1 Signaling Is Pivotal for the Initiation of Liver Injury in Murine Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2020;21:E8602. [PMID: 33202693 DOI: 10.3390/ijms21228602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
216 Zhang S, Wang Y, Wang Z, Wang H, Xue C, Li Q, Guan W, Yuan J. Rotating night shift work and non-alcoholic fatty liver disease among steelworkers in China: a cross-sectional survey. Occup Environ Med 2020;77:333-9. [PMID: 32019846 DOI: 10.1136/oemed-2019-106220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
217 Eslam M, Sanyal AJ, George J. Toward More Accurate Nomenclature for Fatty Liver Diseases. Gastroenterology 2019;157:590-3. [DOI: 10.1053/j.gastro.2019.05.064] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 18.5] [Reference Citation Analysis]
218 Kim G, Lee HC, Choe J, Kim M, Lee MJ, Chang H, Bae IY, Kim H, An J, Shim JH, Kim KM, Lim Y. Association between non-alcoholic fatty liver disease and cancer incidence rate. Journal of Hepatology 2018;68:140-6. [DOI: 10.1016/j.jhep.2017.09.012] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 20.3] [Reference Citation Analysis]
219 Alferink LJM, Erler NS, de Knegt RJ, Janssen HLA, Metselaar HJ, Darwish Murad S, Kiefte-de Jong JC. Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. Eur J Epidemiol 2020;35:1069-85. [PMID: 32323115 DOI: 10.1007/s10654-020-00627-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
220 Jeon D, Son M, Shim J. Dynamics of Serum Retinol and Alpha-Tocopherol Levels According to Non-Alcoholic Fatty Liver Disease Status. Nutrients 2021;13:1720. [PMID: 34069568 DOI: 10.3390/nu13051720] [Reference Citation Analysis]
221 Haldrup D, Heebøll S, Thomsen KL, Andersen KJ, Meier M, Mortensen FV, Nyengaard JR, Hamilton-Dutoit S, Grønbæk H. Preserved liver regeneration capacity after partial hepatectomy in rats with non-alcoholic steatohepatitis. World J Hepatol 2018;10:8-21. [PMID: 29399274 DOI: 10.4254/wjh.v10.i1.8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
222 Reimer KC, Wree A, Roderburg C, Tacke F. New drugs for NAFLD: lessons from basic models to the clinic. Hepatol Int 2020;14:8-23. [PMID: 31802390 DOI: 10.1007/s12072-019-10001-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
223 Liu WY, Eslam M, Zheng KI, Ma HL, Rios RS, Lv MZ, Li G, Tang LJ, Zhu PW, Wang XD, Byrne CD, Targher G, George J, Zheng MH. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:194-202. [PMID: 34007801 DOI: 10.14218/JCTH.2020.00151] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
224 Myers S, Neyroud-Caspar I, Spahr L, Gkouvatsos K, Fournier E, Giostra E, Magini G, Frossard JL, Bascaron ME, Vernaz N, Zampaglione L, Negro F, Goossens N. NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Rep 2021;3:100231. [PMID: 33748726 DOI: 10.1016/j.jhepr.2021.100231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
225 Brennan P, Clare K, George J, Dillon JF. Determining the role for uric acid in non-alcoholic steatohepatitis development and the utility of urate metabolites in diagnosis: An opinion review. World J Gastroenterol 2020;26:1683-90. [PMID: 32351286 DOI: 10.3748/wjg.v26.i15.1683] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
226 Tanajewski L, Harris R, Harman DJ, Aithal GP, Card TR, Gkountouras G, Berdunov V, Guha IN, Elliott RA. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study. BMJ Open. 2017;7:e015659. [PMID: 28679676 DOI: 10.1136/bmjopen-2016-015659] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
227 Lazaridis N, Tsochatzis E. Current and future treatment options in non-alcoholic steatohepatitis (NASH). Expert Review of Gastroenterology & Hepatology 2017;11:357-69. [DOI: 10.1080/17474124.2017.1293523] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
228 Beier JI, Banales JM. Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications. J Hepatol. 2018;68:643-645. [PMID: 29408544 DOI: 10.1016/j.jhep.2018.01.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
229 Yen YH, Kee KM, Chen CH, Hu TH, Lu SN, Wang JH, Hung CH. Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C. PLoS One 2019;14:e0208858. [PMID: 30625158 DOI: 10.1371/journal.pone.0208858] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
230 Karamfilova V, Gateva A, Alexiev A, Zheleva N, Velikova T, Ivanova-Boyanova R, Ivanova R, Cherkezov N, Kamenov Z, Mateva L. The association between retinol-binding protein 4 and prediabetes in obese patients with nonalcoholic fatty liver disease. Arch Physiol Biochem 2019;:1-6. [PMID: 31588816 DOI: 10.1080/13813455.2019.1673429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
231 Anisonyan AV, Sandler YG, Khaimenova TY, Keyan VA, Saliev KG, Sbikina ES, Vinnitskaya EV. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus: issues of the liver fibrosis diagnostics]. Ter Arkh 2020;92:73-8. [PMID: 33346465 DOI: 10.26442/00403660.2020.08.000770] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Asai A, Yokohama K, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K. Association between Administration of Antithrombotics and Intraperitoneal Hemorrhage in Patients Undergoing Percutaneous Interventions for Liver Diseases. J Clin Med 2021;10:2527. [PMID: 34200283 DOI: 10.3390/jcm10112527] [Reference Citation Analysis]
233 Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, Pinter M, Hernández-Gea V, Fritzer-Szekeres M, Steindl-Munda P, Trauner M, Peck-Radosavljevic M, García-Pagán JC, Ferenci P, Reiberger T. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology 2020;71:1023-36. [PMID: 31365764 DOI: 10.1002/hep.30885] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 23.5] [Reference Citation Analysis]
234 Puoti C, Elmo MG, Ceccarelli D, Ditrinco M. Liver steatosis: The new epidemic of the Third Millennium. Benign liver state or silent killer? European Journal of Internal Medicine 2017;46:1-5. [DOI: 10.1016/j.ejim.2017.06.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
235 Vuille-lessard É, Lange N, Riebensahm C, Dufour J, Berzigotti A. Dietary Interventions in Liver Diseases: Focus on MAFLD and Cirrhosis. Curr Hepatology Rep 2021;20:61-76. [DOI: 10.1007/s11901-021-00563-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Lassailly G, Caiazzo R, Ntandja-Wandji LC, Gnemmi V, Baud G, Verkindt H, Ningarhari M, Louvet A, Leteurtre E, Raverdy V, Dharancy S, Pattou F, Mathurin P. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020. [PMID: 32553765 DOI: 10.1053/j.gastro.2020.06.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 50.0] [Reference Citation Analysis]
237 Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology 2020;158:1984-1998.e3. [PMID: 32061596 DOI: 10.1053/j.gastro.2020.01.051] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 29.0] [Reference Citation Analysis]
238 Yao R, Zhu L, Wang J, Liu J, Xue R, Xue L, Liu L, Li C, Zhao H, Cheng J, Huang S, Li Y, Zhao XA, Zhu C, Li M, Huang R, Wu C. Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores. J Clin Lab Anal 2021;35:e23880. [PMID: 34213039 DOI: 10.1002/jcla.23880] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
239 Kim HY, Baik SJ, Lee HA, Lee BK, Lee HS, Kim TH, Yoo K. Relative fat mass at baseline and its early change may be a predictor of incident nonalcoholic fatty liver disease. Sci Rep 2020;10:17491. [PMID: 33060775 DOI: 10.1038/s41598-020-74659-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
240 Xu L, Lu W, Li P, Shen F, Mi Y, Fan J. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B. Digestive and Liver Disease 2017;49:910-7. [DOI: 10.1016/j.dld.2017.03.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
241 Yen Y, Chang K, Tsai M, Tseng P, Lin M, Wu C, Lin J, Hu T, Wang J, Chen C. Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease. Journal of the Formosan Medical Association 2018;117:268-75. [DOI: 10.1016/j.jfma.2017.09.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
242 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
243 Fabrellas N, Carol M, Torrabadella F, de Prada G. Nursing care of patients with chronic liver diseases: Time for action. J Adv Nurs 2018;74:498-500. [DOI: 10.1111/jan.13350] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
244 Mikolasevic I, Filipec-Kanizaj T, Mijic M, Jakopcic I, Milic S, Hrstic I, Sobocan N, Stimac D, Burra P. Nonalcoholic fatty liver disease and liver transplantation - Where do we stand? World J Gastroenterol. 2018;24:1491-1506. [PMID: 29662288 DOI: 10.3748/wjg.v24.i14.1491] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 15.7] [Reference Citation Analysis]
245 Cabrera D, Cabello-Verrugio C, Solís N, San Martín D, Cofré C, Pizarro M, Arab JP, Abrigo J, Campos F, Irigoyen B, Carrasco-Avino G, Bezares K, Riquelme V, Riquelme A, Arrese M, Barrera F. Somatotropic Axis Dysfunction in Non-Alcoholic Fatty Liver Disease: Beneficial Hepatic and Systemic Effects of Hormone Supplementation. Int J Mol Sci 2018;19:E1339. [PMID: 29724029 DOI: 10.3390/ijms19051339] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
246 Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
247 Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Seko Y, Mori K, Kanemasa K, Shimada K, Imai S, Imajo K, Kawaguchi T, Nakajima A, Chayama K, Saibara T, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD). The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study. J Gastroenterol. 2018;53:1216-1224. [PMID: 29744597 DOI: 10.1007/s00535-018-1474-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
248 Mirea AM, Toonen EJM, van den Munckhof I, Munsterman ID, Tjwa ETTL, Jaeger M, Oosting M, Schraa K, Rutten JHW, van der Graaf M, Riksen NP, de Graaf J, Netea MG, Tack CJ, Chavakis T, Joosten LAB. Increased proteinase 3 and neutrophil elastase plasma concentrations are associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes. Mol Med 2019;25:16. [PMID: 31046673 DOI: 10.1186/s10020-019-0084-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
249 Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, De Lorenzo A. Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease. World J Gastroenterol 2017;23:3150-62. [PMID: 28533672 DOI: 10.3748/wjg.v23.i17.3150] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 39] [Article Influence: 16.7] [Reference Citation Analysis]
250 Wang L, Yao M, Liu S, Yang D, Wen X, Ning J, Wang L, Zhou G, Xu Q, Chen X, Zhao J, Lu F. Serum Golgi Protein 73 as a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis. Dis Markers 2020;2020:6036904. [PMID: 32089754 DOI: 10.1155/2020/6036904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
251 Koo BK, Allison MA, Criqui MH, Denenberg JO, Wright CM. The association between liver fat and systemic calcified atherosclerosis. J Vasc Surg 2020;71:204-211.e4. [PMID: 31153702 DOI: 10.1016/j.jvs.2019.03.044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
252 Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circ Res 2020;126:679-704. [PMID: 32105577 DOI: 10.1161/CIRCRESAHA.119.316337] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 30.0] [Reference Citation Analysis]
253 van der Graaff D, Kwanten WJ, Francque SM. The potential role of vascular alterations and subsequent impaired liver blood flow and hepatic hypoxia in the pathophysiology of non-alcoholic steatohepatitis. Med Hypotheses 2019;122:188-97. [PMID: 30593409 DOI: 10.1016/j.mehy.2018.11.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
254 Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, Anvari M, Hong D. Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:1040-1060.e11. [PMID: 30326299 DOI: 10.1016/j.cgh.2018.10.017] [Cited by in Crossref: 99] [Cited by in F6Publishing: 75] [Article Influence: 33.0] [Reference Citation Analysis]
255 Hörist-kollmann S, Strametz-juranek J. Female Dietary Patterns and the Pathogenesis of NAFLD. Gender and the Genome 2018;2:49-55. [DOI: 10.1177/2470289718787091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
256 Semmler G, Balcar L, Oberkofler H, Zandanell S, Strasser M, Niederseer D, Feldman A, Stickel F, Strnad P, Datz C, Paulweber B, Aigner E. PNPLA3 and SERPINA1 Variants Are Associated with Severity of Fatty Liver Disease at First Referral to a Tertiary Center. J Pers Med 2021;11:165. [PMID: 33804385 DOI: 10.3390/jpm11030165] [Reference Citation Analysis]
257 Marin-Alejandre BA, Abete I, Cantero I, Monreal JI, Elorz M, Herrero JI, Benito-Boillos A, Quiroga J, Martinez-Echeverria A, Uriz-Otano JI, Huarte-Muniesa MP, Tur JA, Martinez JA, Zulet MA. The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. Nutrients 2019;11:E2543. [PMID: 31652512 DOI: 10.3390/nu11102543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
258 Parry SA, Hodson L. Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review. Adv Ther 2020;37:1381-406. [PMID: 32146704 DOI: 10.1007/s12325-020-01281-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
259 Molina-Molina E, Krawczyk M, Stachowska E, Lammert F, Portincasa P. Non-Alcoholic Fatty Liver Disease in Non-Obese Individuals: Prevalence, Pathogenesis and Treatment. Clin Res Hepatol Gastroenterol. 2019;43:638-645. [PMID: 31196707 DOI: 10.1016/j.clinre.2019.04.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
260 Cheng JY, Wong VW, Tse Y, Chim AM, Chan HL, Wong GL. Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B: Cheng et al. Hepatology 2016;64:1507-17. [DOI: 10.1002/hep.28778] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
261 Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic Fatty Liver Disease and the Heart: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73:948-963. [PMID: 30819364 DOI: 10.1016/j.jacc.2018.11.050] [Cited by in Crossref: 80] [Cited by in F6Publishing: 63] [Article Influence: 80.0] [Reference Citation Analysis]
262 Marietti M, Bugianesi E. Obesity: Childhood obesity: time bomb for future burden of chronic liver disease. Nat Rev Gastroenterol Hepatol 2016;13:506-7. [PMID: 27485787 DOI: 10.1038/nrgastro.2016.120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
263 Pais R, Maurel T. Natural History of NAFLD. J Clin Med 2021;10:1161. [PMID: 33802047 DOI: 10.3390/jcm10061161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
264 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 47] [Cited by in F6Publishing: 33] [Article Influence: 47.0] [Reference Citation Analysis]
265 Tada T, Kumada T, Toyoda H, Yasuda S, Sone Y, Hashinokuchi S, Ogawa S, Oguri T, Kamiyama N, Chuma M, Akita T, Tanaka J. Liver stiffness does not affect ultrasound‐guided attenuation coefficient measurement in the evaluation of hepatic steatosis. Hepatol Res 2020;50:190-8. [DOI: 10.1111/hepr.13442] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
266 Perazzo H, Dufour JF. The therapeutic landscape of non-alcoholic steatohepatitis. Liver Int. 2017;37:634-647. [PMID: 27727520 DOI: 10.1111/liv.13270] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
267 Bedogni G, Tamini S, Caroli D, Cicolini S, Domenicali M, Sartorio A. Development and Internal Validation of Fatty Liver Prediction Models in Obese Children and Adolescents. J Clin Med 2021;10:1470. [PMID: 33918271 DOI: 10.3390/jcm10071470] [Reference Citation Analysis]
268 Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: What we do, what we should do. World J Hepatol 2017;9:697-703. [PMID: 28596817 DOI: 10.4254/wjh.v9.i15.697] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
269 Braud L, Battault S, Meyer G, Nascimento A, Gaillard S, de Sousa G, Rahmani R, Riva C, Armand M, Maixent J, Reboul C. Antioxidant properties of tea blunt ROS-dependent lipogenesis: beneficial effect on hepatic steatosis in a high fat-high sucrose diet NAFLD obese rat model. The Journal of Nutritional Biochemistry 2017;40:95-104. [DOI: 10.1016/j.jnutbio.2016.10.012] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
270 Talavera-Urquijo E, Beisani M, Balibrea JM, Alverdy JC. Is bariatric surgery resolving NAFLD via microbiota-mediated bile acid ratio reversal? A comprehensive review. Surg Obes Relat Dis 2020;16:1361-9. [PMID: 32336663 DOI: 10.1016/j.soard.2020.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
271 Fabrellas N, Hernández R, Graupera I, Solà E, Ramos P, Martín N, Sáez G, Simón C, Pérez A, Graell T, Larrañaga A, Garcia M, de la Arada A, Juanola A, Coiduras A, Duaso I, Casado A, Martin J, Ginès M, Moreno N, Gema Perez A, Marti L, Bernat M, Sola M, Olivé C, Solé C, Ginès P. Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study. PLoS One 2018;13:e0200656. [PMID: 30226889 DOI: 10.1371/journal.pone.0200656] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
272 Chung SM, Moon JS, Yoon JS, Won KC, Lee HW. The sex-specific effects of blood lead, mercury, and cadmium levels on hepatic steatosis and fibrosis: Korean nationwide cross-sectional study. J Trace Elem Med Biol 2020;62:126601. [PMID: 32634767 DOI: 10.1016/j.jtemb.2020.126601] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
273 Ebadi M, Bhanji RA, Tandon P, Mazurak V, Baracos VE, Montano-Loza AJ. Review article: prognostic significance of body composition abnormalities in patients with cirrhosis. Aliment Pharmacol Ther 2020;52:600-18. [PMID: 32621329 DOI: 10.1111/apt.15927] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
274 Vassilatou E, Lafoyianni S, Vassiliadi DA, Ioannidis D, Paschou SA, Mizamtsidi M, Panagou M, Vryonidou A. Visceral adiposity index for the diagnosis of nonalcoholic fatty liver disease in premenopausal women with and without polycystic ovary syndrome. Maturitas 2018;116:1-7. [DOI: 10.1016/j.maturitas.2018.06.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
275 Patra J, Buckley C, Kerr WC, Brennan A, Purshouse RC, Rehm J. Impact of body mass and alcohol consumption on all‐cause and liver mortality in 240 000 adults in the United States. Drug Alcohol Rev 2021;40:1061-70. [DOI: 10.1111/dar.13265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
276 Ma K, Tang D, Yu C, Zhao L. Progress in research on the roles of TGR5 receptor in liver diseases. Scand J Gastroenterol 2021;56:717-26. [PMID: 33771073 DOI: 10.1080/00365521.2021.1903547] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
277 van den Berg EH, Gruppen EG, Blokzijl H, Bakker SJL, Dullaart RPF. Higher Sodium Intake Assessed by 24 Hour Urinary Sodium Excretion Is Associated with Non-Alcoholic Fatty Liver Disease: The PREVEND Cohort Study. J Clin Med 2019;8:E2157. [PMID: 31817623 DOI: 10.3390/jcm8122157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
278 Kang SH, Cho KH, Do JY. Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. Int J Med Sci 2019;16:285-91. [PMID: 30745809 DOI: 10.7150/ijms.28264] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
279 Kim YS, Kim SG. Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases. Clin Mol Hepatol 2020;26:715-27. [PMID: 32951410 DOI: 10.3350/cmh.2020.0173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
280 Chen J, Chen J, Huang J, Li Z, Gong Y, Zou B, Liu X, Ding L, Li P, Zhu Z, Zhang B, Guo H, Cai C, Li J. HIF-2α upregulation mediated by hypoxia promotes NAFLD-HCC progression by activating lipid synthesis via the PI3K-AKT-mTOR pathway. Aging (Albany NY) 2019;11:10839-60. [PMID: 31796646 DOI: 10.18632/aging.102488] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
281 Dufour JF, Caussy C, Loomba R. Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges. Gut 2020;69:1877-84. [PMID: 32381514 DOI: 10.1136/gutjnl-2019-319104] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 34.0] [Reference Citation Analysis]
282 Tsochatzis EA, Newsome PN. Non-alcoholic fatty liver disease and the interface between primary and secondary care. Lancet Gastroenterol Hepatol 2018;3:509-17. [PMID: 29893235 DOI: 10.1016/S2468-1253(18)30077-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
283 Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, Fracanzani AL, Rosso C, Blanco MJG, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Valenti L, Anstee QM, Bugianesi E. Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2020;115:1289-92. [PMID: 32453041 DOI: 10.14309/ajg.0000000000000676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
284 Semmler G, Scheiner B, Schwabl P, Bucsics T, Paternostro R, Chromy D, Stättermayer AF, Trauner M, Mandorfer M, Ferlitsch A, Reiberger T. The impact of hepatic steatosis on portal hypertension. PLoS One 2019;14:e0224506. [PMID: 31693695 DOI: 10.1371/journal.pone.0224506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
285 Wu D, Zhang M, Xu S, Wu K, Wang N, Wang Y, Wu J, Lu G, Gong W, Ding Y, Xiao W. Nonalcoholic Fatty Liver Disease Aggravated the Severity of Acute Pancreatitis in Patients. Biomed Res Int 2019;2019:9583790. [PMID: 30805370 DOI: 10.1155/2019/9583790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
286 Easter JA, Tian Y, Burrell RC, Hong Y, Bonacorsi SJ Jr. Synthesis of tritium labeled 30-KDa PEG and conjugation to form [3 H]Pegbelfermin. J Labelled Comp Radiopharm 2021. [PMID: 34386991 DOI: 10.1002/jlcr.3940] [Reference Citation Analysis]
287 Shah RA, Kowdley KV. Serum ferritin as a biomarker for NAFLD: ready for prime time? Hepatol Int 2019;13:110-2. [PMID: 30739262 DOI: 10.1007/s12072-019-09934-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
288 Anania C, Perla FM, Olivero F, Pacifico L, Chiesa C. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol. 2018;24:2083-2094. [PMID: 29785077 DOI: 10.3748/wjg.v24.i19.2083] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 49] [Article Influence: 18.3] [Reference Citation Analysis]
289 Xing J, Guan X, Zhang Q, Chen S, Wu S, Sun X. Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study. Obes Facts 2021;14:190-6. [PMID: 33780962 DOI: 10.1159/000514848] [Reference Citation Analysis]
290 Johansen M, Schou M, Rasmussen J, Rossignol P, Holm M, Chabanova E, Dela F, Faber J, Kistorp C. Low N-terminal pro-brain natriuretic peptide levels are associated with non-alcoholic fatty liver disease in patients with type 2 diabetes. Diabetes & Metabolism 2019;45:429-35. [DOI: 10.1016/j.diabet.2018.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
291 Park H, Jun DW, Park HK, Kim M. Clinical implications of serum Mac-2-binding protein glycan isomer as a novel biomarker of advanced hepatic fibrosis in diabetes. Ann Transl Med 2020;8:1583. [PMID: 33437782 DOI: 10.21037/atm-20-5216] [Reference Citation Analysis]
292 Jang DK, Lee JS, Lee JK, Kim YH. Independent Association of Physical Activity with Nonalcoholic Fatty Liver Disease and Alanine Aminotransferase Levels. J Clin Med 2019;8:E1013. [PMID: 31295962 DOI: 10.3390/jcm8071013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
293 Cai J, Sebastiani G. HIV, Elevated Transaminases, Fatty Liver: The Perfect Storm? JAIDS Journal of Acquired Immune Deficiency Syndromes 2019;81:e23-5. [DOI: 10.1097/qai.0000000000001984] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
294 Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocr Connect 2020;9:R173-86. [PMID: 32621584 DOI: 10.1530/EC-20-0174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
295 Oppedisano F, Muscoli C, Musolino V, Carresi C, Macrì R, Giancotta C, Bosco F, Maiuolo J, Scarano F, Paone S, Nucera S, Zito MC, Scicchitano M, Ruga S, Ragusa M, Palma E, Tavernese A, Mollace R, Bombardelli E, Mollace V. The Protective Effect of Cynara Cardunculus Extract in Diet-Induced NAFLD: Involvement of OCTN1 and OCTN2 Transporter Subfamily. Nutrients 2020;12:E1435. [PMID: 32429274 DOI: 10.3390/nu12051435] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
296 Lee HW, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Kim KJ, Han K. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2017;62:2150-8. [DOI: 10.1007/s10620-017-4592-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
297 Jafarov F, Kaya E, Bakir A, Eren F, Yilmaz Y. The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study. Eur J Gastroenterol Hepatol 2020;32:642-9. [PMID: 31651653 DOI: 10.1097/MEG.0000000000001573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
298 Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, Miller V; Liver Forum Case Definitions Working Group. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology 2019;70:1841-55. [PMID: 31034092 DOI: 10.1002/hep.30672] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 40.0] [Reference Citation Analysis]
299 Targher G, Byrne CD. Ad Libitum Mediterranean or Low-Fat Diets as Treatments for Nonalcoholic Fatty Liver Disease? Hepatology 2018;68:1668-71. [PMID: 30070378 DOI: 10.1002/hep.30142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
300 Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S, Giamberardino MA, Cipollone F, Sutton R, Vettor R, Fedorowski A, Meschi T. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019;16. [PMID: 31455011 DOI: 10.3390/ijerph16173104] [Cited by in Crossref: 47] [Cited by in F6Publishing: 31] [Article Influence: 23.5] [Reference Citation Analysis]
301 Francque S, Vonghia L. The future of diagnosing NASH - could a simple blood test be the key? Expert Rev Gastroenterol Hepatol 2017;11:995-7. [PMID: 28862886 DOI: 10.1080/17474124.2017.1374851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
302 Lee S, Kim KW, Lee J, Park T, Park HJ, Song GW, Lee SG. Reduction of Visceral Adiposity as a Predictor for Resolution of Nonalcoholic Fatty Liver in Potential Living Liver Donors. Liver Transpl 2021. [PMID: 33834607 DOI: 10.1002/lt.26071] [Reference Citation Analysis]
303 Johansen ML, Schou M, Rossignol P, Holm MR, Rasmussen J, Brandt N, Frandsen M, Chabanova E, Dela F, Faber J, Kistorp C. Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial (MIRAD trial). Diabetes Obes Metab 2019;21:2305-14. [PMID: 31183945 DOI: 10.1111/dom.13809] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
304 Kang SH, Cho Y, Jeong SW, Kim SU, Lee JW; Korean NAFLD Study Group. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Clin Mol Hepatol 2021;27:257-69. [PMID: 33751877 DOI: 10.3350/cmh.2021.0067] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
305 Hartley A, Santos Ferreira DL, Anderson EL, Lawlor DA. Metabolic profiling of adolescent non-alcoholic fatty liver disease. Wellcome Open Res 2018;3:166. [PMID: 30687796 DOI: 10.12688/wellcomeopenres.14974.2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
306 Mirabelli M, Chiefari E, Arcidiacono B, Corigliano DM, Brunetti FS, Maggisano V, Russo D, Foti DP, Brunetti A. Mediterranean Diet Nutrients to Turn the Tide against Insulin Resistance and Related Diseases. Nutrients 2020;12:E1066. [PMID: 32290535 DOI: 10.3390/nu12041066] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 30.0] [Reference Citation Analysis]
307 Azzaroli F, Mazzella G, Marchesini G, Brodosi L, Petroni ML. Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Rev Gastroenterol Hepatol 2020;14:127-35. [PMID: 31928239 DOI: 10.1080/17474124.2020.1715210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
308 Abou Assi R, Abdulbaqi IM, Siok Yee C. The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. Pharmaceuticals (Basel) 2021;14:215. [PMID: 33806527 DOI: 10.3390/ph14030215] [Reference Citation Analysis]
309 Roeb E. Non-alcoholic fatty liver diseases: current challenges and future directions. Ann Transl Med 2021;9:726. [PMID: 33987424 DOI: 10.21037/atm-20-3760] [Reference Citation Analysis]
310 Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, David E, Vecchio FM, Maggioni M, Cabibi D, McLeod D, Pareja MJ, Fracanzani AL, Aller R, Rosso C, Ampuero J, Gallego-Durán R, Armandi A, Caviglia GP, Zaki MYW, Liguori A, Francione P, Pennisi G, Grieco A, Birolo G, Fariselli P, Eslam M, Valenti L, George J, Romero-Gómez M, Anstee QM, Bugianesi E. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut 2021:gutjnl-2020-322564. [PMID: 33541866 DOI: 10.1136/gutjnl-2020-322564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
311 Li Y, Xu H, Wu W, Ye J, Fang D, Shi D, Li L. Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Oncotarget 2018;9:24155-67. [PMID: 29844879 DOI: 10.18632/oncotarget.23816] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
312 Tavaglione F, Targher G, Valenti L, Romeo S. Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. Endocrinol Diabetes Metab 2020;3:e00179. [PMID: 33102799 DOI: 10.1002/edm2.179] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
313 Romero-gómez M, Zelber-sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. Journal of Hepatology 2017;67:829-46. [DOI: 10.1016/j.jhep.2017.05.016] [Cited by in Crossref: 360] [Cited by in F6Publishing: 281] [Article Influence: 90.0] [Reference Citation Analysis]
314 Li W, Alazawi W. Non-alcoholic fatty liver disease. Clin Med (Lond) 2020;20:509-12. [PMID: 32934047 DOI: 10.7861/clinmed.2020-0696] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Kanwal F, Shubrook JH, Younossi Z, Natarajan Y, Bugianesi E, Rinella ME, Harrison SA, Mantzoros C, Pfotenhauer K, Klein S, Eckel RH, Kruger D, El-Serag H, Cusi K. Preparing for the NASH epidemic: A call to action. Obesity (Silver Spring) 2021;29:1401-12. [PMID: 34365735 DOI: 10.1002/oby.23250] [Reference Citation Analysis]
316 Hydes T, Brown E, Hamid A, Bateman AC, Cuthbertson DJ. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications. Clin Ther 2021:S0149-2918(21)00256-3. [PMID: 34400007 DOI: 10.1016/j.clinthera.2021.07.012] [Reference Citation Analysis]
317 Arab JP, Barrera F, Arrese M. The evolving role of liver biopsy in non-alcoholic fatty liver disease. Annals of Hepatology 2018;17:899-902. [DOI: 10.5604/01.3001.0012.7188] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
318 Afonso MB, Castro RE, Rodrigues CMP. Processes exacerbating apoptosis in non-alcoholic steatohepatitis. Clin Sci (Lond) 2019;133:2245-64. [PMID: 31742325 DOI: 10.1042/CS20190068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
319 Słomko J, Zalewska M, Niemiro W, Kujawski S, Słupski M, Januszko-Giergielewicz B, Zawadka-Kunikowska M, Newton J, Hodges L, Kubica J, Zalewski P. Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:1659. [PMID: 33924482 DOI: 10.3390/jcm10081659] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Tobari M, Hashimoto E, Taniai M, Kodama K, Kogiso T, Tokushige K, Yamamoto M, Takayoshi N, Satoshi K, Tatsuo A. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis. J Gastroenterol Hepatol. 2020;35:862-869. [PMID: 31597206 DOI: 10.1111/jgh.14867] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
321 Barchetta I, Cimini FA, Cavallo MG. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update. Nutrients 2020;12:E3302. [PMID: 33126575 DOI: 10.3390/nu12113302] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
322 Plaza-Díaz J, Solis-Urra P, Aragón-Vela J, Rodríguez-Rodríguez F, Olivares-Arancibia J, Álvarez-Mercado AI. Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis. Biomedicines 2021;9:145. [PMID: 33546191 DOI: 10.3390/biomedicines9020145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
323 Abenavoli L, Greco M, Milic N, Accattato F, Foti D, Gulletta E, Luzza F. Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients 2017;9:E870. [PMID: 28805669 DOI: 10.3390/nu9080870] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
324 Lonardo A, Nascimbeni F, Ponz de Leon M. Nonalcoholic fatty liver disease and COPD: is it time to cross the diaphragm? Eur Respir J 2017;49:1700546. [DOI: 10.1183/13993003.00546-2017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
325 Infante-Menéndez J, López-Pastor AR, González-López P, Gómez-Hernández A, Escribano O. The Interplay between Oxidative Stress and miRNAs in Obesity-Associated Hepatic and Vascular Complications. Antioxidants (Basel) 2020;9:E607. [PMID: 32664383 DOI: 10.3390/antiox9070607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
326 Bilic-Curcic I, Cigrovski Berkovic M, Virovic-Jukic L, Mrzljak A. Shifting perspectives - interplay between non-alcoholic fatty liver disease and insulin resistance in lean individuals. World J Hepatol 2021;13:80-93. [PMID: 33584988 DOI: 10.4254/wjh.v13.i1.80] [Reference Citation Analysis]
327 Kruse M, Kemper M, Gancheva S, Osterhoff M, Dannenberger D, Markgraf D, Machann J, Hierholzer J, Roden M, Pfeiffer AFH. Dietary Rapeseed Oil Supplementation Reduces Hepatic Steatosis in Obese Men-A Randomized Controlled Trial. Mol Nutr Food Res 2020;64:e2000419. [PMID: 32920973 DOI: 10.1002/mnfr.202000419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
328 Van Campenhout S, Tilleman L, Lefere S, Vandierendonck A, Raevens S, Verhelst X, Geerts A, Van Nieuwerburgh F, Van Vlierberghe H, Devisscher L. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model. Metabolism 2020;107:154220. [PMID: 32243868 DOI: 10.1016/j.metabol.2020.154220] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
329 Ghadimi M, Habibabadi RR, Hazhirkarzar B, Shaghaghi M, Ameli S, Khoshpouri P, Ghasabeh MA, Gurakar A, Pawlik TM, Kamel IR. Advances in Imaging of Diffuse Parenchymal Liver Disease. J Clin Gastroenterol 2020;54:682-95. [PMID: 32554990 DOI: 10.1097/MCG.0000000000001380] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
330 Wong GL. Non-invasive assessments for liver fibrosis: The crystal ball we long for: Assessments for liver fibrosis. Journal of Gastroenterology and Hepatology 2018;33:1009-15. [DOI: 10.1111/jgh.14103] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
331 Chin J, Mori TA, Adams LA, Beilin LJ, Huang RC, Olynyk JK, Ayonrinde OT. Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents. JHEP Rep 2020;2:100150. [PMID: 32984791 DOI: 10.1016/j.jhepr.2020.100150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
332 Hallsworth K, Dombrowski SU, McPherson S, Anstee QM, Avery L. Using the theoretical domains framework to identify barriers and enabling factors to implementation of guidance for the diagnosis and management of nonalcoholic fatty liver disease: a qualitative study. Transl Behav Med 2020;10:1016-30. [PMID: 31120519 DOI: 10.1093/tbm/ibz080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
333 Post A, Garcia E, van den Berg EH, Flores-Guerrero JL, Gruppen EG, Groothof D, Westenbrink BD, Connelly MA, Bakker SJL, Dullaart RPF. Nonalcoholic fatty liver disease, circulating ketone bodies and all-cause mortality in a general population-based cohort. Eur J Clin Invest 2021;:e13627. [PMID: 34120339 DOI: 10.1111/eci.13627] [Reference Citation Analysis]
334 Klieser E, Mayr C, Kiesslich T, Wissniowski T, Fazio PD, Neureiter D, Ocker M. The Crosstalk of miRNA and Oxidative Stress in the Liver: From Physiology to Pathology and Clinical Implications. Int J Mol Sci 2019;20:E5266. [PMID: 31652839 DOI: 10.3390/ijms20215266] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 10.5] [Reference Citation Analysis]
335 Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15:45. [PMID: 28241825 DOI: 10.1186/s12916-017-0806-8] [Cited by in Crossref: 153] [Cited by in F6Publishing: 119] [Article Influence: 38.3] [Reference Citation Analysis]
336 Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, Gwak GY. Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. Int J Epidemiol 2020;49:1562-71. [PMID: 32725117 DOI: 10.1093/ije/dyaa089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
337 Kuchay MS, Choudhary NS, Mishra SK, Bano T, Gagneja S, Mathew A, Singh MK, Kaur P, Gill HK, Wasir JS, Sud R, Mithal A. Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes. JGH Open 2021;5:915-22. [PMID: 34386600 DOI: 10.1002/jgh3.12606] [Reference Citation Analysis]
338 Panke CL, Tovo CV, Villela-nogueira CA, Cravo CM, Ferreira FC, Rezende GF, Calçado FV, Figueiredo-mendes AC, Leite NC, Coral GP, Mattos AA. Evaluation of thrombocytopenia in patients with non-alcoholic fatty liver disease without cirrhosis. Annals of Hepatology 2020;19:88-91. [DOI: 10.1016/j.aohep.2019.05.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
339 Selvaraj EA, Mózes FE, Jayaswal ANA, Zafarmand MH, Vali Y, Lee JA, Levick CK, Young LAJ, Palaniyappan N, Liu CH, Aithal GP, Romero-Gómez M, Brosnan MJ, Tuthill TA, Anstee QM, Neubauer S, Harrison SA, Bossuyt PM, Pavlides M; LITMUS Investigators. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. J Hepatol 2021:S0168-8278(21)00309-3. [PMID: 33991635 DOI: 10.1016/j.jhep.2021.04.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
340 Parente DB, Perazzo H, Paiva FF, Campos CFF, Saboya CJ, Pereira SE, Silva FDE, Rodrigues RS, Perez RM. Higher cut-off values of non-invasive methods might be needed to detect moderate-to-severe steatosis in morbid obese patients: a pilot study. Sci Rep 2020;10:15007. [PMID: 32929103 DOI: 10.1038/s41598-020-71723-2] [Reference Citation Analysis]
341 Huang J, Ou W, Wang M, Singh M, Liu Y, Liu S, Wu Y, Zhu Y, Kumar R, Lin S. MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease. Risk Manag Healthc Policy 2021;14:491-501. [PMID: 33603515 DOI: 10.2147/RMHP.S285880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
342 Niederseer D, Wernly S, Bachmayer S, Wernly B, Bakula A, Huber-Schönauer U, Semmler G, Schmied C, Aigner E, Datz C. Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) Is Independently Associated with Cardiovascular Risk in a Large Austrian Screening Cohort. J Clin Med 2020;9:E1065. [PMID: 32283679 DOI: 10.3390/jcm9041065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
343 Mantovani A, Rigolon R, Pichiri I, Bonapace S, Morani G, Zoppini G, Bonora E, Targher G. Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS One 2017;12:e0185459. [PMID: 28981521 DOI: 10.1371/journal.pone.0185459] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
344 van Welzen BJ, Mudrikova T, El Idrissi A, Hoepelman AIM, Arends JE. A review of Non-Alcoholic Fatty Liver Disease in HIV-infected patients: The next big thing? Infect Dis Ther. 2019;8:33-50. [PMID: 30607807 DOI: 10.1007/s40121-018-0229-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 10.5] [Reference Citation Analysis]
345 Federico A, Dallio M, Caprio GG, Gravina AG, Picascia D, Masarone M, Persico M, Loguercio C. Qualitative and Quantitative Evaluation of Dietary Intake in Patients with Non-Alcoholic Steatohepatitis. Nutrients 2017;9:E1074. [PMID: 28956816 DOI: 10.3390/nu9101074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
346 Lange NF, Radu P, Dufour JF. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention. J Hepatol 2021:S0168-8278(21)01954-1. [PMID: 34339764 DOI: 10.1016/j.jhep.2021.07.025] [Reference Citation Analysis]
347 Tashiro Y, Han Q, Tan Y, Sugisawa N, Yamamoto J, Nishino H, Inubushi S, Sun YU, Lim H, Aoki T, Murakami M, Takahashi Y, Bouvet M, Hoffman RM. Oral Recombinant Methioninase Prevents Nonalcoholic Fatty Liver Disease in Mice on a High Fat Diet. In Vivo 2020;34:979-84. [PMID: 32354883 DOI: 10.21873/invivo.11866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
348 Procter AJ, Sun JY, Malcolm PN, Toms AP. Measuring liver fat fraction with complex-based chemical shift MRI: the effect of simplified sampling protocols on accuracy. BMC Med Imaging 2019;19:14. [PMID: 30736759 DOI: 10.1186/s12880-019-0311-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
349 Dalekos GN, Gatselis NK, Koukoulis GK. Non-alcoholic steatohepatitis or autoimmune hepatitis? Sometimes a closer look under the surface is needed. BMJ Case Rep 2020;13:e238400. [PMID: 33370951 DOI: 10.1136/bcr-2020-238400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol 2019;25:6053-62. [PMID: 31686762 DOI: 10.3748/wjg.v25.i40.6053] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 33] [Article Influence: 41.0] [Reference Citation Analysis]
351 Carlier A, Phan F, Szpigel A, Hajduch E, Salem JE, Gautheron J, Le Goff W, Guérin M, Lachkar F, Ratziu V, Hartemann A, Ferré P, Foufelle F, Bourron O. Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. Cell Rep Med 2020;1:100154. [PMID: 33377125 DOI: 10.1016/j.xcrm.2020.100154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
352 Carrier P, Debette-Gratien M, Jacques J, Loustaud-Ratti V. Cirrhotic patients and older people. World J Hepatol 2019;11:663-77. [PMID: 31598192 DOI: 10.4254/wjh.v11.i9.663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
353 Sumida Y, Seko Y, Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017;47:266-280. [PMID: 28019064 DOI: 10.1111/hepr.12856] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
354 Zhang JZ, Cai JJ, Yu Y, She ZG, Li H. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis. Gene Expr 2019;19:187-98. [PMID: 31010457 DOI: 10.3727/105221619X15553433838609] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
355 Pei C, Wu CZ, Hsieh CH, Chang JB, Liang YJ, Chen YL, Pei D, Lin JD. Protective Effect of Hepatitis B Against Metabolic Syndrome in Patients with Nonalcoholic Fatty Liver Disease But Not in Normal Individuals. Metab Syndr Relat Disord 2019;17:458-64. [PMID: 31545133 DOI: 10.1089/met.2019.0032] [Reference Citation Analysis]
356 Ranjbar G, Mikhailidis DP, Sahebkar A. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box! Metabolism 2019;101:154001. [PMID: 31672448 DOI: 10.1016/j.metabol.2019.154001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
357 Park SY, Noureddin M, Boushey C, Wilkens LR, Setiawan VW. Diet Quality Association with Nonalcoholic Fatty Liver Disease by Cirrhosis Status: The Multiethnic Cohort. Curr Dev Nutr 2020;4:nzaa024. [PMID: 32190810 DOI: 10.1093/cdn/nzaa024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
358 Abenavoli L, Boccuto L, Federico A, Dallio M, Loguercio C, Di Renzo L, De Lorenzo A. Diet and Non-Alcoholic Fatty Liver Disease: The Mediterranean Way. Int J Environ Res Public Health. 2019;16. [PMID: 31438482 DOI: 10.3390/ijerph16173011] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 19.5] [Reference Citation Analysis]
359 Viganò L, Lleo A, Aghemo A. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario. Hepatobiliary Surg Nutr 2018;7:130-3. [PMID: 29744343 DOI: 10.21037/hbsn.2018.01.01] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
360 Forlano R, Mullish BH, Mukherjee SK, Nathwani R, Harlow C, Crook P, Judge R, Soubieres A, Middleton P, Daunt A, Perez-Guzman P, Selvapatt N, Lemoine M, Dhar A, Thursz MR, Nayagam S, Manousou P. In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19. PLoS One. 2020;15:e0240400. [PMID: 33031439 DOI: 10.1371/journal.pone.0240400] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
361 Ginès P, Graupera I, Lammert F, Angeli P, Caballeria L, Krag A, Guha IN, Murad SD, Castera L. Screening for liver fibrosis in the general population: a call for action. The Lancet Gastroenterology & Hepatology 2016;1:256-60. [DOI: 10.1016/s2468-1253(16)30081-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 15] [Article Influence: 12.2] [Reference Citation Analysis]
362 Han E, Lee YH. Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases. Diabetes Metab J 2017;41:430-7. [PMID: 29199410 DOI: 10.4093/dmj.2017.41.6.430] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 8.5] [Reference Citation Analysis]
363 Li J, Yang H, Yeh M, Le MH, Le AK, Yeo YH, Dai C, Barnett S, Zhang JQ, Huang J, Trinh HN, Wong C, Wong C, Hoang JK, Cheung R, Yu M, Nguyen MH. Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. The Journal of Infectious Diseases 2021;224:294-302. [DOI: 10.1093/infdis/jiaa739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
364 Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00112. [PMID: 33102794 DOI: 10.1002/edm2.112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
365 Mazo DF, Malta FM, Stefano JT, Salles APM, Gomes-gouvea MS, Nastri ACS, Almeida JR, Pinho JRR, Carrilho FJ, Oliveira CP. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population. Annals of Hepatology 2019;18:466-71. [DOI: 10.1016/j.aohep.2018.10.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
366 Bertot LC, Jeffrey GP, Wallace M, MacQuillan G, Garas G, Ching HL, Adams LA. Nonalcoholic fatty liver disease-related cirrhosis is commonly unrecognized and associated with hepatocellular carcinoma. Hepatol Commun 2017;1:53-60. [PMID: 29404433 DOI: 10.1002/hep4.1018] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
367 Liu T, Wang P, Cong M, Zhao X, Zhang D, Xu H, Liu L, Jia J, You H. Diethyldithiocarbamate, an anti-abuse drug, alleviates steatohepatitis and fibrosis in rodents through modulating lipid metabolism and oxidative stress. Br J Pharmacol 2018;175:4480-95. [PMID: 30266038 DOI: 10.1111/bph.14503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
368 Weiskirchen R, Tacke F. Combining GP73 with liver stiffness measurements: A proof-of-concept for non-invasive fibrosis assessment in antiviral-naïve HBV patients. Liver Int 2017;37:1605-7. [PMID: 29065256 DOI: 10.1111/liv.13563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
369 Chen K, Sng WK, Quah JH, Liu J, Chong BY, Lee HK, Wang XF, Tan NC, Chang PE, Tan HC, Bee YM, Goh GBB. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.PLoS One. 2020;15:e0236977. [PMID: 32822391 DOI: 10.1371/journal.pone.0236977] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
370 Molina-Molina E, Lunardi Baccetto R, Wang DQ, de Bari O, Krawczyk M, Portincasa P. Exercising the hepatobiliary-gut axis. The impact of physical activity performance. Eur J Clin Invest. 2018;48:e12958. [PMID: 29797516 DOI: 10.1111/eci.12958] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 10.0] [Reference Citation Analysis]
371 Sang C, Yan H, Chan WK, Zhu X, Sun T, Chang X, Xia M, Sun X, Hu X, Gao X, Jia W, Bian H, Chen T, Xie G. Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease. Front Med (Lausanne) 2021;8:637652. [PMID: 33708783 DOI: 10.3389/fmed.2021.637652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Jepsen P, Turati F, La Vecchia C. NAFLD and cancer: More cause for concern? Journal of Hepatology 2018;68:10-2. [DOI: 10.1016/j.jhep.2017.10.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
373 Overi D, Carpino G, Franchitto A, Onori P, Gaudio E. Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis. Cells 2020;9:E590. [PMID: 32131439 DOI: 10.3390/cells9030590] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
374 Sayiner M, Lam B, Golabi P, Younossi ZM. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 2018;11:1756284818811508. [PMID: 30479664 DOI: 10.1177/1756284818811508] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
375 Hong N, Yoon HG, Seo DH, Park S, Kim SI, Sohn JH, Rhee Y. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. Eur J Cancer 2017;82:103-14. [PMID: 28651157 DOI: 10.1016/j.ejca.2017.05.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
376 Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin Investig Drugs. 2018;27:301-311. [PMID: 29448843 DOI: 10.1080/13543784.2018.1442436] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 19.3] [Reference Citation Analysis]
377 Lee HW, Wong GL, Kwok R, Choi KC, Chan CK, Shu SS, Leung JK, Chim AM, Luk AO, Ma RC, Chan HL, Chan JC, Kong AP, Wong VW. Serial transient elastography examinations to monitor patients with type 2 diabetes: A prospective cohort study. Hepatology. 2020;. [PMID: 31991487 DOI: 10.1002/hep.31142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
378 Thiagarajan P, Aithal GP. Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. J Clin Exp Hepatol 2019;9:515-21. [PMID: 31516268 DOI: 10.1016/j.jceh.2019.03.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
379 Katsiki N, Mantzoros C. Making progress towards a better pathophysiological understanding and more promising therapeutic options for treating non-alcoholic steatohepatitis (NASH)/DASH (dysmetabolism associated steatohepatitis). Metabolism 2021;114:154333. [PMID: 32771359 DOI: 10.1016/j.metabol.2020.154333] [Reference Citation Analysis]
380 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
381 Anty R, Gual P. [Pathogenesis of non-alcoholic fatty liver disease]. Presse Med 2019;48:1468-83. [PMID: 31767252 DOI: 10.1016/j.lpm.2019.09.051] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
382 Benmassaoud A, Ghali P, Cox J, Wong P, Szabo J, Deschenes M, Osikowicz M, Lebouche B, Klein MB, Sebastiani G. Screening for nonalcoholic steatohepatitis by using cytokeratin 18 and transient elastography in HIV mono-infection. PLoS One. 2018;13:e0191985. [PMID: 29381754 DOI: 10.1371/journal.pone.0191985] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
383 Lonardo A, Lugari S, Nascimbeni F. Telomere shortening: An innocent bystander at the crossroad of NASH with ageing and cardiometabolic risk? Liver Int 2018;38:1730-2. [PMID: 30256511 DOI: 10.1111/liv.13935] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
384 Lamos EM, Kristan M, Siamashvili M, Davis SN. Effects of anti-diabetic treatments in type 2 diabetes and fatty liver disease. Expert Rev Clin Pharmacol 2021;14:837-52. [PMID: 33882758 DOI: 10.1080/17512433.2021.1917374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
385 Pan Q, Fan JG. Noninvasive diagnosis of nonalcoholic steatohepatitis: Emerging approaches. Hepatobiliary Pancreat Dis Int 2019;18:1-3. [PMID: 30611667 DOI: 10.1016/j.hbpd.2018.12.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
386 Tomah S, Alkhouri N, Hamdy O. Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? Clin Diabetes Endocrinol 2020;6:9. [PMID: 32518675 DOI: 10.1186/s40842-020-00097-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
387 Boutari C, Mantzoros CS. Adiponectin and leptin in the diagnosis and therapy of NAFLD. Metabolism 2020;103:154028. [PMID: 31785257 DOI: 10.1016/j.metabol.2019.154028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
388 Baues M, Dasgupta A, Ehling J, Prakash J, Boor P, Tacke F, Kiessling F, Lammers T. Fibrosis imaging: Current concepts and future directions. Adv Drug Deliv Rev 2017;121:9-26. [PMID: 29108860 DOI: 10.1016/j.addr.2017.10.013] [Cited by in Crossref: 63] [Cited by in F6Publishing: 50] [Article Influence: 15.8] [Reference Citation Analysis]
389 Foschi FG, Bedogni G, Domenicali M, Giacomoni P, Dall'Aglio AC, Dazzani F, Lanzi A, Conti F, Savini S, Saini G, Bernardi M, Andreone P, Gastaldelli A, Casadei Gardini A, Tiribelli C, Bellentani S, Stefanini GF. Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study. BMC Gastroenterol 2018;18:177. [PMID: 30486798 DOI: 10.1186/s12876-018-0906-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
390 Mayo R, Crespo J, Martínez-Arranz I, Banales JM, Arias M, Mincholé I, Aller de la Fuente R, Jimenez-Agüero R, Alonso C, de Luis DA, Vitek L, Stritesky J, Caballería J, Romero-Gómez M, Martín-Duce A, Mugüerza Huguet JM, Busteros-Moraza JI, Idowu MO, Castro A, Martínez-Chantar ML, Ortiz P, Bruha R, Lu SC, Bedossa P, Noureddin M, Sanyal AJ, Mato JM. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatol Commun 2018;2:807-20. [PMID: 30027139 DOI: 10.1002/hep4.1188] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 14.7] [Reference Citation Analysis]
391 Koo BK, Joo SK, Kim D, Lee S, Bae JM, Park JH, Kim JH, Chang MS, Kim W. Development and Validation of a Scoring System, Based on Genetic and Clinical Factors, to Determine Risk of Steatohepatitis in Asian Patients with Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol 2020;18:2592-2599.e10. [PMID: 32062042 DOI: 10.1016/j.cgh.2020.02.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
392 Taniai M, Hashimoto E, Tobari M, Kodama K, Tokushige K, Yamamoto M, Takayama T, Sugitani M, Sano K, Kondo F, Fukusato T. Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: A multicenter study using immunohistochemical analysis of adenoma-related markers. Hepatol Res. 2018;48:947-955. [PMID: 30058778 DOI: 10.1111/hepr.13203] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
393 Lykiardopoulos B, Hagström H, Fredrikson M, Ignatova S, Stål P, Hultcrantz R, Ekstedt M, Kechagias S. Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms. PLoS One 2016;11:e0167776. [PMID: 27936091 DOI: 10.1371/journal.pone.0167776] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
394 Muthiah MD, Sanyal AJ. Burden of Disease due to Nonalcoholic Fatty Liver Disease. Gastroenterol Clin North Am 2020;49:1-23. [PMID: 32033757 DOI: 10.1016/j.gtc.2019.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
395 Elvira-Torales LI, Navarro-González I, González-Barrio R, Martín-Pozuelo G, Doménech G, Seva J, García-Alonso J, Periago-Castón MJ. Tomato Juice Supplementation Influences the Gene Expression Related to Steatosis in Rats. Nutrients 2018;10:E1215. [PMID: 30200543 DOI: 10.3390/nu10091215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
396 Franco I, Bianco A, Mirizzi A, Campanella A, Bonfiglio C, Sorino P, Notarnicola M, Tutino V, Cozzolongo R, Giannuzzi V, Aballay LR, Buongiorno C, Bruno I, Osella AR. Physical Activity and Low Glycemic Index Mediterranean Diet: Main and Modification Effects on NAFLD Score. Results from a Randomized Clinical Trial. Nutrients 2020;13:E66. [PMID: 33379253 DOI: 10.3390/nu13010066] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
397 Petroni ML, Brodosi L, Marchignoli F, Musio A, Marchesini G. Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink? Nutrients 2019;11:E3048. [PMID: 31847199 DOI: 10.3390/nu11123048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
398 Perdomo CM, Garcia-Fernandez N, Escalada J. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate? J Clin Med 2021;10:2040. [PMID: 34068699 DOI: 10.3390/jcm10092040] [Reference Citation Analysis]
399 Åberg F, Puukka P, Salomaa V, Männistö S, Lundqvist A, Valsta L, Perola M, Färkkilä M, Jula A. Risks of Light and Moderate Alcohol Use in Fatty Liver Disease: Follow‐Up of Population Cohorts. Hepatology 2020;71:835-48. [DOI: 10.1002/hep.30864] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 15.0] [Reference Citation Analysis]
400 Trépo E, Valenti L. Update on NAFLD genetics: From new variants to the clinic. J Hepatol 2020;72:1196-209. [PMID: 32145256 DOI: 10.1016/j.jhep.2020.02.020] [Cited by in Crossref: 65] [Cited by in F6Publishing: 47] [Article Influence: 65.0] [Reference Citation Analysis]
401 Scheiner B, Stättermayer AF, Schwabl P, Bucsics T, Paternostro R, Bauer D, Simbrunner B, Schmidt R, Marculescu R, Ferlitsch A, Peck-Radosavljevic M, Pinter M, Trauner M, Reiberger T, Ferenci P, Mandorfer M. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. Liver Int 2020;40:393-404. [PMID: 31967400 DOI: 10.1111/liv.14304] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
402 Cai H, Lu S, Chen Y, Das Mbbs Mrcog S, Niu Z, Zhuo G, Lai L, Zhang Z. Serum retinol binding protein 4 and galectin-3 binding protein as novel markers for postmenopausal nonalcoholic fatty liver disease. Clinical Biochemistry 2018;56:95-101. [DOI: 10.1016/j.clinbiochem.2018.04.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
403 Kim MN, Han K, Yoo J, Ha Y, Chon YE, Lee JH, Simon TG, Chan AT, Hwang SG. Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Sci Rep 2021;11:9154. [PMID: 33911167 DOI: 10.1038/s41598-021-88733-3] [Reference Citation Analysis]
404 Hallsworth K, McPherson S, Anstee QM, Flynn D, Haigh L, Avery L. Digital Intervention With Lifestyle Coach Support to Target Dietary and Physical Activity Behaviors of Adults With Nonalcoholic Fatty Liver Disease: Systematic Development Process of VITALISE Using Intervention Mapping. J Med Internet Res 2021;23:e20491. [PMID: 33448929 DOI: 10.2196/20491] [Reference Citation Analysis]
405 Wang Y, Guo X, Xu W, Cai J, Zhang Y, Wu C, Li S, Sun Y, Liu W, Tao T. Role of Androgen in Liver Fat Content in Women: Metabolically Advantageous or Disadvantageous? Endocr Pract 2020;26:1003-16. [PMID: 33471689 DOI: 10.4158/EP-2019-0407] [Reference Citation Analysis]
406 Di Ciaula A, Calamita G, Shanmugam H, Khalil M, Bonfrate L, Wang DQ, Baffy G, Portincasa P. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. Int J Mol Sci 2021;22:7702. [PMID: 34299321 DOI: 10.3390/ijms22147702] [Reference Citation Analysis]
407 Barros BSV, Monteiro FC, Terra C, Gomes MB. Prevalence of non-alcoholic fatty liver disease and its associated factors in individuals with type 1 diabetes: a cross-sectional study in a tertiary care center in Brazil. Diabetol Metab Syndr 2021;13:33. [PMID: 33741024 DOI: 10.1186/s13098-021-00649-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
408 Cicero AFG, Gitto S, Fogacci F, Rosticci M, Giovannini M, D'Addato S, Andreone P, Borghi C; Brisighella Heart Study Group Medical and Surgical Sciences Dept., University of Bologna. Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study. Eur J Intern Med 2018;53:29-33. [PMID: 29580767 DOI: 10.1016/j.ejim.2018.03.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
409 De Lorenzo S, Tovoli F, Mazzotta A, Vasuri F, Edeline J, Malvi D, Boudjema K, Renzulli M, Jeddou H, D'Errico A, Turlin B, Cescon M, Uguen T, Granito A, Lièvre A, Brandi G. Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role. Cancers (Basel) 2020;12:E3182. [PMID: 33138044 DOI: 10.3390/cancers12113182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
410 Leitão J, Carvalhana S, Cochicho J, Silva AP, Velasco F, Medeiros I, Alves AC, Bourbon M, Oliveiros B, Rodrigues V, Sousa R, Sampaio F, Carvalho A, Cortez-Pinto H. Prevalence and risk factors of fatty liver in Portuguese adults.Eur J Clin Invest. 2020;50:e13235. [PMID: 32289180 DOI: 10.1111/eci.13235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
411 Grattagliano I, Montezinho LP, Oliveira PJ, Frühbeck G, Gómez-Ambrosi J, Montecucco F, Carbone F, Wieckowski MR, Wang DQ, Portincasa P. Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease. Biochem Pharmacol 2019;160:34-45. [PMID: 30508523 DOI: 10.1016/j.bcp.2018.11.020] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
412 Vukovic R, Dos Santos TJ, Ybarra M, Atar M. Children With Metabolically Healthy Obesity: A Review. Front Endocrinol (Lausanne) 2019;10:865. [PMID: 31920976 DOI: 10.3389/fendo.2019.00865] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
413 Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. Ann Gastroenterol 2019;32:1-23. [PMID: 30598587 DOI: 10.20524/aog.2018.0330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
414 Thurner A, Augustin AM, Götze O, Bley TA, Kickuth R. Percutaneous mechanical thrombectomy device assisted TIPS recanalization: a feasibility study. Acta Radiol 2021;:2841851211034041. [PMID: 34323588 DOI: 10.1177/02841851211034041] [Reference Citation Analysis]
415 Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterol 2018;18:3. [PMID: 29304731 DOI: 10.1186/s12876-017-0736-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
416 Budd J, Cusi K. Nonalcoholic Fatty Liver Disease: What Does the Primary Care Physician Need to Know? Am J Med 2020;133:536-43. [PMID: 32017891 DOI: 10.1016/j.amjmed.2020.01.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
417 Lin YC, Wu CC, Ni YH. New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. Front Pediatr 2020;8:603654. [PMID: 33363067 DOI: 10.3389/fped.2020.603654] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
418 Ratziu V, Ghabril M, Romero-Gomez M, Svegliati-Baroni G. Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. Transplantation 2019;103:28-38. [PMID: 30300289 DOI: 10.1097/TP.0000000000002483] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
419 Wasilewska N, Lebensztejn DM. Non-alcoholic fatty liver disease and lipotoxicity. Clin Exp Hepatol 2021;7:1-6. [PMID: 34027109 DOI: 10.5114/ceh.2021.104441] [Reference Citation Analysis]
420 Neokosmidis G, Cholongitas E, Tziomalos K. Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit? WJG 2021;27:6522-6. [DOI: 10.3748/wjg.v27.i39.6522] [Reference Citation Analysis]
421 Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018;179:16-29. [PMID: 29235656 DOI: 10.1111/bjd.16239] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
422 Kornoukhova LA, Emanuel VL, Denisov NL. Laboratory predictors of metabolic liver dysfunction in obesity. Dok gastroenterol 2019;8:16. [DOI: 10.17116/dokgastro2019801116] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Demirtas CO, Keklikkiran C, Ergenc I, Erturk Sengel B, Eskidemir G, Cinel I, Odabasi Z, Korten V, Yilmaz Y. Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study. Int J Clin Pract 2021;75:e14363. [PMID: 33993597 DOI: 10.1111/ijcp.14363] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
424 Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics. Eur J Clin Invest. 2020;50:e13338. [PMID: 32589264 DOI: 10.1111/eci.13338] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 25.0] [Reference Citation Analysis]
425 Lopez-Pastor AR, Gomez-Hernandez A, Diaz-Castroverde S, Gonzalez-Aseguinolaza G, Gonzalez-Rodriguez A, Garcia G, Fernandez S, Escribano O, Benito M. Liver-specific insulin receptor isoform A expression enhances hepatic glucose uptake and ameliorates liver steatosis in a mouse model of diet-induced obesity. Dis Model Mech 2019;12:dmm036186. [PMID: 30642871 DOI: 10.1242/dmm.036186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
426 Harrison SA, Calanna S, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal A, Sejling AS, Newsome PN. Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. Contemp Clin Trials 2020;97:106174. [PMID: 33039693 DOI: 10.1016/j.cct.2020.106174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
427 Björkström K, Stål P, Holmer M, Bengtsson B, Staaf A, Hoffstedt J, Hagström H. A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis. Eur J Gastroenterol Hepatol 2021;33:1420-6. [PMID: 32796353 DOI: 10.1097/MEG.0000000000001882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
428 Gillessen A, Schmidt HH. Silymarin as Supportive Treatment in Liver Diseases: A Narrative Review. Adv Ther 2020;37:1279-301. [PMID: 32065376 DOI: 10.1007/s12325-020-01251-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 26.0] [Reference Citation Analysis]
429 Blake L, Duarte RV, Cummins C. Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging. BMJ Open 2016;6:e010507. [PMID: 27650757 DOI: 10.1136/bmjopen-2015-010507] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
430 Harris R, Card TR, Delahooke T, Aithal GP, Guha IN. The XL probe: A luxury or a necessity? Risk stratification in an obese community cohort using transient elastography. United European Gastroenterol J 2018;6:1372-9. [PMID: 30386610 DOI: 10.1177/2050640618772944] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
431 Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G. Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertension 2020;76:562-8. [PMID: 32594797 DOI: 10.1161/HYPERTENSIONAHA.120.15220] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
432 Tallarico V, Recinella G, Magalotti D, Muscari A, Zoli M, Bianchi G. Prognostic value of non-alcoholic fatty liver disease in the elderly patients. Aging Clin Exp Res 2020;32:2657-65. [PMID: 32008226 DOI: 10.1007/s40520-020-01487-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
433 Dai L, Zhou WJ, Zhong LLD, Tang XD, Ji G. Chinese medicine formulas for nonalcoholic fatty liver disease: Overview of systematic reviews. World J Clin Cases 2021;9:102-17. [PMID: 33511176 DOI: 10.12998/wjcc.v9.i1.102] [Reference Citation Analysis]
434 Shi X, Ye W, Liu F, Zhang R, Hou Q, Shi C, Yu J, Shi Y. Ultrasonic liver steatosis quantification by a learning-based acoustic model from a novel shear wave sequence. Biomed Eng Online 2019;18:121. [PMID: 31864367 DOI: 10.1186/s12938-019-0742-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
435 Kornoukhova LA, Emanuel VL, Denisov NL. [The role of adipose tissue and laboratory predictors of primary osteoporosis.]. Klin Lab Diagn 2020;65:205-11. [PMID: 32227724 DOI: 10.18821/0869-2084-2020-65-4-205-211] [Reference Citation Analysis]
436 Stern C, Castera L. Non-invasive diagnosis of hepatic steatosis. Hepatol Int 2017;11:70-8. [PMID: 27783208 DOI: 10.1007/s12072-016-9772-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 10.0] [Reference Citation Analysis]
437 Broussier T, Lannes A, Zuberbuhler F, Oberti F, Fouchard I, Hunault G, Cales P, Boursier J. Simple blood fibrosis tests reduce unnecessary referrals for specialized evaluations of liver fibrosis in NAFLD and ALD patients. Clin Res Hepatol Gastroenterol 2020;44:349-55. [PMID: 31422033 DOI: 10.1016/j.clinre.2019.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
438 Townsend SA, Newsome PN. Review article: new treatments in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:494-507. [PMID: 28677333 DOI: 10.1111/apt.14210] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
439 Worm N. Beyond Body Weight-Loss: Dietary Strategies Targeting Intrahepatic Fat in NAFLD. Nutrients 2020;12:E1316. [PMID: 32384593 DOI: 10.3390/nu12051316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
440 Björkström K, Franzén S, Eliasson B, Miftaraj M, Gudbjörnsdottir S, Trolle-Lagerros Y, Svensson AM, Hagström H. Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. Clin Gastroenterol Hepatol 2019;17:2769-2775.e4. [PMID: 31009793 DOI: 10.1016/j.cgh.2019.04.038] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
441 O'Hara J, Finnegan A, Dhillon H, Ruiz-Casas L, Pedra G, Franks B, Morgan G, Hebditch V, Jönsson B, Mabhala M, Reic T, Van Thiel I, Ratziu V, Romero-Gomez M, Bugianesi E, Schattenberg JM, Anstee QM. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. JHEP Rep 2020;2:100142. [PMID: 32775976 DOI: 10.1016/j.jhepr.2020.100142] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
442 Gehrke N, Biedenbach J, Huber Y, Straub BK, Galle PR, Simon P, Schattenberg JM. Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD. Sci Rep 2019;9:4007. [PMID: 30850619 DOI: 10.1038/s41598-018-38321-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
443 Besutti G, Bonilauri L, Manicardi E, Venturelli F, Bonelli E, Monelli F, Manicardi V, Valenti L, Ligabue G, Schianchi S, Massari M, Riva N, Froio E, Tagliavini E, Pattacini P, Giorgi Rossi P. Feasibility and efficiency of European guidelines for NAFLD assessment in patients with type 2 diabetes: A prospective study. Diabetes Res Clin Pract 2021;177:108882. [PMID: 34082056 DOI: 10.1016/j.diabres.2021.108882] [Reference Citation Analysis]
444 Cespiati A, Petta S, Lombardi R, Di Marco V, Calvaruso V, Bertelli C, Pisano G, Fatta E, Sigon G, Iuculano F, Crapanzano L, Gibilaro G, Francione P, Craxì A, Fargion S, Fracanzani AL. Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). Dig Liver Dis 2020:S1590-8658(20)30997-X. [PMID: 33214063 DOI: 10.1016/j.dld.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
445 Salomone F, Micek A, Godos J. Simple Scores of Fibrosis and Mortality in Patients with NAFLD: A Systematic Review with Meta-Analysis. J Clin Med 2018;7:E219. [PMID: 30111756 DOI: 10.3390/jcm7080219] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
446 Kawaguchi T, Charlton M, Kawaguchi A, Yamamura S, Nakano D, Tsutsumi T, Zafer M, Torimura T. Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials. Semin Liver Dis 2021;41:225-34. [PMID: 34147036 DOI: 10.1055/s-0041-1723751] [Reference Citation Analysis]
447 Chen J, Duan S, Ma J, Wang R, Chen J, Liu X, Xue L, Xie S, Yao S. MRI-determined liver fat correlates with risk of metabolic syndrome in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2020;32:754-61. [PMID: 32091437 DOI: 10.1097/MEG.0000000000001688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
448 Arrese M, Arab JP, Barrera F, Kaufmann B, Valenti L, Feldstein AE. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity. Semin Liver Dis 2021. [PMID: 34233370 DOI: 10.1055/s-0041-1730927] [Reference Citation Analysis]
449 Loong TC, Wei JL, Leung JC, Wong GL, Shu SS, Chim AM, Chan AW, Choi PC, Tse YK, Chan HL, Wong VW. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2017;32:1363-1369. [PMID: 27936280 DOI: 10.1111/jgh.13671] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 7.8] [Reference Citation Analysis]
450 Morrison AE, Zaccardi F, Khunti K, Davies MJ. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. Liver Int 2019;39:557-67. [DOI: 10.1111/liv.13994] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
451 Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther 2016;8:75-84. [PMID: 28670148 DOI: 10.4137/cmt.s18885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
452 Cheng BC, Yen YH, Chen JF, Wu CK, Chang KC, Tseng PL, Tsai MC, Lin MT, Lin JT, Chen JB, Hu TH. Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population. Sci Rep 2017;7:46458. [PMID: 28422172 DOI: 10.1038/srep46458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
453 Hegazy M, Elsayed NM, Ali HM, Hassan HG, Rashed L. Diabetes Mellitus, Nonalcoholic Fatty Liver Disease, and Conjugated Linoleic Acid (Omega 6): What Is the Link? J Diabetes Res 2019;2019:5267025. [PMID: 31089474 DOI: 10.1155/2019/5267025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
454 Wang JH, Ou HY, Yen YH, Chen CH, Lu SN. Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference. Dig Dis Sci 2020;65:1512-9. [PMID: 31617130 DOI: 10.1007/s10620-019-05883-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
455 VanWagner LB. New insights into NAFLD and subclinical coronary atherosclerosis. J Hepatol 2018;68:890-2. [PMID: 29410378 DOI: 10.1016/j.jhep.2018.01.023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
456 Zhang CH, Zhou BG, Sheng JQ, Chen Y, Cao YQ, Chen C. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies. Pharmacol Res 2020;159:104984. [PMID: 32502637 DOI: 10.1016/j.phrs.2020.104984] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
457 Daniels SJ, Leeming DJ, Detlefsen S, Bruun MF, Hjuler ST, Henriksen K, Hein P, Krag A, Karsdal MA, Nielsen MJ, Brockbank S, Cruwys S. Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2020;318:G410-8. [PMID: 31905026 DOI: 10.1152/ajpgi.00066.2019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
458 Papamichalis PA, Zachou K, Papamichali RA, Ioannou M, Gatselis NK, Dalekos GN, Koukoulis GK. Promyelocytic Leukemia Antigen Expression: a Histological Marker for Primary Biliary Cholangitis Diagnosis? J Transl Int Med 2021;9:43-51. [PMID: 33850801 DOI: 10.2478/jtim-2021-0008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
459 Lykke Eriksen P, Sørensen M, Grønbæk H, Hamilton-Dutoit S, Vilstrup H, Thomsen KL. Non-alcoholic fatty liver disease causes dissociated changes in metabolic liver functions. Clin Res Hepatol Gastroenterol 2019;43:551-60. [PMID: 30770336 DOI: 10.1016/j.clinre.2019.01.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
460 Simeone JC, Bae JP, Hoogwerf BJ, Li Q, Haupt A, Ali AK, Boardman MK, Nordstrom BL. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes. Clin Epidemiol 2017;9:679-88. [PMID: 29276410 DOI: 10.2147/CLEP.S144368] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
461 Katsarou A, Moustakas II, Pyrina I, Lembessis P, Koutsilieris M, Chatzigeorgiou A. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease. World J Gastroenterol 2020;26:1993-2011. [PMID: 32536770 DOI: 10.3748/wjg.v26.i17.1993] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
462 Chen B, Pan CQ. Non-Invasive Assessment of Fibrosis and Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. Clin Res Hepatol Gastroenterol 2021;:101755. [PMID: 34311134 DOI: 10.1016/j.clinre.2021.101755] [Reference Citation Analysis]
463 Tovoli F, Negrini G, Farì R, Guidetti E, Faggiano C, Napoli L, Bolondi L, Granito A. Increased risk of nonalcoholic fatty liver disease in patients with coeliac disease on a gluten-free diet: beyond traditional metabolic factors. Aliment Pharmacol Ther 2018;48:538-46. [PMID: 29984415 DOI: 10.1111/apt.14910] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
464 Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V; LIDO (Liver Injury in Diabetes and Obesity) Study Group. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol 2020;72:828-38. [PMID: 31862486 DOI: 10.1016/j.jhep.2019.12.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
465 Greber-Platzer S, Thajer A, Bohn S, Brunert A, Boerner F, Siegfried W, Artlich A, Moeckel A, Waldecker-Krebs H, Pauer S, Holl RW; APV-Study Group. Increased liver echogenicity and liver enzymes are associated with extreme obesity, adolescent age and male gender: analysis from the German/Austrian/Swiss obesity registry APV. BMC Pediatr 2019;19:332. [PMID: 31514755 DOI: 10.1186/s12887-019-1711-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
466 Araujo LCC, Feitosa KB, Murata GM, Furigo IC, Teixeira SA, Lucena CF, Ribeiro LM, Muscará MN, Costa SKP, Donato J Jr, Bordin S, Curi R, Carvalho CRO. Uncaria tomentosa improves insulin sensitivity and inflammation in experimental NAFLD. Sci Rep 2018;8:11013. [PMID: 30030460 DOI: 10.1038/s41598-018-29044-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
467 Khan RS, Bril F, Cusi K, Newsome PN. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Hepatology. 2019;70:711-724. [PMID: 30556145 DOI: 10.1002/hep.30429] [Cited by in Crossref: 39] [Cited by in F6Publishing: 50] [Article Influence: 19.5] [Reference Citation Analysis]
468 Zhu K, Guo Y, Zhao C, Kang S, Li J, Wang J, Tang Z, Lin B, Li W. Etiology Exploration of Non-alcoholic Fatty Liver Disease From Traditional Chinese Medicine Constitution Perspective: A Cross-Sectional Study. Front Public Health 2021;9:635818. [PMID: 34055713 DOI: 10.3389/fpubh.2021.635818] [Reference Citation Analysis]
469 Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020;111S:154183. [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 14.0] [Reference Citation Analysis]
470 Jung Y, Koo BK, Jang SY, Kim D, Lee H, Lee DH, Joo SK, Jung YJ, Park JH, Yoo T, Choi M, Lee MK, Kang SW, Chang MS, Kim W, Hwang GS; Innovative Target Exploration of NAFLD (ITEN) consortium. Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus. Liver Int 2021. [PMID: 34358397 DOI: 10.1111/liv.15030] [Reference Citation Analysis]
471 Szanto KB, Li J, Cordero P, Oben JA. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:357-367. [PMID: 30936733 DOI: 10.2147/dmso.s182331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
472 Targher G, Mantovani A, Alisi A, Mosca A, Panera N, Byrne CD, Nobili V. Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. Hepatology. 2019;70:142-153. [PMID: 30912854 DOI: 10.1002/hep.30625] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
473 Cai S, Ou Z, Liu D, Liu L, Liu Y, Wu X, Yu T, Peng J. Risk factors associated with liver steatosis and fibrosis in chronic hepatitis B patient with component of metabolic syndrome. United European Gastroenterol J. 2018;6:558-566. [PMID: 29881611 DOI: 10.1177/2050640617751252] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 8.7] [Reference Citation Analysis]
474 Sanai FM, Abaalkhail F, Hasan F, Farooqi MH, Nahdi NA, Younossi ZM. Management of nonalcoholic fatty liver disease in the Middle East. World J Gastroenterol 2020;26:3528-41. [PMID: 32742124 DOI: 10.3748/wjg.v26.i25.3528] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
475 Lang S, Demir M, Martin A, Jiang L, Zhang X, Duan Y, Gao B, Wisplinghoff H, Kasper P, Roderburg C, Tacke F, Steffen HM, Goeser T, Abraldes JG, Tu XM, Loomba R, Stärkel P, Pride D, Fouts DE, Schnabl B. Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease.Gastroenterology. 2020;159:1839-1852. [PMID: 32652145 DOI: 10.1053/j.gastro.2020.07.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
476 Koo BK, Um SH, Seo DS, Joo SK, Bae JM, Park JH, Chang MS, Kim JH, Lee J, Jeong WI, Kim W. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver Int 2018;38:695-705. [PMID: 28898507 DOI: 10.1111/liv.13587] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 8.5] [Reference Citation Analysis]
477 Vespasiani-Gentilucci U, Gallo P, Dell'Unto C, Volpentesta M, Antonelli-Incalzi R, Picardi A. Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables. World J Gastroenterol. 2018;24:4835-4845. [PMID: 30487694 DOI: 10.3748/wjg.v24.i43.4835] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
478 Li J, Wang S, Yao L, Ma P, Chen Z, Han TL, Yuan C, Zhang J, Jiang L, Liu L, Ke D, Li C, Yamahara J, Li Y, Wang J. 6-gingerol ameliorates age-related hepatic steatosis: Association with regulating lipogenesis, fatty acid oxidation, oxidative stress and mitochondrial dysfunction. Toxicol Appl Pharmacol. 2019;362:125-135. [PMID: 30408433 DOI: 10.1016/j.taap.2018.11.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
479 Thompson RB, Chow K, Mager D, Pagano JJ, Grenier J. Simultaneous proton density fat-fraction and R 2 imaging with water-specific T1 mapping (PROFIT1 ): application in liver. Magn Reson Med 2021;85:223-38. [PMID: 32754942 DOI: 10.1002/mrm.28434] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
480 Dyson JK, De Martin E, Dalekos GN, Drenth JP, Herkel J, Hubscher SG, Kelly D, Lenzi M, Milkiewicz P, Oo YH, Heneghan MA, Lohse AW; the IAIHG Consortium. Review article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop. Aliment Pharmacol Ther 2019;49:528-36. [DOI: 10.1111/apt.15111] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
481 Sberna AL, Bouillet B, Rouland A, Brindisi MC, Nguyen A, Mouillot T, Duvillard L, Denimal D, Loffroy R, Vergès B, Hillon P, Petit JM. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes. Diabet Med 2018;35:368-75. [PMID: 29247558 DOI: 10.1111/dme.13565] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
482 Zhang J, Li K, Pan L, Teng F, Zhang P, Lin B, Yuan Y, Wei X, Li W, Zhang H. Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study. BMC Gastroenterol 2021;21:131. [PMID: 33743586 DOI: 10.1186/s12876-021-01721-9] [Reference Citation Analysis]
483 Tincopa MA. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00177. [PMID: 33102798 DOI: 10.1002/edm2.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
484 Kirkegaard-Klitbo DM, Fuchs A, Stender S, Sigvardsen PE, Kühl JT, Kofoed KF, Køber L, Nordestgaard BG, Bendtsen F, Mocroft A, Lundgren J, Nielsen SD, Benfield T. Prevalence and Risk Factors of Moderate-to-Severe Hepatic Steatosis in Human Immunodeficiency Virus Infection: The Copenhagen Co-morbidity Liver Study. J Infect Dis 2020;222:1353-62. [PMID: 32417886 DOI: 10.1093/infdis/jiaa246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
485 Jin S, Jiang S, Hu A. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Sleep Breath. 2018;22:841-851. [PMID: 29335916 DOI: 10.1007/s11325-018-1625-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 10.7] [Reference Citation Analysis]
486 Zhou J, Ho CT, Long P, Meng Q, Zhang L, Wan X. Preventive Efficiency of Green Tea and Its Components on Nonalcoholic Fatty Liver Disease. J Agric Food Chem 2019;67:5306-17. [PMID: 30892882 DOI: 10.1021/acs.jafc.8b05032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 12.5] [Reference Citation Analysis]
487 Bredin C, Naimimohasses S, Norris S, Wright C, Hancock N, Hart K, Moore JB. Development and relative validation of a short food frequency questionnaire for assessing dietary intakes of non-alcoholic fatty liver disease patients. Eur J Nutr 2020;59:571-80. [PMID: 30805696 DOI: 10.1007/s00394-019-01926-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
488 Kriss M, Golden-Mason L, Kaplan J, Mirshahi F, Setiawan VW, Sanyal AJ, Rosen HR. Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. PLoS One 2020;15:e0236353. [PMID: 32730345 DOI: 10.1371/journal.pone.0236353] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
489 Yip R, Jirapatnakul A, Hu M, Chen X, Han D, Ma T, Zhu Y, Salvatore MM, Margolies LR, Yankelevitz DF, Henschke CI. Added benefits of early detection of other diseases on low-dose CT screening. Transl Lung Cancer Res 2021;10:1141-53. [PMID: 33718052 DOI: 10.21037/tlcr-20-746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
490 Ishiba H, Sumida Y, Seko Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Mori K, Kanemasa K, Shimada K, Imajo K, Yamaguchi K, Kawaguchi T, Nakajima A, Chayama K, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of NAFLD. Type IV Collagen 7S Is the Most Accurate Test For Identifying Advanced Fibrosis in NAFLD With Type 2 Diabetes. Hepatol Commun 2021;5:559-72. [PMID: 33860115 DOI: 10.1002/hep4.1637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
491 Lin M, Zeng H, Deng G, Lei J, Li J. Vitamin E in paediatric non-alcoholic fatty liver disease: a meta-analysis. Clin Res Hepatol Gastroenterol 2021;45:101530. [PMID: 33272889 DOI: 10.1016/j.clinre.2020.08.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
492 Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol 2018;24:3361-73. [PMID: 30122876 DOI: 10.3748/wjg.v24.i30.3361] [Cited by in CrossRef: 138] [Cited by in F6Publishing: 106] [Article Influence: 46.0] [Reference Citation Analysis]
493 Ogawa Y, Yoneda M, Kobayashi T, Honda Y, Kessoku T, Imajo K, Saito S, Nakajima A. Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults. Expert Opinion on Pharmacotherapy 2018;20:69-82. [DOI: 10.1080/14656566.2018.1543403] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
494 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
495 Jiang W, Guo MH, Hai X. Hepatoprotective and antioxidant effects of lycopene on non-alcoholic fatty liver disease in rat. World J Gastroenterol. 2016;22:10180-10188. [PMID: 28028366 DOI: 10.3748/wjg.v22.i46.10180] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
496 Timperi E, Barnaba V. Viral Hepatitides, Inflammation and Tumour Microenvironment. Adv Exp Med Biol 2020;1263:25-43. [PMID: 32588321 DOI: 10.1007/978-3-030-44518-8_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
497 Klaebel JH, Skjødt M, Skat-Rørdam J, Rakipovski G, Ipsen DH, Schou-Pedersen AMV, Lykkesfeldt J, Tveden-Nyborg P. Atorvastatin and Vitamin E Accelerates NASH Resolution by Dietary Intervention in a Preclinical Guinea Pig Model. Nutrients 2019;11:E2834. [PMID: 31752351 DOI: 10.3390/nu11112834] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
498 Sima A, Sporea I, Timar R, Vlad M, Braha A, Popescu A, Nistorescu S, Mare R, Sirli R, Albai A, Albai O, Diaconu L, Sorescu T, Popescu S, Sima L. Non-Invasive Assessment of Liver Steatosis and Fibrosis using Transient Elastography and Controlled Attenuation Parameter in Type 2 Diabetes Patients. Acta Endocrinol (Buchar). 2018;14:394-400. [PMID: 31149289 DOI: 10.4183/aeb.2018.394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
499 Hsu CS, Kao JH. An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia. Expert Rev Gastroenterol Hepatol 2017;11:759-72. [PMID: 28613087 DOI: 10.1080/17474124.2017.1342535] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
500 Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci (Lond) 2017;131:2701-4. [PMID: 29109303 DOI: 10.1042/CS20170987] [Cited by in Crossref: 47] [Cited by in F6Publishing: 25] [Article Influence: 11.8] [Reference Citation Analysis]
501 Zhou Z, Zhang Q, Wu W, Wu S, Tsui P. Hepatic Steatosis Assessment Using Quantitative Ultrasound Parametric Imaging Based on Backscatter Envelope Statistics. Applied Sciences 2019;9:661. [DOI: 10.3390/app9040661] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
502 Hempel F, Roderfeld M, Müntnich LJ, Albrecht J, Oruc Z, Arneth B, Karrasch T, Pons-Kühnemann J, Padberg W, Renz H, Schäffler A, Roeb E. Caspase-Cleaved Keratin 18 Measurements Identified Ongoing Liver Injury after Bariatric Surgery. J Clin Med 2021;10:1233. [PMID: 33809676 DOI: 10.3390/jcm10061233] [Reference Citation Analysis]
503 Grander C, Grabherr F, Moschen AR, Tilg H. Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome. Visc Med 2016;32:329-34. [PMID: 27921044 DOI: 10.1159/000448940] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
504 Xie X, Yan D, Li H, Zhu Q, Li J, Fang YP, Cheung CW, Irwin MG, Xia Z, Lian Q. Enhancement of Adiponectin Ameliorates Nonalcoholic Fatty Liver Disease via Inhibition of FoxO1 in Type I Diabetic Rats. J Diabetes Res 2018;2018:6254340. [PMID: 30186875 DOI: 10.1155/2018/6254340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
505 Byambasukh O, Zelle D, Corpeleijn E. Physical Activity, Fatty Liver, and Glucose Metabolism Over the Life Course: The Lifelines Cohort. Am J Gastroenterol 2019;114:907-15. [PMID: 30865013 DOI: 10.14309/ajg.0000000000000168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
506 Strasser SI, Thompson AJ, Roberts SK, George J; Clinical Cases in Hepatitis 2018 Steering Committee. Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. J Gastroenterol Hepatol 2019;34 Suppl 1:5-15. [PMID: 31282011 DOI: 10.1111/jgh.14720] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
507 Klisic A, Kavaric N, Ninic A. Predictive Values of Serum Uric Acid and Alanine-aminotransferase for Fatty Liver Index in Montenegrin Population. J Med Biochem. 2019;38:407-417. [PMID: 31496904 DOI: 10.2478/jomb-2019-0001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
508 Scheen AJ. Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications. Diabetes Metab. 2019;45:213-223. [PMID: 30708071 DOI: 10.1016/j.diabet.2019.01.008] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 27.0] [Reference Citation Analysis]
509 Tan Y, Tang X, Mu P, Yang Y, Li M, Nie Y, Li H, Zhu Y, Chen Y. High-Normal Serum Thyrotropin Levels Increased the Risk of Non-Alcoholic Fatty Liver Disease in Euthyroid Subjects with Type 2 Diabetes. Diabetes Metab Syndr Obes 2021;14:2841-9. [PMID: 34188507 DOI: 10.2147/DMSO.S313224] [Reference Citation Analysis]
510 Ioannou GN, Nagana Gowda GA, Djukovic D, Raftery D. Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach. Metabolites 2020;10:E168. [PMID: 32344559 DOI: 10.3390/metabo10040168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
511 Johari MI, Yusoff K, Haron J, Nadarajan C, Ibrahim KN, Wong MS, Hafidz MIA, Chua BE, Hamid N, Arifin WN, Ma ZF, Lee YY. A Randomised Controlled Trial on the Effectiveness and Adherence of Modified Alternate-day Calorie Restriction in Improving Activity of Non-Alcoholic Fatty Liver Disease. Sci Rep 2019;9:11232. [PMID: 31375753 DOI: 10.1038/s41598-019-47763-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
512 Ivancovsky-Wajcman D, Zelber-Sagi S, Fliss Isakov N, Webb M, Zemel M, Shibolet O, Kariv R. Serum Soluble Receptor for AGE (sRAGE) Levels Are Associated With Unhealthy Lifestyle and Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2019;10:1-10. [PMID: 31082855 DOI: 10.14309/ctg.0000000000000040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
513 Huang G, Zhou H, Shen C, Sheng Y, Xue R, Dong C, Zhang S. Bi-directional and temporal relationship between elevated alanine aminotransferase and hypertension in a longitudinal study of Chinese adults. Clin Exp Hypertens 2021;:1-8. [PMID: 34355631 DOI: 10.1080/10641963.2021.1960364] [Reference Citation Analysis]
514 Scragg J, Avery L, Cassidy S, Taylor G, Haigh L, Boyle M, Trenell MI, Anstee QM, McPherson S, Hallsworth K. Feasibility of a Very Low Calorie Diet to Achieve a Sustainable 10% Weight Loss in Patients With Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol 2020;11:e00231. [PMID: 33094956 DOI: 10.14309/ctg.0000000000000231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
515 Carvajal S, Perramón M, Oró D, Casals E, Fernández-Varo G, Casals G, Parra M, González de la Presa B, Ribera J, Pastor Ó, Morales-Ruíz M, Puntes V, Jiménez W. Cerium oxide nanoparticles display antilipogenic effect in rats with non-alcoholic fatty liver disease. Sci Rep 2019;9:12848. [PMID: 31492960 DOI: 10.1038/s41598-019-49262-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
516 Parola M, Vajro P. Nocturnal hypoxia in obese-related obstructive sleep apnea as a putative trigger of oxidative stress in pediatric NAFLD progression. Journal of Hepatology 2016;65:470-2. [DOI: 10.1016/j.jhep.2016.05.042] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
517 Klujszo EH, Parcheta P, Witkowska AB, Krecisz B. Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications. Postepy Dermatol Alergol 2020;37:468-74. [PMID: 32994765 DOI: 10.5114/ada.2019.83983] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
518 Ezquerro S, Méndez-Giménez L, Becerril S, Moncada R, Valentí V, Catalán V, Gómez-Ambrosi J, Frühbeck G, Rodríguez A. Acylated and desacyl ghrelin are associated with hepatic lipogenesis, β-oxidation and autophagy: role in NAFLD amelioration after sleeve gastrectomy in obese rats. Sci Rep 2016;6:39942. [PMID: 28008992 DOI: 10.1038/srep39942] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
519 Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-171. [PMID: 30266282 DOI: 10.1016/j.jhep.2018.09.014] [Cited by in Crossref: 615] [Cited by in F6Publishing: 475] [Article Influence: 205.0] [Reference Citation Analysis]
520 Dietrich CG, Rau M, Jahn D, Geier A. Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. Expert Opin Drug Metab Toxicol 2017;13:625-40. [PMID: 28359183 DOI: 10.1080/17425255.2017.1314461] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
521 Yuwaki K, Shimazu T, Yamagiwa Y, Inoue M, Goto A, Yamaji T, Iwasaki M, Sawada N, Tsugane S; JPHC Study Group. Association between serum liver enzymes and all-cause mortality: The Japan Public Health Center-based Prospective Study. Liver Int 2019;39:1566-76. [PMID: 30566759 DOI: 10.1111/liv.14030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
522 Liu F, Goh GB, Tiniakos D, Wee A, Leow W, Zhao J, Rao H, Wang X, Wang Q, Wan W, Lim K, Romero‐gomez M, Petta S, Bugianesi E, Tan C, Harrison SA, Anstee QM, Chang PJ, Wei L. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis. Hepatology 2020;71:1953-66. [DOI: 10.1002/hep.30986] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
523 Adinolfi LE, Marrone A, Rinaldi L. Non-alcoholic fatty liver disease: beyond the liver is an emerging multifaceted systemic disease. Hepatobiliary Surg Nutr 2018;7:143-6. [PMID: 29744347 DOI: 10.21037/hbsn.2018.02.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
524 Zelber-Sagi S, Salomone F, Mlynarsky L. The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms. Liver Int. 2017;37:936-949. [PMID: 28371239 DOI: 10.1111/liv.13435] [Cited by in Crossref: 109] [Cited by in F6Publishing: 90] [Article Influence: 27.3] [Reference Citation Analysis]
525 Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, Pasqua A, Lapi F, Rijnbeek P, Mosseveld M, Avillach P, Egger P, Kendrick S, Waterworth DM, Sattar N, Alazawi W. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 2018;16:130. [PMID: 30099968 DOI: 10.1186/s12916-018-1103-x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 52] [Article Influence: 24.0] [Reference Citation Analysis]
526 Watanabe M, Risi R, Camajani E, Contini S, Persichetti A, Tuccinardi D, Ernesti I, Mariani S, Lubrano C, Genco A, Spera G, Gnessi L, Basciani S. Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study. Nutrients 2020;12:E2141. [PMID: 32708435 DOI: 10.3390/nu12072141] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
527 Lee SB, Kim MK, Kang S, Park K, Kim JH, Baik SJ, Nam JS, Ahn CW, Park JS. Triglyceride Glucose Index Is Superior to the Homeostasis Model Assessment of Insulin Resistance for Predicting Nonalcoholic Fatty Liver Disease in Korean Adults. Endocrinol Metab (Seoul) 2019;34:179-86. [PMID: 31257745 DOI: 10.3803/EnM.2019.34.2.179] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 22.0] [Reference Citation Analysis]
528 Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 2020;111S:154170. [PMID: 32006558 DOI: 10.1016/j.metabol.2020.154170] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 58.0] [Reference Citation Analysis]
529 Miele L, Alberelli MA, Martini M, Liguori A, Marrone G, Cocomazzi A, Vecchio FM, Landolfi R, Gasbarrini A, Grieco A, De Candia E. Nonalcoholic fatty liver disease (NAFLD) severity is associated to a nonhemostatic contribution and proinflammatory phenotype of platelets. Transl Res 2021;231:24-38. [PMID: 33171266 DOI: 10.1016/j.trsl.2020.11.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
530 Zhang QZ, Liu YL, Wang YR, Fu LN, Zhang J, Wang XR, Wang BM. Effects of telmisartan on improving leptin resistance and inhibiting hepatic fibrosis in rats with non-alcoholic fatty liver disease. Exp Ther Med. 2017;14:2689-2694. [PMID: 28962213 DOI: 10.3892/etm.2017.4809] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
531 Ayonrinde OT. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. JHEP Rep 2021;3:100261. [PMID: 34036255 DOI: 10.1016/j.jhepr.2021.100261] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
532 Pan J, Ou Z, Cai C, Li P, Gong J, Ruan XZ, He K. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release. Cell Immunol. 2018;332:111-120. [PMID: 30103942 DOI: 10.1016/j.cellimm.2018.08.006] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 13.0] [Reference Citation Analysis]
533 Canbay A, Kachru N, Haas JS, Sowa J, Meise D, Ozbay AB. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;52:1185-94. [DOI: 10.1111/apt.16016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
534 Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, Ruckes C, Galle PR, Romero-gómez M, Anstee QM, Schattenberg JM. Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. Clinical Gastroenterology and Hepatology 2019;17:2085-2092.e1. [DOI: 10.1016/j.cgh.2018.12.016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 19.0] [Reference Citation Analysis]
535 Lallukka S, Yki-Järvinen H. Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2016;30:385-95. [PMID: 27432073 DOI: 10.1016/j.beem.2016.06.006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 15.0] [Reference Citation Analysis]
536 Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-pinto H, Targher G, Lonardo A. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Review of Gastroenterology & Hepatology 2018;12:351-67. [DOI: 10.1080/17474124.2018.1415756] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
537 Wong VW, Irles M, Wong GL, Shili S, Chan AW, Merrouche W, Shu SS, Foucher J, Le Bail B, Chan WK, Chan HL, de Ledinghen V. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut 2019;68:2057-64. [PMID: 30658997 DOI: 10.1136/gutjnl-2018-317334] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 24.0] [Reference Citation Analysis]
538 De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM, Foster GR, Syn WK, Alazawi W. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Frontline Gastroenterol 2018;9:115-21. [PMID: 29588839 DOI: 10.1136/flgastro-2017-100865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
539 Chen KW, Meng FC, Shih YL, Su FY, Lin YP, Lin F, Lin JW, Chang WK, Lee CJ, Li YH, Hsieh CB, Lin GM. Sex-Specific Association between Metabolic Abnormalities and Elevated Alanine Aminotransferase Levels in a Military Cohort: The CHIEF Study. Int J Environ Res Public Health. 2018;15:545. [PMID: 29562671 DOI: 10.3390/ijerph15030545] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
540 Jiang T, Guo XJ, Tu LP, Lu Z, Cui J, Ma XX, Hu XJ, Yao XH, Cui LT, Li YZ, Huang JB, Xu JT. Application of computer tongue image analysis technology in the diagnosis of NAFLD. Comput Biol Med 2021;135:104622. [PMID: 34242868 DOI: 10.1016/j.compbiomed.2021.104622] [Reference Citation Analysis]
541 Vincent RK, Williams DM, Evans M. A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer? Diabetes Obes Metab 2020;22:2227-40. [DOI: 10.1111/dom.14196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
542 Kozłowska-Petriczko K, Wunsch E, Petriczko J, Syn WK, Milkiewicz P. Diagnostic Accuracy of Non-Imaging and Ultrasound-Based Assessment of Hepatic Steatosis Using Controlled Attenuation Parameter (CAP) as Reference. J Clin Med 2021;10:1507. [PMID: 33916626 DOI: 10.3390/jcm10071507] [Reference Citation Analysis]
543 Lai HTM, de Oliveira Otto MC, Lee Y, Wu JHY, Song X, King IB, Psaty BM, Lemaitre RN, McKnight B, Siscovick DS, Mozaffarian D. Serial Plasma Phospholipid Fatty Acids in the De Novo Lipogenesis Pathway and Total Mortality, Cause-Specific Mortality, and Cardiovascular Diseases in the Cardiovascular Health Study. J Am Heart Assoc 2019;8:e012881. [PMID: 31711385 DOI: 10.1161/JAHA.119.012881] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
544 Lin YC, Lian IB, Kor CT, Chang CC, Su PY, Chang WT, Liang YF, Su WW, Soon MS. Association between soil heavy metals and fatty liver disease in men in Taiwan: a cross sectional study. BMJ Open 2017;7:e014215. [PMID: 28115335 DOI: 10.1136/bmjopen-2016-014215] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
545 Younossi ZM, Stepanova M, Taub RA, Barbone JM, Harrison SA. Hepatic Fat Reduction Due to Resmetirom in Patients With Nonalcoholic Steatohepatitis Is Associated With Improvement of Quality of Life. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00821-1. [PMID: 34329774 DOI: 10.1016/j.cgh.2021.07.039] [Reference Citation Analysis]
546 Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung S, Gu S, Rhee P, Paik SW, Son HJ, Gwak G. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther 2017;45:345-53. [DOI: 10.1111/apt.13866] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
547 Gao F, Huang JF, Zheng KI, Pan XY, Ma HL, Liu WY, Byrne CD, Targher G, Li YY, Chen YP, Chan WK, Zheng MH. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2020;35:1804-12. [PMID: 32246876 DOI: 10.1111/jgh.15055] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
548 Alkayyali T, Qutranji L, Kaya E, Bakir A, Yilmaz Y. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. Acta Diabetol 2020;57:613-8. [PMID: 31897769 DOI: 10.1007/s00592-019-01467-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
549 Eslam M, Alvani R, Shiha G. Obeticholic acid: towards first approval for NASH. Lancet. 2019;394:2131-2133. [PMID: 31813639 DOI: 10.1016/s0140-6736(19)32963-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
550 Mantovani A, Zusi C, Dalbeni A, Grani G, Buzzetti E. Risk of Kidney Dysfunction IN Nafld. CPD 2020;26:1045-61. [DOI: 10.2174/1381612825666191026113119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
551 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
552 Rispo A, Imperatore N, Guarino M, Tortora R, Alisi A, Cossiga V, Testa A, Ricciolino S, Fiorentino A, Morisco F. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease. Liver Int 2021;41:788-98. [PMID: 33319459 DOI: 10.1111/liv.14767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
553 Kim YS, Lee SH, Park SG, Won BY, Chun H, Cho DY, Kim MJ, Lee JE, Haam JH, Han K. Low levels of total and high-molecular-weight adiponectin may predict non-alcoholic fatty liver in Korean adults. Metabolism 2020;103:154026. [PMID: 31765666 DOI: 10.1016/j.metabol.2019.154026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
554 Tamaki N, Kurosaki M, Takahashi Y, Itakura Y, Kirino S, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Loomba R, Izumi N. Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. Int J Mol Sci 2020;22:E40. [PMID: 33375190 DOI: 10.3390/ijms22010040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
555 Ojeda-Granados C, Roman S. Mediterranean diet or genome-based nutrition diets in Latin America's clinical practice guidelines for managing chronic liver diseases? Ann Hepatol 2021;20:100291. [PMID: 33388121 DOI: 10.1016/j.aohep.2020.100291] [Reference Citation Analysis]
556 Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, Zafarmand MH. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int 2021;41:261-70. [PMID: 32946642 DOI: 10.1111/liv.14669] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
557 Avila MA, Dufour JF, Gerbes AL, Zoulim F, Bataller R, Burra P, Cortez-Pinto H, Gao B, Gilmore I, Mathurin P, Moreno C, Poznyak V, Schnabl B, Szabo G, Thiele M, Thursz MR. Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut 2020;69:764-80. [PMID: 31879281 DOI: 10.1136/gutjnl-2019-319720] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
558 Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018;41:328-49. [PMID: 29631866 DOI: 10.1016/j.gastrohep.2017.12.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 7.7] [Reference Citation Analysis]
559 Loosen SH, Demir M, Kunstein A, Jördens M, Qvarskhava N, Luedde M, Luedde T, Roderburg C, Kostev K. Variables associated with increased incidence of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes. BMJ Open Diabetes Res Care 2021;9:e002243. [PMID: 34049870 DOI: 10.1136/bmjdrc-2021-002243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
560 El-Agroudy NN, Kurzbach A, Rodionov RN, O'Sullivan J, Roden M, Birkenfeld AL, Pesta DH. Are Lifestyle Therapies Effective for NAFLD Treatment? Trends Endocrinol Metab. 2019;30:701-709. [PMID: 31422872 DOI: 10.1016/j.tem.2019.07.013] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 21.0] [Reference Citation Analysis]
561 Westerouen Van Meeteren MJ, Drenth JPH, Tjwa ETTL. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs 2020;29:117-23. [PMID: 31523999 DOI: 10.1080/13543784.2020.1668375] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
562 Coelho FDS, Borges-Canha M, von Hafe M, Neves JS, Vale C, Leite AR, Carvalho D, Leite-Moreira A. Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials. Diabetes Metab Res Rev 2021;37:e3413. [PMID: 33010191 DOI: 10.1002/dmrr.3413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
563 Khalatbari-Soltani S, Imamura F, Brage S, De Lucia Rolfe E, Griffin SJ, Wareham NJ, Marques-Vidal P, Forouhi NG. The association between adherence to the Mediterranean diet and hepatic steatosis: cross-sectional analysis of two independent studies, the UK Fenland Study and the Swiss CoLaus Study. BMC Med 2019;17:19. [PMID: 30674308 DOI: 10.1186/s12916-019-1251-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
564 Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol. 2017;23:7495-7504. [PMID: 29204050 DOI: 10.3748/wjg.v23.i42.7495] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
565 Coccia F, Testa M, Guarisco G, Bonci E, Di Cristofano C, Silecchia G, Leonetti F, Gastaldelli A, Capoccia D. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity. Endocrine 2020;67:569-78. [PMID: 31858390 DOI: 10.1007/s12020-019-02155-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
566 Boursier J, Shreay S, Fabron C, Torreton E, Fraysse J. Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database. EClinicalMedicine 2020;25:100445. [PMID: 32775971 DOI: 10.1016/j.eclinm.2020.100445] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
567 Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305-315. [PMID: 29154965 DOI: 10.1016/j.jhep.2017.11.013] [Cited by in Crossref: 190] [Cited by in F6Publishing: 155] [Article Influence: 47.5] [Reference Citation Analysis]
568 Scheen AJ. Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection? Ann Transl Med. 2018;6:S68. [PMID: 30613643 DOI: 10.21037/atm.2018.10.39] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
569 Hohenester S, Christiansen S, Nagel J, Wimmer R, Artmann R, Denk G, Bischoff M, Bischoff G, Rust C. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation, and fibrosis. Am J Physiol Gastrointest Liver Physiol. 2018;315:G329-G338. [PMID: 29878845 DOI: 10.1152/ajpgi.00044.2018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
570 Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, Necsoi C, Campa P, Huefner AD, Schulze Zur Wiesch J, Rougier H, Bastard JP, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D; ANRS-ECHAM Group. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. J Acquir Immune Defic Syndr 2019;80:e86-94. [PMID: 30570529 DOI: 10.1097/QAI.0000000000001936] [Cited by in Crossref: 24] [Cited by in F6Publishing: 6] [Article Influence: 12.0] [Reference Citation Analysis]
571 Moret A, Boursier J, Houssel Debry P, Riou J, Crouan A, Dubois M, Michalak Provost S, Aubé C, Paisant A. Evaluation of the Hepatorenal B-Mode Ratio and the "Controlled Attenuation Parameter" for the Detection and Grading of Steatosis. Ultraschall Med 2020. [PMID: 32992377 DOI: 10.1055/a-1233-2290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
572 Fontes A, Alemany-Pagès M, Oliveira PJ, Ramalho-Santos J, Zischka H, Azul AM. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. Int J Mol Sci 2019;20:E3987. [PMID: 31426291 DOI: 10.3390/ijms20163987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
573 Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F, Petta S. Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once? Pharmaceuticals (Basel). 2018;11:121. [PMID: 30413050 DOI: 10.3390/ph11040121] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
574 Fan JG, Wei L, Zhuang H; National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Disease Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis 2019;20:163-73. [PMID: 30444584 DOI: 10.1111/1751-2980.12685] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
575 Chen PC, Kao WY, Cheng YL, Wang YJ, Hou MC, Wu JC, Su CW. The correlation between fatty liver disease and chronic kidney disease. J Formos Med Assoc. 2020;119:42-50. [PMID: 30876789 DOI: 10.1016/j.jfma.2019.02.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
576 Hallsworth K, Trenell M. Physical Activity in NAFLD: What and How Much? In: Bugianesi E, editor. Non-Alcoholic Fatty Liver Disease. Cham: Springer International Publishing; 2020. pp. 289-307. [DOI: 10.1007/978-3-319-95828-6_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
577 Bray TJ, Chouhan MD, Punwani S, Bainbridge A, Hall-Craggs MA. Fat fraction mapping using magnetic resonance imaging: insight into pathophysiology. Br J Radiol 2018;91:20170344. [PMID: 28936896 DOI: 10.1259/bjr.20170344] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
578 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236. [PMID: 29628281 DOI: 10.1016/j.jhep.2018.03.019] [Cited by in Crossref: 2122] [Cited by in F6Publishing: 1683] [Article Influence: 707.3] [Reference Citation Analysis]
579 Karlas T, Petroff D, Sasso M, Fan J, Mi Y, de Lédinghen V, Kumar M, Lupsor-platon M, Han K, Cardoso AC, Ferraioli G, Chan W, Wong VW, Myers RP, Chayama K, Friedrich-rust M, Beaugrand M, Shen F, Hiriart J, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. Journal of Hepatology 2017;66:1022-30. [DOI: 10.1016/j.jhep.2016.12.022] [Cited by in Crossref: 342] [Cited by in F6Publishing: 272] [Article Influence: 85.5] [Reference Citation Analysis]
580 De Fré CH, De Fré MA, Kwanten WJ, Op de Beeck BJ, Van Gaal LF, Francque SM. Sarcopenia in patients with non-alcoholic fatty liver disease: is it a clinically significant entity?: Sarcopenia in patients with NAFLD. Obesity Reviews 2019;20:353-63. [DOI: 10.1111/obr.12776] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
581 Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
582 Rowe IA. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 2018;3:66-72. [PMID: 29254617 DOI: 10.1016/S2468-1253(17)30142-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
583 Pugliese N, Plaz Torres MC, Petta S, Valenti L, Giannini EG, Aghemo A. Is there an 'ideal' diet for patients with NAFLD? Eur J Clin Invest 2021;:e13659. [PMID: 34309833 DOI: 10.1111/eci.13659] [Reference Citation Analysis]
584 Mori S, Arima N, Ito M, Ueki Y, Abe Y, Aoyagi K, Fujiyama S. Incidence, predictive factors and severity of methotrexate-related liver injury in rheumatoid arthritis: a longitudinal cohort study. Rheumatol Adv Pract 2020;4:rkaa020. [PMID: 33134809 DOI: 10.1093/rap/rkaa020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
585 Biolato M, Manca F, Marrone G, Cefalo C, Racco S, Miggiano GA, Valenza V, Gasbarrini A, Miele L, Grieco A. Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease. World J Gastroenterol. 2019;25:509-520. [PMID: 30700946 DOI: 10.3748/wjg.v25.i4.509] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 10.5] [Reference Citation Analysis]
586 Sebastiani G, Saeed S, Lebouche B, de Pokomandy A, Szabo J, Haraoui LP, Routy JP, Wong P, Deschenes M, Ghali P, Klein M; LIVEHIV Study Group. Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients. AIDS 2020;34:237-44. [PMID: 31651429 DOI: 10.1097/QAD.0000000000002412] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
587 Grzych G, Chávez-Talavera O, Descat A, Thuillier D, Verrijken A, Kouach M, Legry V, Verkindt H, Raverdy V, Legendre B, Caiazzo R, Van Gaal L, Goossens JF, Paumelle R, Francque S, Pattou F, Haas JT, Tailleux A, Staels B. NASH-related increases in plasma bile acid levels depend on insulin resistance. JHEP Rep 2021;3:100222. [PMID: 33615207 DOI: 10.1016/j.jhepr.2020.100222] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
588 Halfon P, Ansaldi C, Penaranda G, Chiche L, Dukan P, Stavris C, Plauzolles A, Retornaz F, Bourliere M. Prospective screening of liver fibrosis in a primary care cohort using systematic calculation of fib-4 in routine results. PLoS One 2021;16:e0254939. [PMID: 34293022 DOI: 10.1371/journal.pone.0254939] [Reference Citation Analysis]
589 Wessels DH, Rosenberg Z. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us? World J Hepatol 2021;13:233-41. [PMID: 33708352 DOI: 10.4254/wjh.v13.i2.233] [Reference Citation Analysis]
590 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 16.0] [Reference Citation Analysis]
591 Rajcic D, Brandt A, Jin CJ, Sánchez V, Engstler AJ, Jung F, Nier A, Baumann A, Bergheim I. Exchanging dietary fat source with extra virgin olive oil does not prevent progression of diet-induced non-alcoholic fatty liver disease and insulin resistance. PLoS One 2020;15:e0237946. [PMID: 32881925 DOI: 10.1371/journal.pone.0237946] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
592 Henson JB, Roden M, Targher G, Corey KE, Corey KE, Malhi H. Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart. Hepatology 2020;71:1867-9. [DOI: 10.1002/hep.31156] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
593 Rinaldi L, Pafundi PC, Galiero R, Caturano A, Morone MV, Silvestri C, Giordano M, Salvatore T, Sasso FC. Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. Antioxidants (Basel) 2021;10:270. [PMID: 33578702 DOI: 10.3390/antiox10020270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
594 Kim D, Kim WR. Nonobese Fatty Liver Disease. Clin Gastroenterol Hepatol. 2017;15:474-485. [PMID: 27581063 DOI: 10.1016/j.cgh.2016.08.028] [Cited by in Crossref: 149] [Cited by in F6Publishing: 127] [Article Influence: 29.8] [Reference Citation Analysis]
595 Oikonomidou AC, Doundoulakis I, Antza C, Kalopitas G, Dardavessis T, Chourdakis M. Evaluation of subclinical cardiac damage in biopsy-proven nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:424-30. [PMID: 33948069 DOI: 10.20524/aog.2021.0594] [Reference Citation Analysis]
596 Thiagarajan P, Chalmers J, Guha IN, James MW. Detecting chronic liver disease: are liver function tests the solution? Br J Hosp Med (Lond) 2020;81:1-8. [PMID: 32097065 DOI: 10.12968/hmed.2019.0308] [Reference Citation Analysis]
597 Lang S, Martin A, Farowski F, Wisplinghoff H, Vehreschild MJGT, Liu J, Krawczyk M, Nowag A, Kretzschmar A, Herweg J, Schnabl B, Tu XM, Lammert F, Goeser T, Tacke F, Heinzer K, Kasper P, Steffen HM, Demir M. High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. Hepatol Commun 2020;4:681-95. [PMID: 32363319 DOI: 10.1002/hep4.1509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
598 Protopapas AA, Cholongitas E, Chrysavgis L, Tziomalos K. Alcohol consumption in patients with nonalcoholic fatty liver disease: yes, or no? Ann Gastroenterol 2021;34:476-86. [PMID: 34276185 DOI: 10.20524/aog.2021.0641] [Reference Citation Analysis]
599 Krawczyk M, Maciejewska D, Ryterska K, Czerwińka-Rogowska M, Jamioł-Milc D, Skonieczna-Żydecka K, Milkiewicz P, Raszeja-Wyszomirska J, Stachowska E. Gut Permeability Might be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction. Nutrients 2018;10:E1793. [PMID: 30453660 DOI: 10.3390/nu10111793] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
600 Parra-Robert M, Casals E, Massana N, Zeng M, Perramón M, Fernández-Varo G, Morales-Ruiz M, Puntes V, Jiménez W, Casals G. Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis. Biomolecules 2019;9:E425. [PMID: 31470518 DOI: 10.3390/biom9090425] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
601 Eslamparast T, Tandon P, Raman M. Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. Nutrients. 2017;9. [PMID: 28933748 DOI: 10.3390/nu9080800] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 10.8] [Reference Citation Analysis]
602 Tovo CV, Villela-Nogueira CA, Leite NC, Panke CL, Port GZ, Fernandes S, Buss C, Coral GP, Cardoso AC, Cravo CM, Calçado FL, Rezende GFM, Ferreira FC, Araujo-Neto JM, Perez RM, Moraes-Coelho HS, de Mattos AA. Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2019;18:445-9. [PMID: 31031166 DOI: 10.1016/j.aohep.2018.09.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
603 Carruthers JE, Bottle A, Laverty AA, Khan SA, Millett C, Vamos EP. Nation-wide trends in non-alcoholic steatohepatitis (NASH) in patients with and without diabetes between 2004-05 and 2014-15 in England. Diabetes Res Clin Pract 2017;132:102-7. [PMID: 28829976 DOI: 10.1016/j.diabres.2017.07.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
604 Luu HN, Neelakantan N, Geng TT, Wang R, Goh GB, Clemente JC, Jin A, van Dam RM, Jia W, Behari J, Koh WP, Yuan JM. Quality diet indexes and risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study. Int J Cancer 2021;148:2102-14. [PMID: 33129230 DOI: 10.1002/ijc.33367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
605 Katsagoni CN, Georgoulis M, Papatheodoridis GV, Fragopoulou E, Ioannidou P, Papageorgiou M, Alexopoulou A, Papadopoulos N, Deutsch M, Kontogianni MD. Associations Between Lifestyle Characteristics and the Presence of Nonalcoholic Fatty Liver Disease: A Case-Control Study. Metab Syndr Relat Disord 2017;15:72-9. [PMID: 27869531 DOI: 10.1089/met.2016.0105] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
606 Zeng Q, Song Z, Zhao Y, Wu J, Wang L, Ye H, Wang Y, Wu T, Yuan S, Yuan H. Controlled attenuation parameter by vibration-controlled transient elastography for steatosis assessment in members of the public undergoing regular health checkups with reference to magnetic resonance imaging-based proton density fat fraction. Hepatol Res 2020;50:578-87. [PMID: 31883216 DOI: 10.1111/hepr.13481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
607 Fiorentino TV, Miceli S, Succurro E, Sciacqua A, Andreozzi F, Sesti G. Nonalcoholic fatty liver disease is associated with a decreased myocardial mechano-energetic efficiency. J Intern Med 2021;289:221-31. [PMID: 32633873 DOI: 10.1111/joim.13155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
608 Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 2021;50:101122. [PMID: 33220492 DOI: 10.1016/j.molmet.2020.101122] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
609 Boursier J, de Ledinghen V, Leroy V, Anty R, Francque S, Salmon D, Lannes A, Bertrais S, Oberti F, Fouchard-hubert I, Calès P. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. Journal of Hepatology 2017;66:1158-65. [DOI: 10.1016/j.jhep.2017.01.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 11.3] [Reference Citation Analysis]
610 Fukunaga S, Nakano D, Kawaguchi T, Eslam M, Ouchi A, Nagata T, Kuroki H, Kawata H, Abe H, Nouno R, Kawaguchi K, George J, Mitsuyama K, Torimura T. Non-Obese MAFLD Is Associated with Colorectal Adenoma in Health Check Examinees: A Multicenter Retrospective Study. Int J Mol Sci 2021;22:5462. [PMID: 34067258 DOI: 10.3390/ijms22115462] [Reference Citation Analysis]
611 Nier A, Huber Y, Labenz C, Michel M, Bergheim I, Schattenberg JM. Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E699. [PMID: 32151020 DOI: 10.3390/nu12030699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
612 Schreiner AD, Zhang J, Durkalski-Mauldin V, Livingston S, Marsden J, Bian J, Mauldin PD, Moran WP, Rockey DC. Advanced liver fibrosis and the metabolic syndrome in a primary care setting. Diabetes Metab Res Rev 2021. [PMID: 33759300 DOI: 10.1002/dmrr.3452] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
613 Zhang P, Feng W, Chu X, Sun X, Zhu D, Bi Y. A newly noninvasive model for prediction of non-alcoholic fatty liver disease: utility of serum prolactin levels. BMC Gastroenterol 2019;19:202. [PMID: 31775658 DOI: 10.1186/s12876-019-1120-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
614 Li R, Zhu W, Huang P, Yang Y, Luo F, Dai W, Shen L, Pei W, Huang X. Olanzapine leads to nonalcoholic fatty liver disease through the apolipoprotein A5 pathway. Biomed Pharmacother 2021;141:111803. [PMID: 34146854 DOI: 10.1016/j.biopha.2021.111803] [Reference Citation Analysis]
615 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
616 Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int. 2019;13:674-687. [PMID: 31705444 DOI: 10.1007/s12072-019-09996-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 8.5] [Reference Citation Analysis]
617 de Sousa Magalhães R, Xavier S, Magalhães J, Rosa B, Marinho C, Cotter J. Transient elastography through controlled attenuated parameter assisting the stratification of cardiovascular disease risk in NAFLD patients. Clin Res Hepatol Gastroenterol 2020;:101580. [PMID: 33279452 DOI: 10.1016/j.clinre.2020.11.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
618 Mikolasevic I, Lukenda Zanko V, Jakopcic I, Domislovic V, Mijic A, Stevanovic T, Delija B, Bokun T, Dinjar Kujundzic P, Ostojic A, Filipec Kanizaj T, Grgurevic I, Krznaric Z, Stimac D, Targher G. Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. J Diabetes Complications 2020;34:107512. [PMID: 31882273 DOI: 10.1016/j.jdiacomp.2019.107512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
619 Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-gomez M, Zelber-sagi S, Wai-sun Wong V, Dufour J, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-järvinen H, Fan J, Grønbæk H, Yilmaz Y, Cortez-pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng M, Fouad Y, Chan W, Mendez-sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology 2020;73:202-9. [DOI: 10.1016/j.jhep.2020.03.039] [Cited by in Crossref: 390] [Cited by in F6Publishing: 332] [Article Influence: 390.0] [Reference Citation Analysis]
620 Caballería L, Pera G, Arteaga I, Rodríguez L, Alumà A, Morillas RM, de la Ossa N, Díaz A, Expósito C, Miranda D, Sánchez C, Prats RM, Urquizu M, Salgado A, Alemany M, Martinez A, Majeed I, Fabrellas N, Graupera I, Planas R, Ojanguren I, Serra M, Torán P, Caballería J, Ginès P. High Prevalence of Liver Fibrosis Among European Adults With Unknown Liver Disease: A Population-Based Study. Clin Gastroenterol Hepatol 2018;16:1138-1145.e5. [PMID: 29452268 DOI: 10.1016/j.cgh.2017.12.048] [Cited by in Crossref: 74] [Cited by in F6Publishing: 57] [Article Influence: 24.7] [Reference Citation Analysis]
621 Nogami A, Yoneda M, Kobayashi T, Kessoku T, Honda Y, Ogawa Y, Suzuki K, Tomeno W, Imajo K, Kirikoshi H, Koide T, Fujikawa H, Saito S, Nakajima A. Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease. Hepatol Res 2019;49:872-80. [PMID: 30974498 DOI: 10.1111/hepr.13349] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
622 Xue X, Liao W, Xing Y. Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma. Infect Agent Cancer 2020;15:11. [PMID: 32082414 DOI: 10.1186/s13027-020-0273-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
623 Chen MM, Cai JJ, Yu Y, She ZG, Li H. Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment. Gene Expr 2019;19:175-85. [PMID: 30940296 DOI: 10.3727/105221619X15536120524171] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
624 Zhang GL, Zhao QY, Lin CS, Hu ZX, Zhang T, Gao ZL. Transient Elastography and Ultrasonography: Optimal Evaluation of Liver Fibrosis and Cirrhosis in Patients with Chronic Hepatitis B Concurrent with Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:3951574. [PMID: 30809540 DOI: 10.1155/2019/3951574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
625 Vasseur P, Dion S, Filliol A, Genet V, Lucas-Clerc C, Jean-Philippe G, Silvain C, Lecron JC, Piquet-Pellorce C, Samson M. Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis. Oncotarget 2017;8:48563-74. [PMID: 28611297 DOI: 10.18632/oncotarget.18335] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
626 Meringer H, Shibolet O, Deutsch L. Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm? World J Gastroenterol. 2019;25:3929-3940. [PMID: 31413528 DOI: 10.3748/wjg.v25.i29.3929] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
627 Niriella MA, Ediriweera DS, Kasturiratne A, Gunasekara D, De Silva ST, Dassanayaka AS, De Silva AP, Kato N, Pathmeswaran A, Wickramasinghe AR, de Silva HJ. The clinical utility of accurate NAFLD ultrasound grading: Results from a community-based, prospective cohort study. Eur J Radiol 2021;136:109516. [PMID: 33421884 DOI: 10.1016/j.ejrad.2020.109516] [Reference Citation Analysis]
628 Petta S, Wai-sun Wong V, Bugianesi E, Fracanzani AL, Cammà C, Hiriart J, Lai-hung Wong G, Vergniol J, Wing-hung Chan A, Giannetti A, Merrouche W, Lik-yuen Chan H, Le-bail B, Lombardi R, Guastella S, Craxì A, de Ledinghen V. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol 2019;114:916-28. [DOI: 10.14309/ajg.0000000000000153] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
629 Durazzo M, Marzari L, Bonetto S, Ferro A, Ghigo MC, Belci P, Collo A, Fagoonee S. Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores. Minerva Gastroenterol Dietol 2020;66:301-6. [PMID: 32700500 DOI: 10.23736/S1121-421X.20.02753-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
630 Kao WY, Chang IW, Chen CL, Su CW, Fang SU, Tang JH, Chang CC, Chang YJ, Wang W. Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease. Obes Surg 2020;30:1249-57. [PMID: 31953745 DOI: 10.1007/s11695-019-04192-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
631 Soret PA, Magusto J, Housset C, Gautheron J. In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal. J Clin Med 2020;10:E36. [PMID: 33374435 DOI: 10.3390/jcm10010036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
632 Caprio M, Infante M, Moriconi E, Armani A, Fabbri A, Mantovani G, Mariani S, Lubrano C, Poggiogalle E, Migliaccio S, Donini LM, Basciani S, Cignarelli A, Conte E, Ceccarini G, Bogazzi F, Cimino L, Condorelli RA, La Vignera S, Calogero AE, Gambineri A, Vignozzi L, Prodam F, Aimaretti G, Linsalata G, Buralli S, Monzani F, Aversa A, Vettor R, Santini F, Vitti P, Gnessi L, Pagotto U, Giorgino F, Colao A, Lenzi A; Cardiovascular Endocrinology Club of the Italian Society of Endocrinology. Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE). J Endocrinol Invest 2019;42:1365-86. [PMID: 31111407 DOI: 10.1007/s40618-019-01061-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 41] [Article Influence: 27.5] [Reference Citation Analysis]
633 Sebastiani G, Cocciolillo S, Mazzola G, Malagoli A, Falutz J, Cervo A, Petta S, Pembroke T, Ghali P, Besutti G, Franconi I, Milic J, Cascio A, Guaraldi G. Application of guidelines for the management of nonalcoholic fatty liver disease in three prospective cohorts of HIV-monoinfected patients. HIV Med 2020;21:96-108. [PMID: 31642599 DOI: 10.1111/hiv.12799] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
634 Nelson JE, Handa P, Aouizerat B, Wilson L, Vemulakonda LA, Yeh MM, Kowdley KV; NASH Clinical Research Network. Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. Aliment Pharmacol Ther 2016;44:1253-64. [PMID: 27730688 DOI: 10.1111/apt.13824] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
635 Arai T, Atsukawa M, Tsubota A, Kato K, Abe H, Ono H, Kawano T, Yoshida Y, Tanabe T, Okubo T, Hayama K, Nakagawa-Iwashita A, Itokawa N, Kondo C, Kaneko K, Emoto N, Nagao M, Inagaki K, Fukuda I, Sugihara H, Iwakiri K. Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease. Sci Rep 2021;11:15938. [PMID: 34354193 DOI: 10.1038/s41598-021-95581-8] [Reference Citation Analysis]
636 Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53:362-376. [PMID: 29247356 DOI: 10.1007/s00535-017-1415-1] [Cited by in Crossref: 227] [Cited by in F6Publishing: 189] [Article Influence: 56.8] [Reference Citation Analysis]
637 Giandalia A, Romeo EL, Ruffo MC, Muscianisi M, Giorgianni L, Forte F, Cucinotta D, Russo GT. Clinical correlates of persistently elevated liver enzymes in type 2 diabetic outpatients. Prim Care Diabetes 2017;11:226-32. [PMID: 28017576 DOI: 10.1016/j.pcd.2016.12.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
638 Son Y, Park J, Lee JM, Grimm R, Kim IY. Comparison of the Effects of Hepatic Steatosis on Monoexponential DWI, Intravoxel Incoherent Motion Diffusion-weighted Imaging and Diffusion Kurtosis Imaging. Acad Radiol 2021:S1076-6332(21)00211-7. [PMID: 34119399 DOI: 10.1016/j.acra.2021.04.016] [Reference Citation Analysis]
639 Ni X, Jiao L, Zhang Y, Xu J, Zhang Y, Zhang X, Du Y, Sun Z, Wang S. Relationship Between Non-Alcoholic Fatty Liver Disease and Abdominal and Pericardial Adipose Tissue in Middle-Aged and Elderly Subjects. Int J Gen Med 2021;14:3439-44. [PMID: 34285567 DOI: 10.2147/IJGM.S317081] [Reference Citation Analysis]
640 Moszak M, Szulińska M, Walczak-Gałęzewska M, Bogdański P. Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. Int J Environ Res Public Health 2021;18:1616. [PMID: 33567710 DOI: 10.3390/ijerph18041616] [Reference Citation Analysis]
641 Carino A, Marchianò S, Biagioli M, Fiorucci C, Zampella A, Monti MC, Morretta E, Bordoni M, Di Giorgio C, Roselli R, Ricci P, Distrutti E, Fiorucci S. Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation. Nutrients 2019;11:E1132. [PMID: 31117231 DOI: 10.3390/nu11051132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
642 Pérez‐pevida B, Díaz‐gutiérrez J, Miras AD, Silva C, Romero S, Salvador J, Escalada J, Frühbeck G. High Body Adiposity Drives Glucose Intolerance and Increases Cardiovascular Risk in Normoglycemic Subjects. Obesity 2018;26:672-82. [DOI: 10.1002/oby.22147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
643 Simes BC, MacGregor GG. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide. Diabetes Metab Syndr Obes. 2019;12:2125-2136. [PMID: 31686884 DOI: 10.2147/dmso.s212003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
644 Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138-1153. [PMID: 28314735 DOI: 10.1136/gutjnl-2017-313884] [Cited by in Crossref: 384] [Cited by in F6Publishing: 326] [Article Influence: 96.0] [Reference Citation Analysis]
645 Chao CY, Battat R, Al Khoury A, Restellini S, Sebastiani G, Bessissow T. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World J Gastroenterol. 2016;22:7727-7734. [PMID: 27678354 DOI: 10.3748/wjg.v22.i34.7727] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
646 Rau M, Geier A. An update on drug development for the treatment of nonalcoholic fatty liver disease - from ongoing clinical trials to future therapy.Expert Rev Clin Pharmacol. 2021;14:333-340. [PMID: 33535836 DOI: 10.1080/17512433.2021.1884068] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
647 Zelber-Sagi S, Ivancovsky-Wajcman D, Fliss Isakov N, Webb M, Orenstein D, Shibolet O, Kariv R. High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance. J Hepatol. 2018;68:1239-1246. [PMID: 29571924 DOI: 10.1016/j.jhep.2018.01.015] [Cited by in Crossref: 78] [Cited by in F6Publishing: 62] [Article Influence: 26.0] [Reference Citation Analysis]
648 Bertasso IM, Pietrobon CB, Lopes BP, Peixoto TC, Soares PN, Oliveira E, Manhães AC, Bonfleur ML, Balbo SL, Cabral SS, Gabriel Kluck GE, Atella GC, Gaspar de Moura E, Lisboa PC. Programming of hepatic lipid metabolism in a rat model of postnatal nicotine exposure – Sex-related differences. Environmental Pollution 2020;258:113781. [DOI: 10.1016/j.envpol.2019.113781] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
649 Ntandja Wandji LC, Gnemmi V, Mathurin P, Louvet A. Combined alcoholic and non-alcoholic steatohepatitis. JHEP Rep 2020;2:100101. [PMID: 32514497 DOI: 10.1016/j.jhepr.2020.100101] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
650 Dewidar B, Kahl S, Pafili K, Roden M. Metabolic liver disease in diabetes - From mechanisms to clinical trials. Metabolism 2020;111S:154299. [PMID: 32569680 DOI: 10.1016/j.metabol.2020.154299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
651 Ciardullo S, Muraca E, Perra S, Bianconi E, Zerbini F, Oltolini A, Cannistraci R, Parmeggiani P, Manzoni G, Gastaldelli A, Lattuada G, Perseghin G. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Res Care. 2020;8. [PMID: 32049637 DOI: 10.1136/bmjdrc-2019-000904] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
652 Verhoeven F, Weil-Verhoeven D, Prati C, Martino VD, Thevenot T, Wendling D. Safety of TNF inhibitors in rheumatic disease in case of NAFLD and cirrhosis. Semin Arthritis Rheum 2020;50:544-8. [PMID: 32446022 DOI: 10.1016/j.semarthrit.2020.03.013] [Reference Citation Analysis]
653 Kasper P, Martin A, Lang S, Kütting F, Goeser T, Demir M, Steffen HM. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol 2021;110:921-37. [PMID: 32696080 DOI: 10.1007/s00392-020-01709-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
654 Croci I, Byrne NM, Chachay VS, Hills AP, Clouston AD, O'Moore-Sullivan TM, Prins JB, Macdonald GA, Hickman IJ. Independent effects of diet and exercise training on fat oxidation in non-alcoholic fatty liver disease. World J Hepatol 2016;8:1137-48. [PMID: 27721919 DOI: 10.4254/wjh.v8.i27.1137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
655 Shah RA, Alkhouri N, Kowdley KV. Emerging drugs for the treatment of non-alcoholic steatohepatitis: a focused review of farnesoid X receptor agonists. Expert Opinion on Emerging Drugs 2020;25:251-60. [DOI: 10.1080/14728214.2020.1796968] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
656 Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation. 2019;103:22-27. [PMID: 30335697 DOI: 10.1097/tp.0000000000002484] [Cited by in Crossref: 120] [Cited by in F6Publishing: 49] [Article Influence: 60.0] [Reference Citation Analysis]
657 Zhou Z, Zhang Q, Wu W, Lin YH, Tai DI, Tseng JH, Lin YR, Wu S, Tsui PH. Hepatic steatosis assessment using ultrasound homodyned-K parametric imaging: the effects of estimators. Quant Imaging Med Surg 2019;9:1932-47. [PMID: 31929966 DOI: 10.21037/qims.2019.08.03] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
658 Li QP, Dou YX, Huang ZW, Chen HB, Li YC, Chen JN, Liu YH, Huang XQ, Zeng HF, Yang XB, Su ZR, Xie JH. Therapeutic effect of oxyberberine on obese non-alcoholic fatty liver disease rats. Phytomedicine 2021;85:153550. [PMID: 33831691 DOI: 10.1016/j.phymed.2021.153550] [Reference Citation Analysis]
659 Qin S, Wang S, Wang X, Wang J. Non-alcoholic fatty liver disease and the risk of urolithiasis: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e12092. [PMID: 30170429 DOI: 10.1097/MD.0000000000012092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
660 Lin SZ, Chen YW, Fan JG. Non‐alcoholic fatty liver disease to metabolic dysfunction‐associated fatty liver disease : Conceptual changes for clinicians, researchers and patients. J Dig Dis 2020;21:604-9. [DOI: 10.1111/1751-2980.12944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
661 Takeuchi M. Toxic AGEs (TAGE) theory: a new concept for preventing the development of diseases related to lifestyle. Diabetol Metab Syndr 2020;12:105. [PMID: 33292465 DOI: 10.1186/s13098-020-00614-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
662 Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S. Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2021;53:79-85. [PMID: 33144054 DOI: 10.1016/j.dld.2020.10.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
663 Chang Y, Ryu S, Kim Y, Cho YK, Sung E, Kim H, Ahn J, Jung H, Yun KE, Kim S, Sung K, Sohn CI, Shin H, Wild SH, Byrne CD. Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis. Hepatology 2020;71:861-73. [DOI: 10.1002/hep.30867] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
664 Doulberis M, Kotronis G, Gialamprinou D, Kountouras J, Katsinelos P. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota. Metabolism 2017;71:182-97. [DOI: 10.1016/j.metabol.2017.03.013] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 16.8] [Reference Citation Analysis]
665 Zeng J, Liu XL, Xin FZ, Zhao ZH, Shao YL, Yang RX, Pan Q, Fan JG. Effects and therapeutic mechanism of Yinzhihuang on steatohepatitis in rats induced by a high-fat, high-cholesterol diet. J Dig Dis 2020;21:179-88. [PMID: 31950587 DOI: 10.1111/1751-2980.12845] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
666 Losurdo G, La Fortezza RF, Iannone A, Contaldo A, Barone M, Ierardi E, Di Leo A, Principi M. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study. World J Gastroenterol 2020;26:7528-37. [PMID: 33384552 DOI: 10.3748/wjg.v26.i47.7528] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
667 Kalinowski P, Paluszkiewicz R, Ziarkiewicz-Wróblewska B, Wróblewski T, Remiszewski P, Grodzicki M, Krawczyk M. Liver Function in Patients With Nonalcoholic Fatty Liver Disease Randomized to Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy: A Secondary Analysis of a Randomized Clinical Trial. Ann Surg 2017;266:738-45. [PMID: 28767558 DOI: 10.1097/SLA.0000000000002397] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 10.8] [Reference Citation Analysis]
668 Lee JH, Lee HS, Lee BK, Kwon YJ, Lee JW. Relationship between Muscle Mass and Non-Alcoholic Fatty Liver Disease. Biology (Basel) 2021;10:122. [PMID: 33562473 DOI: 10.3390/biology10020122] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
669 Gitto S, Guarneri V, Sartini A, Andreone P. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. Expert Rev Gastroenterol Hepatol 2018;12:165-71. [PMID: 29082798 DOI: 10.1080/17474124.2018.1399060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
670 Balcar L, Semmler G, Pomej K, Simbrunner B, Bauer D, Hartl L, Jachs M, Paternostro R, Bucsics T, Pinter M, Trauner M, Mandorfer M, Reiberger T, Scheiner B. Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. United European Gastroenterol J 2021;9:427-37. [PMID: 34050619 DOI: 10.1002/ueg2.12089] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
671 El Hadi H, Di Vincenzo A, Vettor R, Rossato M. Cardio-Metabolic Disorders in Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2019;20:E2215. [PMID: 31064058 DOI: 10.3390/ijms20092215] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
672 Tana C, Schiavone C, Ticinesi A, Lauretani F, Nouvenne A, Dietrich CF, Meschi T. Hepatic artery resistive index as surrogate marker for fibrosis progression in NAFLD patients: A clinical perspective. Int J Immunopathol Pharmacol 2018;32:2058738418781373. [PMID: 29873275 DOI: 10.1177/2058738418781373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
673 Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: Which Has Closer Association With All-Cause and Cause-Specific Mortality?-Results From NHANES III. Front Med (Lausanne) 2021;8:693507. [PMID: 34277667 DOI: 10.3389/fmed.2021.693507] [Reference Citation Analysis]
674 Yun Y, Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, Kim HL, Kim TH, Yoo K, Kim HY. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese vs lean subjects. PLoS One. 2019;14:e0213692. [PMID: 30870486 DOI: 10.1371/journal.pone.0213692] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
675 Plauth M, Bernal W, Dasarathy S, Merli M, Plank LD, Schütz T, Bischoff SC. ESPEN guideline on clinical nutrition in liver disease. Clin Nutr 2019;38:485-521. [PMID: 30712783 DOI: 10.1016/j.clnu.2018.12.022] [Cited by in F6Publishing: 96] [Reference Citation Analysis]
676 Lisboa QC, Nardelli MJ, Pereira PA, Miranda DM, Ribeiro SN, Costa RSN, Versiani CA, Vidigal PVT, Ferrari TCA, Couto CA. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol 2020;12:792-806. [PMID: 33200017 DOI: 10.4254/wjh.v12.i10.792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
677 Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 12.0] [Reference Citation Analysis]
678 Barré T, Protopopescu C, Bani-Sadr F, Piroth L, Rojas Rojas T, Salmon-Ceron D, Wittkop L, Esterle L, Sogni P, Lacombe K, Chas J, Zaegel O, Chaix ML, Miailhes P, Serfaty L, Marcellin F, Carrieri MP; ANRS CO13 HEPAVIH Study Group. Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). Hepatology 2020;71:1182-97. [PMID: 31466125 DOI: 10.1002/hep.30914] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
679 Virarkar M, Szklaruk J, Jensen CT, Taggart MW, Bhosale P. What's New in Hepatic Steatosis. Semin Ultrasound CT MR 2021;42:405-15. [PMID: 34130852 DOI: 10.1053/j.sult.2021.03.001] [Reference Citation Analysis]
680 Mitsinikos FT, Chac D, Schillingford N, DePaolo RW. Modifying macronutrients is superior to microbiome transplantation in treating nonalcoholic fatty liver disease. Gut Microbes 2020;12:1-16. [PMID: 32816619 DOI: 10.1080/19490976.2020.1792256] [Reference Citation Analysis]
681 Foschi FG, Conti F, Domenicali M, Giacomoni P, Borghi A, Bevilacqua V, Napoli L, Berardinelli D, Altini M, Cucchetti A, Ercolani G, Casadei-Gardini A, Bellentani S, Gastaldelli A, Tiribelli C, Bedogni G, Group BS. External Validation of Surrogate Indices of Fatty Liver in the General Population: the Bagnacavallo Study. J Clin Med 2021;10:520. [PMID: 33535679 DOI: 10.3390/jcm10030520] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
682 Shen B, Lu LG. Efficacy and safety of drugs for nonalcoholic steatohepatitis. J Dig Dis 2021;22:72-82. [PMID: 33385317 DOI: 10.1111/1751-2980.12967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
683 Miele L, De Michele T, Marrone G, Isgrò MA, Basile U, Cefalo C, Biolato M, Vecchio FM, Rapaccini GL, Gasbarrini A, Zuppi C, Grieco A. Enhanced Liver Fibrosis Test as a Reliable Tool for Assessing Fibrosis in Nonalcoholic Fatty Liver Disease in a Clinical Setting. Int J Biol Markers 2017;32:397-402. [DOI: 10.5301/ijbm.5000292] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
684 Wong VW, Singal AK. Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis. Transl Gastroenterol Hepatol. 2019;4:53. [PMID: 31463412 DOI: 10.21037/tgh.2019.06.06] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
685 Alhinai A, Patel K, Fonseca VA, Sebastiani G. Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetes. J Diabetes Complications 2021;35:107978. [PMID: 34183247 DOI: 10.1016/j.jdiacomp.2021.107978] [Reference Citation Analysis]
686 Castera L. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough. Liver Int 2018;38:67-70. [DOI: 10.1111/liv.13658] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29